KOL | Charles L LoprinziMayo Clinic, Rochester, MN; | Division of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA;, cloprinzi@mayo.edu | Department of Oncology, Mayo Clinic, Rochester, MN ... |
Kol currículo para Charles L Loprinzi
| Year | |
|---|---|
| 2022 | Mayo Clinic, Rochester, MN; |
| 2021 | Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Mayo Clinic, Rochester, MN, USA |
| 2020 | Department of Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, United States of America Division of Medical Oncology, Mayo Clinic, Rochester, USA North Central Cancer Treatment Group, Mayo Clinic, Rochester, Minnesota Mayo Clinic, Rochester, MN, United States. |
| 2019 | Department of Oncology; Mayo Clinic; Rochester, Minnesota Mayo Clinic Rochester, Florida, USA Medical Oncology |
| 2018 | Department of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA Division of Medical Oncology, Mayo Clinic, Rochester, MN |
| 2017 | Division of Medical Oncology, Mayo Clinic, Rochester, MN. Timothy Gilligan, Cleveland Clinic, Cleveland, OH ; Nessa Coyle, Memorial Sloan Kettering Cancer Center, New York; Ronald M. Epstein, University of Rochester School of Medicine, Rochester, NY; Richard M. Frankel, Regenstrief Institute, Indiana University School of Medicine, Indianapolis, IN; Donna L. Berry and Christopher S. Lathan, Dana-Farber Cancer Institute, Harvard Medical School; Vicki A. Jackson, Massachusetts General Hospital, Harvard Medical School, Boston; Carole Seigel, Patient/Advocacy Representative, Brookline, MA; Kari Bohlke, American Society of Clinical Oncology, Alexandria, VA; Esme Finlay, University of New Mexico School of Medicine, Albuquerque, NM; Charles L. Loprinzi, Mayo Clinic, Rochester, MN; and Lynne H. Nguyen and Walter F. Baile, The University of Texas MD Anderson Cancer Center, Houston, TX. Mayo Clinic Minnesota Department of Oncology Rochester Minnesota The Cancer Center |
| 2016 | Alliance Statistics and Data Center, Mayo Clinic (R.Q., H.L.), and Mayo Clinic (K.J.R., J.M.L., C.L.L.), Rochester, MN Mayo Clinic Cancer Center, Rochester, Minnesota |
| 2015 | Departments of Neurology, Oncology, Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN, USA Mayo Clinic Division of Medical Oncology Rochester Minnesota |
| 2014 | Mayo Clinic Cancer Center Rochester MN |
| 2013 | From the Department of Oncology and Cancer Center Statistics, Mayo Clinic, Rochester, MN. Mayo Clinic Rochester, 200 First Street, SW, 55905, Rochester, MN, USA |
| 2012 | Department of Oncology, Mayo Clinic, 55905, Rochester, MN, USA Mayo Clinic, Rochester, MN, United States |
Charles L Loprinzi: Influência estatística
Relatório de execução
| Concept | World rank |
|---|---|
| nonfluid bodyweights | #1 |
| trial n00cb | #1 |
| ssc device prototype | #1 |
| paclitaxel acute | #1 |
| ncctg trial n06ca | #1 |
| hot flashes weeks | #1 |
| ambulatory patients opioids | #1 |
| cancer hot | #1 |
| device 5 weeks | #1 |
| aminobutyric acid hec | #1 |
| bellergal | #1 |
| hot flashes | #1 |
| managing hot | #1 |
| paclitaxel favor | #1 |
| leucovorin breast cancer | #1 |
| n08c3 | #1 |
| acetate hot | #1 |
| patients hot flashes | #1 |
| oral cryotherapy | #1 |
| ulabtka arm | #1 |
| nonfluid weight gain | #1 |
| cachexia studies | #1 |
| patients dfs predictions | #1 |
| score baseline values | #1 |
| 43 oral complications | #1 |
| treatment cipn | #1 |
| bridging editorial | #1 |
| control hot flashes | #1 |
| fsfi 95 | #1 |
| underdescribers | #1 |
| oral cryotherapy prevention | #1 |
| prtmethodsdata | #1 |
| prevention induced cipn | #1 |
| acetate anorexia | #1 |
| darbepoetin alfa head | #1 |
| nonhormonal | #1 |
| therapy numbness | #1 |
| anthracycline data | #1 |
| qlq cipn20 | #1 |
| prognosis items | #1 |
| polyneuropathy allelic variability | #1 |
| n08ca | #1 |
| acetate dexamethasone | #1 |
| female services tpn | #1 |
| attribution clinical trials | #1 |
| antibiotic lozenge | #1 |
| managing hot flashes | #1 |
| altered sensory organization | #1 |
| cipn adult | #1 |
| n08cb | #1 |
| effects limited efficacy | #1 |
| 5fuinduced ocular toxicity | #1 |
| physical consequences cipn | #1 |
| sae δ − | #1 |
| humans ganglion surveys | #1 |
| a151408 | #1 |
| bakplo | #1 |
| oestrogen survivors | #1 |
| dmc assay | #1 |
| hot flash relief | #1 |
| pregabalin paclitaxel | #1 |
| drowsiness doxepin mouthwash | #1 |
| gsm fsfi | #1 |
| bortezomib alters | #1 |
| agents humans clinicians | #1 |
| active nonhormonal | #1 |
| adam vte trial | #1 |
| prevention paps | #1 |
| women 65 day | #1 |
| discrepancies women | #1 |
| severe stomatitis | #1 |
| toxicity gabapentin | #1 |
| resected cutaneous melanomas | #1 |
| cipn agents | #1 |
| hot flash score | #1 |
| adam vte | #1 |
| ganglion surveys humans | #1 |
| drug humans interferons | #1 |
| nonestrogenic management | #1 |
| crc patients 95 | #1 |
| numbness scores | #1 |
| bakplo placebo | #1 |
| oral mucositisrelated pain | #1 |
| gabapentin arm | #1 |
| duloxetine response | #1 |
| gas menopause patient | #1 |
| single snv rs9657362 | #1 |
| cancer anorexia cachexia | #1 |
| rs9657362 previous study | #1 |
| flashes prospective | #1 |
| oncologists competence | #1 |
| placebo 15 points | #1 |
| discrepancies clinicians assessment | #1 |
| suggestion pregabalin | #1 |
| patients nasal vestibulitis | #1 |
| cvte rivaroxaban | #1 |
| vte recurrence enoxaparin | #1 |
| cachexia carcinoma life | #1 |
| antidepressive agents gamma | #1 |
| cipn methods | #1 |
| 30 points 95 | #1 |
| sensory subscale | #1 |
| compounded topical gel | #1 |
| ganglion surveys | #1 |
| cipn function | #1 |
| 5fuinduced stomatitis | #1 |
| effects cipn | #1 |
| duloxetine response patients | #1 |
| cipn development severity | #1 |
| hot flash control | #1 |
| digital melt curve | #1 |
| flashes prostate | #1 |
| antineoplastic agents nrs | #1 |
| joints syndrome | #1 |
| fluorouracilinduced stomatitis | #1 |
| acetate appetite | #1 |
| gait testing patients | #1 |
| symptom intervention | #1 |
| peripheral neuropathy | #1 |
| mouthwash placebo | #1 |
| oxybutynin hot flashes | #1 |
| extreme phenotyping | #1 |
| cipn20 questionnaire | #1 |
| alliance a151724 | #1 |
| paclitaxel study arms | #1 |
| newer antidepressants | #1 |
| purposehot | #1 |
| conducted studies hrt | #1 |
| oxybutynin doses | #1 |
| ru221408i | #1 |
| compliance institutional guideline | #1 |
| oil nasal | #1 |
| favor placebo | #1 |
| papsmethodspatients | #1 |
| trust oncologists competence | #1 |
| items uncertain gbu | #1 |
| neuropathic symptoms breast | #1 |
| therapeutic targets cipn | #1 |
| reduction hot | #1 |
| pilot trial hands | #1 |
| olanzapine projects vomiting | #1 |
| patients paclitaxel polyneuropathy | #1 |
| response relationship odc | #1 |
| baseline prognosis | #1 |
| vaginal cytology women | #1 |
| methylphenidate cancer patients | #1 |
| decrease hot | #1 |
| agents cyclohexanecarboxylic | #1 |
| ulabtka placebo cream | #1 |
| 65 day | #1 |
| alliance n08c1 | #1 |
| cipn trials | #1 |
| n08c1 | #1 |
| lenolidamide | #1 |
| ocular ice packs | #1 |
| vaginal dehydroepiandrosterone | #1 |
| tools oncologists | #1 |
| preceding 2 months | #1 |
| tpn longterm survival | #1 |
| cipn20 data | #1 |
| loe prevention | #1 |
| placebo drowsiness | #1 |
| skin dermatitis trials | #1 |
| paclitaxel polyneuropathy | #1 |
| treating institution intervention | #1 |
| cipn postural control | #1 |
| agents antihypertensive agents | #1 |
| burning pain | #1 |
| toxicities opioids | #1 |
| arthralgia breast life | #1 |
| neoplasm recurrence apixaban | #1 |
| flashes androgen | #1 |
| isae patients | #1 |
| gabapentin baseline week | #1 |
| dfs 5fu | #1 |
| patientreported nasal symptoms | #1 |
| fsfi udi | #1 |
| cachexia megestrol | #1 |
| aimss life | #1 |
| 1 month appetite | #1 |
| weeks hot flashes | #1 |
| rom leap | #1 |
| recommended colorectal | #1 |
| deprivation symptoms | #1 |
| neuronal uptake transporters | #1 |
| bupropion nicotine dependence | #1 |
| ctcae grade | #1 |
| cipnmethodspatients | #1 |
| numbness tingling | #1 |
| reducing hot | #1 |
| postsurgical neuropathic pain | #1 |
| intervention leap | #1 |
| difference cipn20 scores | #1 |
| relatedness treatment | #1 |
| purposepaclitaxel | #1 |
| numeracy benefit | #1 |
| patients placebo pellet | #1 |
| alopecia ocular toxicity | #1 |
| chemotherapy response rates | #1 |
| placebo anecdotal observations | #1 |
| improvements hot flashes | #1 |
| positive indication prognosis | #1 |
| tpn female services | #1 |
| cryotherapy mucositis | #1 |
| eortc qlqcipn20 instrument | #1 |
| receiving fluorouracil | #1 |
| prominent clinical problem | #1 |
| flashes objective | #1 |
| agents cipn | #1 |
| flashes common | #1 |
| records adult patients | #1 |
| nociceptors putative mechanism | #1 |
| hot flashes patients | #1 |
| treatment hot | #1 |
| inadequate hot | #1 |
| 20 data patients | #1 |
| stellate ganglion block | #1 |
| current trial | #1 |
| hot flash data | #1 |
| cancerassociated anorexia cachexia | #1 |
| megestrol acetate | #1 |
| cinv day | #1 |
| bothersome hot flashes | #1 |
| relatedness treatment arms | #1 |
| uncertain gbu gbu | #1 |
| flash scores | #1 |
| or1 year patients | #1 |
| infliximab cancer | #1 |
| recommendation prevention | #1 |
| phase iii evaluation | #1 |
| motor subscales | #1 |
| middle aged minocycline | #1 |
| numbness hands | #1 |
| cipn topical gel | #1 |
| populations neurologic humans | #1 |
| longitudinal continuation | #1 |
| 2 study arms | #1 |
| flash therapies | #1 |
| udi scores baseline | #1 |
| uncertain gbu | #1 |
| estimated benefit dfs | #1 |
| isae | #1 |
| paps fatigue | #1 |
| patients underdescribers | #1 |
| treating hot | #1 |
| topical cannabinoids | #1 |
| mascc isoo evidence | #1 |
| gabapentin hot | #1 |
| dfs predictions adjuvant | #1 |
| grade peripheral neuropathy | #1 |
| lymphedema hrqol outcomes | #1 |
| oral cryotherapy patients | #1 |
| sensory neuropathy symptoms | #1 |
| flaxseed bar lignans | #1 |
| cancers prevalence | #1 |
| judicious tpn | #1 |
| patients ulabtka | #1 |
| newer antidepressants gabapentin | #1 |
| hormone deprivation symptoms | #1 |
| antidepressants gabapentin | #1 |
| cipn paps | #1 |
| institutional guidelines patients | #1 |
| initiation tpn | #1 |
| backgrounddehydroepiandrosterone | #1 |
| nonhormonal therapies paroxetine | #1 |
| acute pain syndrome | #1 |
| placebo arms percentage | #1 |
| chemotherapy treatment chemotherapy | #1 |
| neuropathic pain difficulty | #1 |
| alleviate hot | #1 |
| flashes stellate | #1 |
| supportive nsclc | #1 |
| n00cb | #1 |
| premenopause radiotherapy | #1 |
| prevent oxaliplatin | #1 |
| neuropathy 20 | #1 |
| data clinical histories | #1 |
| suggested gabapentin | #1 |
| hot flash | #1 |
| neuropathy randomized | #1 |
| drowsiness unpleasant taste | #1 |
| women inadequate control | #1 |
| benefit 5fu | #1 |
| individuals cipn | #1 |
| qolresultsfrom | #1 |
| dronabinol combination | #1 |
| anecdotal observations | #1 |
| daily questionnaires | #1 |
| δ − 95 | #1 |
| patients 25 micrograms | #1 |
| adt cyclohexanecarboxylic acids | #1 |
| toxicity ocular | #1 |
| appetite stimulation patients | #1 |
| aes relatedness | #1 |
| uniscale qol baseline | #1 |
| benefit fluoxetine | #1 |
| antiemetic prescribing practices | #1 |
| flashes venlafaxine | #1 |
| education lymphedema prevention | #1 |
| patients physical examinations | #1 |
| nonhormonal hot | #1 |
| olanzapine arm emesis | #1 |
| differences neuropathy syndromes | #1 |
| tingling | #1 |
| antiemetic prescribing | #1 |
| oncologists prognostic | #1 |
| neoplasms climacteric | #1 |
| acetate doses | #1 |
| 1year survival trials | #1 |
| n08cb alliance | #1 |
| evidence cipn | #1 |
| testosterone improvements | #1 |
| accru study | #1 |
| doxepin mouthwash patients | #1 |
| cipn clinical trial | #1 |
| time publication attitude | #1 |
| megestrol acetate nausea | #1 |
| gabapentin hot flashes | #1 |
| taxane treatment development | #1 |
| gabapentin antidepressant | #1 |
| week tamoxifen | #1 |
| shooting burning | #1 |
| cachexia cancer anorexia | #1 |
| 95 increased difficulty | #1 |
| baseline prognosis values | #1 |
| hot flashes day | #1 |
| deprivation therapy patients | #1 |
| underdescribers weeks | #1 |
| regional hypothermia burden | #1 |
| placebo mouthwash | #1 |
| flash score | #1 |
| neuropathy prevention | #1 |
| oestrogen hot flashes | #1 |
| routine feces sensitivity | #1 |
| cryotherapy hands | #1 |
| treatment attribution | #1 |
| efficacy agent | #1 |
| baseline week gabapentin | #1 |
| topic rectum surveys | #1 |
| tpn initiation death | #1 |
| alliance n08ca | #1 |
| compliance institutional guidelines | #1 |
| rest psychostimulants | #1 |
| patients subcutaneous testosterone | #1 |
| prestudy hypothesis | #1 |
| oncology providers crci | #1 |
| overview oncology providers | #1 |
| baseline neuropathic pain | #1 |
| 81 patients patients | #1 |
| infliximab lung | #1 |
| extensive animal data | #1 |
| oncologists competence 95ci | #1 |
| outcomes study points | #1 |
| flashes gabapentin | #1 |
| doxepin mouthwash | #1 |
| hot flashes acceptability | #1 |
| magnesium oxaliplatininduced neurotoxicity | #1 |
| placebo oral mucositis | #1 |
| authors 115 patients | #1 |
| prevention cipn | #1 |
| 22 nonestrogenic management | #1 |
| centrally active agent | #1 |
| hot flash mechanism | #1 |
| hec cisplatin therapy | #1 |
| n08ca patients | #1 |
| balance impairments patients | #1 |
| 5fu adjuvant | #1 |
| nonfluid weight | #1 |
| aes placebo arm | #1 |
| qol reported difficulty | #1 |
| underdescribing | #1 |
| glutamine toxicity | #1 |
| isaes | #1 |
| hot flash activity | #1 |
| adjuvant numeracy calculators | #1 |
| nsclc response rate | #1 |
| lymphedema incidence intervention | #1 |
| pregabalin paps | #1 |
| baseline fsfi score | #1 |
| residual hot flashes | #1 |
| stomatitis administration | #1 |
| adjuvant numeracy | #1 |
| anorexia appetite | #1 |
| natural postural instability | #1 |
| accru study ru221408i | #1 |
| slight appetite stimulation | #1 |
| lymphedemafree rates groups | #1 |
| highdose melphalan intervention | #1 |
| weight megestrol acetate | #1 |
| glutathione cipn | #1 |
| chamomile mouthwash toxicity | #1 |
| individuals impaired balance | #1 |
| combination chemotherapy hec | #1 |
| flashes women | #1 |
| cipn data | #1 |
| incurable cancer records | #1 |
| hot flash frequency | #1 |
| antidepressant gabapentin | #1 |
| aminobutyric acid adt | #1 |
| − fsfi | #1 |
| nasal vestibulitis | #1 |
| nonhormonal agent | #1 |
| taxane infusion | #1 |
| attribution treatment | #1 |
| enoxaparin cvte | #1 |
| fluoxetine hot | #1 |
| chemotherapy regimen type | #1 |
| flashes quality | #1 |
| paclitaxel weekly cryotherapy | #1 |
| lignans 6 weeks | #1 |
| cancerrelated fatigue interventions | #1 |
| gene arhgef10 | #1 |
| subcutaneous testosterone improvements | #1 |
| cipn phase iii | #1 |
| patientcompleted questionnaires | #1 |
| survivors genitourinary syndrome | #1 |
| flashes treatment | #1 |
| ocular ice | #1 |
| doubleblinded manner | #1 |
| purposehot flashes | #1 |
| gabapentin aminobutyric acid | #1 |
| head therapeutic equivalency | #1 |
| association arhgef10 | #1 |
| historical placebo response | #1 |
| cryotherapy auc | #1 |
| symptoms hands | #1 |
| rs2294039 | #1 |
| toxicity agent | #1 |
| guidelineendorsed treatment | #1 |
| preliminary promising data | #1 |
| nonhormonal agents treatment | #1 |
| randomized study lymphedema | #1 |
| balance gait testing | #1 |
| recurrences clinical histories | #1 |
| increased difficulty patients | #1 |
| anecdotal observations gabapentin | #1 |
| n08ca association | #1 |
| hot flashes treatment | #1 |
| ulabtka | #1 |
| women megestrol acetate | #1 |
| difficulty neuropathic pain | #1 |
| toxicity anecdotal observations | #1 |
| patients megestrol acetate | #1 |
| isae data | #1 |
| fractures infertility | #1 |
| pilot trials citalopram | #1 |
| accru trial | #1 |
| efficacy gabapentin | #1 |
| mascc isoo guidelines | #1 |
| tingling numbness | #1 |
| placebo 30 points | #1 |
| baseline week followup | #1 |
| antibiotic lozenge placebo | #1 |
| symptoms cipn | #1 |
| therapy hot | #1 |
| amines antidepressive | #1 |
| balance patientreported outcomes | #1 |
| hours nighttime sleep | #1 |
| minocycline cipn | #1 |
| antacid mouthwash | #1 |
| safety progestational agents | #1 |
| diphenhydraminelidocaineantacid | #1 |
| rs17683288 | #1 |
| lymphedemafree rates | #1 |
| small cell continuity | #1 |
| antiserotonergic drug | #1 |
| oral cryotherapy management | #1 |
| flashes pilot | #1 |
| bothersome hot | #1 |
| pilot trials venlafaxine | #1 |
| mouthwash diphenhydramine | #1 |
| prominent toxicity | #1 |
| n01c9 | #1 |
| acceptability ssc device | #1 |
| daily hot | #1 |
| management hot | #1 |
| doxepin mouthwash placebo | #1 |
| paresthesia peripheral | #1 |
| phytotherapy vitamin | #1 |
| effects hot flashes | #1 |
| metastatic disease initiation | #1 |
| hfs trial | #1 |
| topical cannabinoids patients | #1 |
| pharmacological targeting oct2 | #1 |
| data hot | #1 |
| treatment symptom intervention | #1 |
| complete response authors | #1 |
| day cisplatin therapy | #1 |
| hot flashes gabapentin | #1 |
| modalities cancer patients | #1 |
| placebo arm gabapentin | #1 |
| patients dosing guidelines | #1 |
| sham acupuncture participants | #1 |
| hormonal ablation andropause | #1 |
| fosaprepitant isae | #1 |
| cinv neoplasms vomiting | #1 |
| cytotoxic chemotherapy supportive | #1 |
| toxicity prospective trial | #1 |
| iii double | #1 |
| eortc cipn20 | #1 |
| leap lymphedema | #1 |
| rose geranium | #1 |
| inadequate control antidepressant | #1 |
| progestational agents patients | #1 |
| aps paclitaxel | #1 |
| hfs ulabtka | #1 |
| neoplasms placebos | #1 |
| cipn20 | #1 |
| coasting phenomenon | #1 |
| fourth treatment week | #1 |
| venous toxicity fosaprepitant | #1 |
| tools hypothetical scenarios | #1 |
| supportive cytotoxic chemotherapy | #1 |
| treatment hot flashes | #1 |
| weeks hot | #1 |
| 12 months anticoagulation | #1 |
| burden alopecia | #1 |
| symptoms hormone deprivation | #1 |
| leucovorin breast | #1 |
| patients gabapentin | #1 |
| life cipn | #1 |
| dmc samples | #1 |
| symptoms feet | #1 |
| ulabtka hfs | #1 |
| hot flash scores | #1 |
| chemotherapy neuropathy | #1 |
| life megestrol acetate | #1 |
| placebos pregabalin quality | #1 |
| treatments modalities | #1 |
| overview crci | #1 |
| vaginal dehydroepiandrosterone dhea | #1 |
| pregenplus | #1 |
| megestrol acetate patients | #1 |
| pilot trials efficacy | #1 |
| patient followup studies | #1 |
| purpose hot | #1 |
| tpn death | #1 |
| treatment alteration | #1 |
| 137 patients cycle | #1 |
| snv rs9657362 | #1 |
| cachexia cyproheptadine | #1 |
| dronabinol megestrol acetate | #1 |
| alliance trial | #1 |
| topical keratolytic | #1 |
| background hot | #1 |
| week hot | #1 |
| vitamin cipn | #1 |
| women male megestrol | #1 |
| cyclohexanecarboxylic acids gamma | #1 |
| isae anthracycline | #1 |
| placebo pilot trials | #1 |
| 2007 guidelines guideline | #1 |
| median δ qs | #1 |
| a151408 study data | #1 |
| alleviating hot | #1 |
| pilot study minocycline | #1 |
| cyproheptadine appetite | #1 |
| revisitation doc | #1 |
| flashes patients | #1 |
| leap 12 months | #1 |
| chamomile mouthwash | #1 |
| safety oestrogen | #1 |
| hot flashes women | #1 |
| pain chemotherapy | #1 |
| understanding potential benefits | #1 |
| compassionate honesty | #1 |
| 8week observation period | #1 |
| flaxseed hot flashes | #1 |
| auc cryotherapy | #1 |
| hot flashes quality | #1 |
| life leap | #1 |
| 95 doxepin mouthwash | #1 |
| suggestion toxicity | #1 |
| neuropathy data | #1 |
| acetate versus | #1 |
| 2007 guidelines suggestion | #1 |
| postural instability chemotherapy | #1 |
| breakthrough nausea patients | #1 |
| life study arms | #1 |
| numerical analogue scale | #1 |
| attribution percentage | #1 |
| items positive indication | #1 |
| nonfluid | #1 |
| patients spray product | #1 |
| cipnsummarythere | #1 |
| peripheral neuropathy paclitaxel | #1 |
| paclitaxel coasting phenomenon | #1 |
| weight loss investigation | #1 |
| placebo 15 glutathione | #1 |
| arhgef10 cipn | #1 |
| disease patient factors | #1 |
| based chemotherapy isae | #1 |
| 5 methylphenidate | #1 |
| megestrol acetate weeks | #1 |
| pharmacologic therapeutics | #1 |
| study dmc assay | #1 |
| cisplatin therapy cinv | #1 |
| rs9657362 | #1 |
| oral mucositis alopecia | #1 |
| study stool samples | #1 |
| baseline assessment week | #1 |
| life qlqcipn20 | #1 |
| feet oxaliplatin | #1 |
| bakplo symptoms | #1 |
| male megestrol megestrol | #1 |
| cyclohexanols female | #1 |
| hormone deprivation cancer | #1 |
| suggestion oral cryotherapy | #1 |
| lymphedema prevention education | #1 |
| leap rom | #1 |
| pilot evaluation | #1 |
| established cipn | #1 |
| education lymphedema education | #1 |
| stomatitis scores | #1 |
| eortc cipn | #1 |
| qolconclusionsthe | #1 |
| replacement testosterone andropause | #1 |
| patientreported outcomes balance | #1 |
| flaxseed bar | #1 |
| topic peripheral neuropathy | #1 |
| dmc mutations | #1 |
| cipn nervous diseases | #1 |
| cipn common | #1 |
| individual patients understanding | #1 |
| authors 30 minutes | #1 |
| induced neurotoxicity oct2 | #1 |
| preliminary evidence improvement | #1 |
| diseases pilot | #1 |
| hormone deprivation | #1 |
| acute symptoms cycle | #1 |
| impaired postural control | #1 |
| subsequent chemotherapy cycles | #1 |
| painful oxaliplatininduced cipn | #1 |
| nonhormonal agents | #1 |
| ncctg n08c3 | #1 |
| magnesium camg | #1 |
| hfs symptoms patients | #1 |
| flashes week | #1 |
| points doxepin | #1 |
| induced cipn | #1 |
| 5 weeks device | #1 |
| flashes breast | #1 |
| 95 neuropathic pain | #1 |
| oral mucosa study | #1 |
| survival tpn initiation | #1 |
| cachexia trial | #1 |
| cipn20 sensory | #1 |
| cachexia dexamethasone | #1 |
| patients highdose interferon | #1 |
| anorexia antineoplastic agents | #1 |
| myalgias arthralgias | #1 |
| prevention oral cryotherapy | #1 |
| developed mucositis | #1 |
| creatine placebo groups | #1 |
| supportive cryotherapy | #1 |
| alliance study a221102 | #1 |
| illness neuropathic symptoms | #1 |
| n06ca | #1 |
| points diphenhydramine | #1 |
| tested interventions lymphedema | #1 |
| studies cyproheptadine | #1 |
| patients cancer anorexia | #1 |
| ncctg n08c1 | #1 |
| numeracy adjuvant | #1 |
| management genital symptoms | #1 |
| male megestrol life | #1 |
| udi δ − | #1 |
| lidocaine antacid | #1 |
| patients 10 range | #1 |
| management hot flashes | #1 |
| advanced cancer anorexia | #2 |
| efficacy scrambler therapy | #2 |
| surveys repeated measures | #2 |
| week black cohosh | #2 |
| dosing zoledronic | #2 |
| acttionconsortium | #2 |
| hot flash frequencies | #2 |
| chemotherapy peripheral neuropathy | #2 |
| cachexia acetate | #2 |
| anthraquinones agents breast | #2 |
| cipn peripheral neuropathy | #2 |
| n06c4 | #2 |
| stomatitis sex | #2 |
| day average pain | #2 |
| 46 screenrelevant neoplasms | #2 |
| hemoccultsensa hemoccult | #2 |
| design considerations recommendations | #2 |
| neuropathy paclitaxel | #2 |
| shark cartilage product | #2 |
| supplementary n03cb | #2 |
| citalopram cyclohexanols humans | #2 |
| aprepitant 4 weeks | #2 |
| 40k arm | #2 |
| daily mmf radiotherapy | #2 |
| women rom | #2 |
| “use vitamin | #2 |
| neuropathy caused | #2 |
| 14 hot flashes | #2 |
| alternative treatment regimen | #2 |
| reduce hot | #2 |
| megestrol acetate dexamethasone | #2 |
| life venlafaxine | #2 |
| weekly epoetin | #2 |
| vte recurrence doacs | #2 |
| feet 18 months | #2 |
| paclitaxel chronic neuropathy | #2 |
| patients olanzapine arm | #2 |
| time toxt analysis | #2 |
| mometasone cream | #2 |
| piroxantrone women | #2 |
| cachexia decision | #2 |
| study arms conclusions | #2 |
| 7 control arms | #2 |
| cipn interventions | #2 |
| cipn cases | #2 |
| chronic chemotherapy | #2 |
| locoregional event | #2 |
| placebo vaginal dryness | #2 |
| stage disease 5fu | #2 |
| starting tamoxifen | #2 |
| venlafaxine treatment 75 | #2 |
| detection screenrelevant neoplasms | #2 |
| placebo oxybutynin doses | #2 |
| 120k arm | #2 |
| study arms quality | #2 |
| 75 49 venlafaxine | #2 |
| patients receiving fluorouracil | #2 |
| prevalence weight concerns | #2 |
| nutrition score disagreement | #2 |
| data gabapentin | #2 |
| cck8 anorexia severity | #2 |
| pa outcomes pros | #2 |
| failure prior chemotherapy | #2 |
| scrambler | #2 |
| 135±19 | #2 |
| tamoxifen medications | #2 |
| conceppt | #2 |
| hemoccultsensa sdt1 | #2 |
| 40k arm 120000 | #2 |
| appetite dissent disputes | #2 |
| screenrelevant neoplasms 16 | #2 |
| scrambler therapy treatment | #2 |
| randomized receive | #2 |
| dermatitis symptom evolution | #2 |
| patients adjuvant 5fu | #2 |
| hot flashes pregabalin | #2 |
| females cessation treatment | #2 |
| woman quality | #2 |
| day study week | #2 |
| colonoscopically normal patients | #2 |
| 120000 epoetin alfa | #2 |
| moderate correlations ≤ | #2 |
| postural instability individuals | #2 |
| pain ≥4 10 | #2 |
| suggested agents | #2 |
| venlafaxine gabapentin | #2 |
| mometasone time | #2 |
| n03cb | #2 |
| qol crc | #2 |
| pregabalin arms | #2 |
| humans postmenopause pregabalin | #2 |
| prevent paclitaxel | #2 |
| 1 oral megestrol | #2 |
| patients daily mmf | #2 |
| 800 liquid suspension | #2 |
| arms conclusions | #2 |
| 150 groups patients | #2 |
| neoplasms double | #2 |
| methylphenidate cancer | #2 |
| infliximab 5 day | #2 |
| life aimss | #2 |
| time randomized study | #2 |
| tamoxifen metabolism evidence | #2 |
| folfox alliance | #2 |
| trials newer antidepressants | #2 |
| dhea vaginal symptoms | #2 |
| vitamin hot | #2 |
| cipn cohort | #2 |
| sdt2 sdt1 | #2 |
| cipn primary outcomes | #2 |
| infertility ovarian failure | #2 |
| pilot citalopram | #2 |
| subsequent mucositis | #2 |
| n01c4 | #2 |
| increased risk cipn | #2 |
| treatment baseline week | #2 |
| palliative communications | #2 |
| treatment alterations | #2 |
| indirect comparison apixaban | #2 |
| improvement hot | #2 |
| starting tamoxifen women | #2 |
| trial baseline week | #2 |
| flash diary | #2 |
| manuscript “use | #2 |
| folfox auc p0·0001 | #2 |
| thiophenes treatment life | #2 |
| patients black cohosh | #2 |
| skindex16 ctcae | #2 |
| oxybutynin doses placebo | #2 |
| appetite dissent | #2 |
| magnesium oxaliplatin | #2 |
| hot flashes citalopram | #2 |
| breakthrough cinv | #2 |
| vitamin hot flashes | #2 |
| single snv | #2 |
| anabolic corticosteroid | #2 |
| cipn cancer treatment | #2 |
| tingling shooting | #2 |
| postmenopausal women previous | #2 |
| cycle chronic neurotoxicity | #2 |
| npy anorexia cholecystokinin | #2 |
| week baseline week | #2 |
| cipn clinical | #2 |
| tamoxifenassociated hot flashes | #2 |
| life illness tetracycline | #2 |
| local antineoplastic agents | #2 |
| kps nutrition scores | #2 |
| singleagent megestrol acetate | #2 |
| established chemotherapy | #2 |
| hot flash management | #2 |
| detection dna markers | #2 |
| symptoms skin toxicity | #2 |
| cipn cancer survivors | #2 |
| nutrition scores physicians | #2 |
| incidence severity stomatitis | #2 |
| acknowledged loss | #2 |
| sunscreen arms | #2 |
| phytogenic female humans | #2 |
| outcome measures ctcae | #2 |
| depomedroxyprogesterone | #2 |
| women stomatitis | #2 |
| npy levels groups | #2 |
| sensitivity screenrelevant neoplasms | #2 |
| patients oxybutynin doses | #2 |
| longitudinal studies postmenopause | #2 |
| infliximab docetaxel | #2 |
| flashes placebo | #2 |
| sulfate prevent | #2 |
| versus megestrol | #2 |
| duloxetine hydrochloride humans | #2 |
| type chemotherapy drug | #2 |
| scrambler therapy | #2 |
| evaluating venlafaxine | #2 |
| hot flashes data | #2 |
| patients monthly intervals | #2 |
| postchemotherapy rheumatism | #2 |
| standard arm rate | #2 |
| oral iron 46 | #2 |
| cachexia pentoxifylline | #2 |
| screenrelevant neoplasms | #2 |
| stat itching | #2 |
| nicotine inhaler bupropion | #2 |
| prevent radiation | #2 |
| nonestrogenic hot | #2 |
| 95 indirect estimates | #2 |
| central cancer | #2 |
| placebo breast radiotherapy | #2 |
| disagreement patients | #2 |
| hemoccultsensa sensitivity | #2 |
| dexamethasone fluoxymesterone | #2 |
| lmwh arms | #2 |
| real patients treatment | #2 |
| poor qol 95 | #2 |
| glutamine placebo preparation | #2 |
| mmf itching | #2 |
| disagreement increased risk | #2 |
| treatment target doses | #2 |
| appetite improvement | #2 |
| anorexia antineoplastic | #2 |
| patients shark cartilage | #2 |
| nonestrogenic therapies | #2 |
| rash incidence severity | #2 |
| study treatment citalopram | #2 |
| hot flashes aprepitant | #2 |
| treatment minority smokers | #2 |
| differences mometasone | #2 |
| time toxt approach | #2 |
| anemia caa | #2 |
| antidepressant hot flashes | #2 |
| subject global impression | #2 |
| nutrition scores 95 | #2 |
| citalopram hot flashes | #2 |
| 16 hemoccult | #2 |
| cancerassociated wasting | #2 |
| stomatitis women | #2 |
| oral megestrol | #2 |
| 01 mmf | #2 |
| treatment week placebo | #2 |
| provider assessed | #2 |
| mometasone surveys | #2 |
| hot flashes efficacy | #2 |
| qol hb increment | #2 |
| monthly intervals appetite | #2 |
| months randomized | #2 |
| 979254 | #2 |
| 3 months bupropion | #2 |
| baseline week day | #2 |
| tens 2 weeks | #2 |
| ncctg n10c1 | #2 |
| placebo pregabalin treatments | #2 |
| hot flashes bupropion | #2 |
| preventive therapies cipn | #2 |
| topical aged antimetabolites | #2 |
| anorexia severity | #2 |
| cipn20 scores | #2 |
| cancerassociated anorexia | #2 |
| tens global impression | #2 |
| venlafaxine control | #2 |
| dronabinol versus | #2 |
| 5fuinduced mucositis | #2 |
| life treatment weeks | #2 |
| ctcae pruritus | #2 |
| 46 adenomas 1 | #2 |
| hot flash quality | #2 |
| hemoccultsensa detection | #2 |
| treatment breakthrough cinv | #2 |
| vte recurrence dalteparin | #2 |
| 4 treatment weeks | #2 |
| patient‐physician disagreement | #2 |
| n0993 | #2 |
| historic controls npy | #2 |
| pilocarpine arms | #2 |
| doses megestrol | #2 |
| induced peripheral | #2 |
| sdt1 hemoccult | #2 |
| 49 venlafaxine | #2 |
| hot flashes humans | #2 |
| hf frequency placebo | #2 |
| pregabalin hot flashes | #2 |
| shark cartilage patients | #2 |
| autonomic scales | #2 |
| appearing pilot data | #2 |
| physicians kps | #2 |
| trial acetate doses | #2 |
| mucositis 5fubased chemotherapy | #2 |
| natural paps | #2 |
| treating chemotherapy | #2 |
| data relative benefits | #2 |
| study arms | #2 |
| levetiracetam 4 weeks | #2 |
| cycle folfox | #2 |
| newer antidepressants trials | #2 |
| glutathione prevention | #2 |
| folfox auc analysis | #2 |
| guaninemethyltransferase | #2 |
| decreasing stomatitis | #2 |
| antidepressants hot | #2 |
| breast cancer venlafaxine | #2 |
| weight concerns 26 | #2 |
| placebo combination therapy | #2 |
| oxybutynin women | #2 |
| global impression life | #2 |
| substantial hot flashes | #2 |
| treatment smoking abstinence | #2 |
| weekly hf score | #2 |
| cipn prevention trials | #2 |
| treatment cycles cycle | #2 |
| pregabalin treatments placebo | #2 |
| induced peripheral neuropathy | #2 |
| 108±11 | #2 |
| time ncctg alliance | #2 |
| smokers nicotine inhaler | #2 |
| ferric gluconate darbepoetin | #2 |
| venlafaxine oxaliplatin neurotoxicity | #2 |
| leucovorin women | #2 |
| circulating concentrations npy | #2 |
| fsfi score baseline | #2 |
| dhea 4 weeks | #2 |
| sdt2 | #2 |
| fosaprepitant patients | #2 |
| gabapentin symptoms | #2 |
| intermediate term efficacy | #2 |
| study arms tetracycline | #2 |
| dalteparin lowest risk | #2 |
| target doses placebo | #2 |
| evaluate weight | #2 |
| egfr inhibitor tetracycline | #2 |
| tingling patients | #2 |
| study n08cb alliance | #2 |
| life 4week intervention | #2 |
| evaluating gabapentin | #2 |
| paclitaxel induced | #2 |
| 432 smokers treatment | #2 |
| aprepitan | #2 |
| anabolic corticosteroid appetite | #2 |
| hot flash studies | #2 |
| conclusions original report | #2 |
| patients treating institution | #2 |
| predictors disagreement | #2 |
| numeracy prognosis | #2 |
| original report time | #2 |
| coriat | #2 |
| randomized study mometasone | #2 |
| life cipn20 | #2 |
| hot flash trials | #2 |
| guidelines recommendation | #2 |
| positive doseresponse | #2 |
| 80 anorexia | #2 |
| usual breathing | #2 |
| experience hot flashes | #2 |
| symptoms surveys | #2 |
| therapy hot flashes | #2 |
| day baseline week | #2 |
| patients 120k arm | #2 |
| cpmp scrambler therapy | #2 |
| oxaliplatin hands | #2 |
| pilocarpine vaginal dryness | #2 |
| lessons cipn | #2 |
| fluoxymesterone treatment | #2 |
| 34—vitamin | #2 |
| gabapentin 4 weeks | #2 |
| toxicity profiles time | #2 |
| reducing chemotherapy | #2 |
| receive parenteral | #2 |
| ctcae differences | #2 |
| dna markers participants | #2 |
| week breast cancer | #2 |
| descriptive manner | #2 |
| 120 arm | #2 |
| dronabinoltreated patients | #2 |
| folfox symptoms | #2 |
| injections hot flashes | #2 |
| 120k arm patients | #2 |
| control arms rate | #2 |
| declining qol | #2 |
| adjuvant 5fu models | #2 |
| inadequate benefit | #2 |
| cisplatin polymerase inhibitors | #2 |
| lvef 1000 | #2 |
| irox folfox auc | #2 |
| life scrambler therapy | #2 |
| trials suggested | #2 |
| eortc qlqcipn20 | #2 |
| cipn20 factor analysis | #2 |
| skindex16 itching | #2 |
| treatment arm mmf | #2 |
| coumarin placebo | #2 |
| women hot flashes | #2 |
| cipn antineoplastic agents | #2 |
| clinical trials n9741 | #2 |
| pilocarpine vaginal | #2 |
| cdf score | #2 |
| fatigue improvement methylphenidate | #2 |
| product hot flashes | #2 |
| placebo hf frequency | #2 |
| placebo arms women | #2 |
| gabapentin venlafaxine hydrochloride | #2 |
| cipn paclitaxel | #2 |
| placebo bar | #2 |
| dronabinol combination therapy | #2 |
| middle aged survivors | #2 |
| chemotherapyassociated anemia caa | #2 |
| life cancerrelated fatigue | #2 |
| ecog nutrition score | #2 |
| peripheral neuropathy cipn | #2 |
| improvement hot flashes | #2 |
| shark cartilage placebo | #2 |
| iii randomized | #2 |
| nonhormonal management | #2 |
| kps nutrition score | #2 |
| average stomatitis sex | #2 |
| flashes citalopram | #2 |
| oxaliplatin doses trends | #2 |
| patients cipn | #2 |
| allopurinol mouthwash | #2 |
| alliance folfox | #2 |
| bupropion nicotine inhaler | #2 |
| treatment aprepitant | #2 |
| appetite cachexia | #2 |
| patients chemotherapyassociated anemia | #2 |
| 40000 40k arm | #2 |
| cipn | #2 |
| hot flashes dehydroepiandrosterone | #2 |
| epoetin alfa 40000 | #2 |
| scrambler therapy tens | #2 |
| lamotrigine neuropathic symptoms | #2 |
| patients difluoromethylornithine | #2 |
| cohosh treatment | #2 |
| older age bupropion | #2 |
| 95 oral placebo | #2 |
| sdt2 hemoccult | #2 |
| neuropathy cipn | #2 |
| patients 40k arm | #2 |
| anthrapyrazoles piroxantrone | #2 |
| oxaliplatin induced neurotoxicity | #2 |
| clinically deficient fatigue | #2 |
| induced arthralgias | #2 |
| tamoxifen percentage reduction | #2 |
| scrambler therapy management | #2 |
| rcts preventive therapies | #2 |
| intervention 18 months | #2 |
| anabolic corticosteroid treatment | #2 |
| sensitivity cold items | #2 |
| survival 3915 patients | #2 |
| 5fubased chemotherapy mucositis | #2 |
| questionnaires antineoplastic agents | #2 |
| topic estrogen | #2 |
| tetracycline rash incidence | #2 |
| worse survivorship | #2 |
| pruritus pros | #2 |
| desipramine hot flashes | #2 |
| illness tetracycline egfr | #2 |
| stat erythema | #2 |
| management genitourinary symptoms | #2 |
| humans citalopram cyclohexanols | #2 |
| advancedstage cancer | #2 |
| 15 points 95 | #2 |
| previous hot flashes | #2 |
| placebo situ carcinoma | #2 |
| trial suggestion | #2 |
| participants 3 stools | #2 |
| conclusions sunscreen | #2 |
| symptomatic cipn | #2 |
| lmwh arms 7 | #2 |
| ncctg trial | #2 |
| ≤ moderate correlations | #2 |
| real real patients | #2 |
| cold items 71 | #2 |
| receiving megestrol | #2 |
| docetaxel serum concentrations | #2 |
| life venlafaxine hydrochloride | #2 |
| hemoccultsensa sdt2 | #2 |
| flash studies | #2 |
| ductal mometasone furoate | #2 |
| original report mometasone | #2 |
| 16 sdt2 | #2 |
| hot flash diary | #2 |
| cipn n08cx population | #3 |
| n03cc | #3 |
| study antidepressive agents | #3 |
| completed diaries | #3 |
| paps dose | #3 |
| evidence prostate adenocarcinoma | #3 |
| etanercept current trial | #3 |
| tamoxifen fluoxetine | #3 |
| pilot trial pregabalin | #3 |
| study population mcbdr | #3 |
| mcbdr | #3 |
| eightyone randomized women | #3 |
| snv charcotmarietooth disease | #3 |
| months bupropion | #3 |
| average severity | #3 |
| clonidine randomized trials | #3 |
| iii evaluation | #3 |
| genetic factors patients | #3 |
| oxaliplatin primary endpoint | #3 |
| cyproheptadine patients | #3 |
| paps scores dose | #3 |
| depression somnolence | #3 |
| cartilage shark | #3 |
| 10 weeks therapy | #3 |
| questionnaires syndrome paclitaxel | #3 |
| genetic predictors cipn | #3 |
| eventual sensory patients | #3 |
| trials newer | #3 |
| 1 month cytokines | #3 |
| epoetin alfa hgb | #3 |
| cipn snv | #3 |
| controlled double | #3 |
| subcutaneous weekly | #3 |
| 40000 units | #3 |
| flutamide hgpin | #3 |
| placebo breast | #3 |
| tingling burning pain | #3 |
| minocycline prevention | #3 |
| pts stage iii | #3 |
| trial bmd | #3 |
| epoetintreated patients incidence | #3 |
| experts cipn | #3 |
| thirdline hormonal therapy | #3 |
| combinationtreated arms survival | #3 |
| projects prospective | #3 |
| ctpm experts | #3 |
| patient completed | #3 |
| epa combinationtreated arms | #3 |
| interventions cancerrelated fatigue | #3 |
| cancer patients drugs | #3 |
| upfront treatment arm | #3 |
| qlqcipn20 scores | #3 |
| paps scores | #3 |
| n08cx | #3 |
| patients scrambler therapy | #3 |
| qol hgb | #3 |
| qlqcipn20 | #3 |
| upfront arm | #3 |
| n05c4 | #3 |
| neuropathy chemotherapy | #3 |
| pros differences | #3 |
| data ginseng | #3 |
| 51 female age | #3 |
| experience greater | #3 |
| dalteparin vte | #3 |
| general subscale mfsisf | #3 |
| chemotherapy induced | #3 |
| survivors gsm | #3 |
| mfsisf 4 weeks | #3 |
| shooting burning pain | #3 |
| recommendations dietary counseling | #3 |
| acute neuropathy | #3 |
| patients chemotherapy cycle | #3 |
| centrally active agents | #3 |
| asco surveillance | #3 |
| hgpin chemoprevention trial | #3 |
| toxicity agents | #3 |
| gwas mayo clinic | #3 |
| patients paps scores | #3 |
| oxaliplatin cipn | #3 |
| mucositis scores | #3 |
| traditional ctcae | #3 |
| oxaliplatininduced neuropathy | #3 |
| primary endpoint gwas | #3 |
| combinationtreated arms | #3 |
| patients lidocaine patch | #3 |
| cmtassociated genes | #3 |
| inhibitorinduced rash | #3 |
| cachexia decision humans | #3 |
| data pilot trials | #3 |
| cvte | #3 |
| crossover methodology | #3 |
| 20 calories | #3 |
| centric decision | #3 |
| snv cmtassociated genes | #3 |
| prophylactic tetracycline | #3 |
| life dronabinol | #3 |
| 95 udi | #3 |
| rash conclusions | #3 |
| repeated measures analyses | #3 |
| rash prevention | #3 |
| survival cancerassociated wasting | #3 |
| relationship numbness | #3 |
| ctcae pros | #3 |
| rash symptoms | #3 |
| longitudinal adverse | #3 |
| qlqcipn20 traditional ctcae | #3 |
| drug toxicity patients | #3 |
| epoetintreated patients | #3 |
| sham acupuncture week | #3 |
| treatment bother | #3 |
| feet 15 | #3 |
| cyclohexanecarboxylic acids | #3 |
| ≤−20 | #3 |
| management cancer cachexia | #3 |
| oral megestrol acetate | #3 |
| mcbdr primary endpoint | #3 |
| acetate treated | #3 |
| relationship response rate | #3 |
| 95 40 points | #3 |
| incurable cancers | #3 |
| rash study arms | #3 |
| anorexia anorexia appetite | #3 |
| neuropathy trials | #3 |
| ginseng crf | #3 |
| corticosteroid medications | #3 |
| ctcae grades patients | #3 |
| 3 weeks 80k | #3 |
| dhea hot flashes | #3 |
| cmt gene | #3 |
| preventing peripheral | #3 |
| baseline treatment day | #3 |
| canada collaborative effort | #3 |
| ginseng arm | #3 |
| cipn ctpm | #3 |
| baseline general subscale | #3 |
| bacterial agents life | #3 |
| fluoxetine arm | #3 |
| oxaliplatinbased therapy | #3 |
| alfa compared | #3 |
| patients antiemetic | #3 |
| ctcae grading arms | #3 |
| oncology colorectal | #3 |
| qol placebotreated patients | #3 |
| controls singleton snv | #3 |
| starting letrozole | #3 |
| pilot evaluation gabapentin | #3 |
| chemotherapy increases | #3 |
| additional 4 weeks | #3 |
| cmt genes oxaliplatin | #3 |
| patients cyproheptadine | #3 |
| ssc device | #3 |
| cipn mcbdr population | #3 |
| numeracy patients | #3 |
| methylphenidate patients | #3 |
| neurotoxic chemotherapies | #3 |
| epoetintreated patients study | #3 |
| purposeoxaliplatin | #3 |
| placebo prostate adenocarcinoma | #3 |
| egfr inhibitorinduced rash | #3 |
| baseline hot | #3 |
| hemoccult hemoccultsensa | #3 |
| male megestrol | #3 |
| trials n9741 | #3 |
| week venlafaxine therapy | #3 |
| neurotoxic chemotherapy cipn | #3 |
| patients cancerassociated wasting | #3 |
| advanced cancer standard | #3 |
| patients upfront arm | #3 |
| prevent epidermal | #3 |
| hgb rbc transfusions | #3 |
| thromboembolism secondary | #3 |
| methodologic lessons | #3 |
| cipn biological targets | #3 |
| topic mayo clinic | #3 |
| stomatitis sucralfate | #3 |
| topical ceramides | #3 |
| chemotherapy‐associated anemia | #3 |
| apixaban lowest risk | #3 |
| frequency hot | #3 |
| female gabapentin | #3 |
| ” numbness | #3 |
| middle aged pilot | #3 |
| receive placebo | #3 |
| survival epa | #3 |
| bit hands | #3 |
| delayed zoledronic | #3 |
| classic sums | #3 |
| undergoing androgen ablation | #3 |
| reported rash | #3 |
| purposefosaprepitant | #3 |
| delayed treatment arm | #3 |
| hands burning pain | #3 |
| aminobutyric acid gabapentin | #3 |
| genetic predictors paclitaxel | #3 |
| cumulative neurotoxicity oxaliplatin | #3 |
| placebo preparation | #3 |
| n08ca n08cb study | #3 |
| chlorhexidine mouthwash | #3 |
| life hospice patients | #3 |
| chronic neuropathy patients | #3 |
| vaginal dhea | #3 |
| weekly arm differences | #3 |
| cold items | #3 |
| measures peripheral | #3 |
| carboplatin gwas | #3 |
| neoplasms vomiting | #3 |
| patients baseline week | #3 |
| asco guideline management | #3 |
| mastectomy rates | #3 |
| median δ | #3 |
| iii controlled | #3 |
| mouthwash patients | #3 |
| bivariate construct | #3 |
| toxicities selfreport | #3 |
| chemotherapy gabapentin | #3 |
| mpa single dose | #3 |
| cipn cmtassociated genes | #3 |
| intravenous calcium magnesium | #3 |
| selfreport ctcae grading | #3 |
| vitamin prevention | #3 |
| hot flashes placebo | #3 |
| hemoccultsensa | #3 |
| hot flashes trial | #3 |
| physiologic pilot | #3 |
| life antineoplastic agents | #3 |
| real day | #3 |
| gabapentin management | #3 |
| week chemotherapy dose | #3 |
| burning pain patients | #3 |
| n08ca paclitaxel | #3 |
| hormonal ablation | #3 |
| cipn evidence | #3 |
| “use | #3 |
| chemotherapyassociated anemia | #3 |
| radiation‐induced mucositis | #3 |
| osteoporosis osteopenia letrozole | #3 |
| egfr inhibitor patients | #3 |
| fasting chemotherapy | #3 |
| follow fsfi | #3 |
| blind trial | #3 |
| life eortc qlq | #3 |
| iron arm | #4 |
| appetite quality | #4 |
| placebo hot | #4 |
| mastectomy rates patients | #4 |
| oxybutynin placebo | #4 |
| weekly toxicity | #4 |
| backgroundhistorically | #4 |
| loss syndrome | #4 |
| hfs quality | #4 |
| cipn20 ctcae | #4 |
| cachexia purpose | #4 |
| rash incidence | #4 |
| paced breathing | #4 |
| colorectal cancer asco | #4 |
| additional meta analysis | #4 |
| qol baseline fatigue | #4 |
| severe stomatitis leukopenia | #4 |
| 3915 patients | #4 |
| followup surveillance protocol | #4 |
| odc odc activity | #4 |
| tpn initiation | #4 |
| 40000 | #4 |
| chemotherapy‐induced peripheral | #4 |
| qol performance score | #4 |
| achievements ncctg | #4 |
| therapy oncologists | #4 |
| anorexia cholecystokinin | #4 |
| therapy aimss | #4 |
| single dose venlafaxine | #4 |
| placebo arms | #4 |
| aimss | #4 |
| based chemotherapy women | #4 |
| nonestrogenic | #4 |
| secondary vte prevention | #4 |
| risk reduction therapy | #4 |
| intrapatient difference | #4 |
| doubleblind manner | #4 |
| control hot | #4 |
| controls imbalance | #4 |
| measurable metastatic disease | #4 |
| daily baseline | #4 |
| odx ctx | #4 |
| recommended endorsement | #4 |
| bupropion 3 months | #4 |
| or1 year | #4 |
| based chemotherapy severity | #4 |
| breast medical oncologists | #4 |
| hemoccult | #4 |
| survivors hot | #4 |
| receive oral | #4 |
| treatment ncctg | #4 |
| 6 months bupropion | #4 |
| anorexia weight | #4 |
| ctx odx | #4 |
| major doselimiting toxicity | #4 |
| symptoms individual patients | #4 |
| topic survivors | #4 |
| anorectic cancer patients | #4 |
| endorsed treatment | #4 |
| inhibitor induced | #4 |
| 900 dose | #4 |
| oral cryotherapy mucositis | #4 |
| weight loss syndrome | #4 |
| general subscale | #4 |
| hgpin antineoplastic agents | #4 |
| rash study | #4 |
| odc activity mice | #4 |
| outcomes olanzapine | #4 |
| cutaneous electrostimulation | #4 |
| severity sexes | #4 |
| predictors duloxetine response | #4 |
| guidelines oral | #4 |
| flash frequency | #4 |
| fluorouracilbased chemotherapy | #4 |
| calgb 70305 | #4 |
| 1093 women | #4 |
| treatment cancer anorexia | #4 |
| aged mouthwashes | #4 |
| publication antiemetics humans | #4 |
| women greater toxicity | #4 |
| benefits adjuvant | #4 |
| appetite stimulation | #4 |
| addition letrozole | #4 |
| day paroxetine | #4 |
| doxepin female head | #4 |
| prominent problem | #4 |
| 95 oral iron | #4 |
| parenteral iron | #4 |
| cancer acute vte | #4 |
| surgery lymphedema | #4 |
| logistic regression incidence | #4 |
| flaxseed placebo | #4 |
| hot flashes therapy | #4 |
| egfr inhibitor rash | #4 |
| administration parp inhibitor | #4 |
| baseline fatigue survival | #4 |
| vaginal assessment scale | #4 |
| chronic neuropathy | #4 |
| suggested efficacy | #4 |
| nsclc trials | #4 |
| hec cisplatin | #4 |
| numbness toes | #4 |
| apr dex | #4 |
| oral cavity mucosa | #4 |
| cco guideline followup | #4 |
| arm breast neoplasms | #4 |
| toxt analysis | #4 |
| to100 | #4 |
| trpa1 cisplatin | #4 |
| nonabsorbable antibiotic | #4 |
| dietician | #4 |
| recommendation ctx | #4 |
| ais biomarkers | #4 |
| bupropion 3 | #4 |
| doac dalteparin | #4 |
| gabapentin day | #4 |
| hot flashes week | #4 |
| libido | #5 |
| gabapentin trial | #5 |
| patients lmwh injections | #5 |
| cyclohexanecarboxylic | #5 |
| crc cancer types | #5 |
| cumulative neurotoxicity | #5 |
| cachexia anorexia | #5 |
| patient outcomes numeracy | #5 |
| cipnrelated symptoms | #5 |
| numeracy online clinical | #5 |
| cipn effects | #5 |
| women 5fu | #5 |
| crc cancers | #5 |
| olanzapine arm | #5 |
| fosaprepitant prevention | #5 |
| discontinuation aimss | #5 |
| placebo exposed | #5 |
| combination electroacupuncture | #5 |
| trial gabapentin | #5 |
| colorectal cancer society | #5 |
| odx | #5 |
| intravenous calcium | #5 |
| mucositis allopurinol | #5 |
| fluoxymesterone patients | #5 |
| colorectal cancer surveillance | #5 |
| neuropathic pain qol | #5 |
| difference control arm | #5 |
| life epa | #5 |
| life lmwh | #5 |
| impaired postural | #5 |
| higher drug doses | #5 |
| hb increment | #5 |
| neoplasms compared | #5 |
| vasomotor hot flashes | #5 |
| death communication humans | #5 |
| numeracy tools | #5 |
| cisplatin ganglia | #5 |
| cipn numbness | #5 |
| oxantrazole | #5 |
| bone loss osteopenia | #5 |
| rectal cancer surveillance | #5 |
| ttr ajcc | #5 |
| ajcc external validation | #5 |
| major outcome measure | #5 |
| pain scores dose | #5 |
| race ttr | #5 |
| additional 8 weeks | #5 |
| genetic quality life | #5 |
| medical oncology outpatients | #5 |
| ttr cindices | #5 |
| acetate placebo | #5 |
| subsets treatment benefits | #5 |
| cindices ajcc | #5 |
| iron oral | #5 |
| disputes female humans | #5 |
| grade model estimates | #5 |
| nutrition scores | #5 |
| groups leptin concentrations | #5 |
| ajcc version staging | #5 |
| postsurgical neuropathic | #5 |
| progestational agent | #5 |
| current trial patients | #5 |
| physicians predictive ttr | #5 |
| flashes data | #5 |
| study dmc | #5 |
| nodal status stage | #5 |
| agents basis | #5 |
| mucositis caused | #5 |
| centrally active | #5 |
| sham real | #5 |
| nodal status grade | #5 |
| physicianreported | #5 |
| fiftynine percent | #5 |
| trial hot | #5 |
| neuropeptide leptin | #5 |
| epa supplement | #5 |
| trial developed | #5 |
| treatment benefits sex | #5 |
| cancer survivors symptoms | #5 |
| trials lessons | #5 |
| ttr variables | #5 |
| editor manuscript | #5 |
| 3 stools | #5 |
| reported hot | #5 |
| neoplasm diagnostic tests | #5 |
| 5fu trials | #5 |
| kps ecog | #5 |
| neuropathy acute | #5 |
| appetite enhancement | #5 |
| induced stomatitis | #5 |
| aapro | #5 |
| cancer anorexia | #5 |
| acetate neoplasms | #5 |
| digital melt | #5 |
| 3 patients 4 | #5 |
| trials cytotoxic chemotherapy | #5 |
| receiving paclitaxel | #5 |
| ajcc tools | #5 |
| models ttr | #5 |
| cancerrelated fatigue patients | #5 |
| gabapentin patients | #5 |
| acetate neoplasms quality | #5 |
| treating postmenopausal | #5 |
| questionnaires pregabalin | #5 |
| ongoing clinical trial | #5 |
| reduce chemotherapy | #5 |
| tools numeracy | #5 |
| cipn participants | #5 |
| flashes humans | #6 |
| daily diary questionnaires | #6 |
| placebo arm patients | #6 |
| staging patient outcomes | #6 |
| nicotine inhaler | #6 |
| apixaban cancer patients | #6 |
| nonanthracycline chemotherapy | #6 |
| proportion aes | #6 |
| bf qol | #6 |
| placebo hfs | #6 |
| induced sensory | #6 |
| longacting methylphenidate | #6 |
| data supporting | #6 |
| pharmaceutic aged aged | #6 |
| intervention lymphedema | #6 |
| cipn treatment | #6 |
| alliance clinical | #6 |
| sensory scale | #6 |
| 5fubased chemotherapy | #6 |
| depomedroxyprogesterone acetate | #6 |
| therapy 10 weeks | #6 |
| sadenosyllmethionine treatment | #6 |
| her2directed therapy | #6 |
| versus combination | #6 |
| placebo hot flashes | #6 |
| methylo | #6 |
| olanzapine prevention | #6 |
| severity data | #6 |
| north central | #6 |
| hrqol breast neoplasms | #6 |
| background chemotherapy | #6 |
| wisconsin ginseng | #6 |
| nci ctcae | #6 |
| smoking abstinence rates | #6 |
| agents breast | #6 |
| active malignancy | #6 |
| death kps | #6 |
| predictive illness surveys | #6 |
| neurological safety | #6 |
| inhaler bupropion | #6 |
| highly emetogenic chemotherapy | #6 |
| loe guidelines | #6 |
| imidazoles letrozole | #6 |
| 4week intervention | #6 |
| mri trends | #6 |
| 71 sensitivity | #6 |
| rs11572080 | #6 |
| paclitaxel peripheral neuropathy | #6 |
| megestrol | #6 |
| selective poly | #6 |
| hospitalized oncology patients | #6 |
| 5fu folfox | #6 |
| participants sham acupuncture | #6 |
| severity neuropathic symptoms | #6 |
| medical acupuncture | #6 |
| breakthrough nausea | #6 |
| fatigue pilot study | #6 |
| cancerrelated fatigue life | #6 |
| studies vomiting | #6 |
| life toxicity | #6 |
| 500 mcg | #6 |
| prevalence moderatetosevere | #7 |
| week followup | #7 |
| 5fu based chemotherapy | #7 |
| rs10509681 | #7 |
| throat discomfort | #7 |
| bupropion relapse | #7 |
| menopause hot | #7 |
| weekly epoetin alfa | #7 |
| blind study | #7 |
| hemoccult hemoquant | #7 |
| outcomes primary outcomes | #7 |
| incidence rbc transfusion | #7 |
| induced rash | #7 |
| toxic polyneuropathy | #7 |
| minority smokers | #7 |
| uniscale | #7 |
| placebocontrolled trial | #7 |
| patient anthracycline | #7 |
| venlafaxine therapy | #7 |
| lower extremity symptoms | #7 |
| 20 percent placebo | #7 |
| pregabalin prevention | #7 |
| stage nodal status | #7 |
| fluoxetine clinical trials | #7 |
| sensitivity fecal | #7 |
| nausea cancer patients | #7 |
| serum concentrations cytokines | #7 |
| lymphedema education | #7 |
| venlafaxine day | #7 |
| patients product | #7 |
| follow year | #7 |
| cryotherapy arm | #7 |
| study drug trial | #7 |
| cyclophosphamidedoxorubicin | #7 |
| letrozole differences | #7 |
| citalopram cyclohexanols | #7 |
| mpa arm | #7 |
| transdermal clonidine | #7 |
| study arms difference | #7 |
| adjuvant interferon patients | #7 |
| weight concerns smokers | #7 |
| model estimates survival | #7 |
| venlafaxine versus | #7 |
| chronic postmastectomy pain | #7 |
| 1week baseline period | #7 |
| appetites | #7 |
| intervention lymphedema status | #7 |
| patients oral cryotherapy | #7 |
| cmt genes | #7 |
| cream versus | #7 |
| vte recurrence doac | #7 |
| neuropathy oxaliplatin | #7 |
| symptom subscale | #7 |
| 12 treatment arms | #7 |
| accru | #7 |
| nutrition score | #7 |
| cancer patients anorexia | #7 |
| odx score | #7 |
| induced neuropathy | #7 |
| illness antimetabolites | #7 |
| pain cipn | #7 |
| intermediate odx | #7 |
| patients hb response | #7 |
| skindex16 | #7 |
| mucositis placebo | #7 |
| fuinduced | #7 |
| smoking 3 | #7 |
| paclitaxel peripheral | #7 |
| uniscale qol | #7 |
| scheduled receive | #7 |
| hemoquant | #7 |
| progestational | #8 |
| venlafaxine hot flashes | #8 |
| cycle capecitabine | #8 |
| oxaliplatin paclitaxel | #8 |
| anecdotal | #8 |
| epa survival | #8 |
| flutamide placebo | #8 |
| oxaliplatin neuropathy | #8 |
| antidepressant patients | #8 |
| chronic neurotoxicity | #8 |
| paclitaxel severity | #8 |
| opioids moderate pain | #8 |
| venous toxicity | #8 |
| administered systemically | #8 |
| placebo suggestion | #8 |
| efficacy newer antidepressants | #8 |
| 18 months symptoms | #8 |
| factors cipn | #8 |
| greater toxicity | #8 |
| fecal blood | #8 |
| topic antineoplastic | #8 |
| nonhormonal treatments | #8 |
| paclitaxel pain | #8 |
| smokers weight concerns | #8 |
| pros aes | #8 |
| odx risk | #8 |
| cancer survivors cipn | #8 |
| direct oral factor | #8 |
| mouth sores | #8 |
| life antibodies | #8 |
| series clinical trials | #8 |
| symptoms neuropathy | #8 |
| neuropathy scale | #8 |
| placebo pilot study | #8 |
| folfox dfs | #8 |
| raw data trials | #8 |
| stomatitis patients | #8 |
| oral iron placebo | #8 |
| women hfs | #8 |
| 70305 | #8 |
| cpmp | #8 |
| 1355 | #8 |
| agents newer | #8 |
| libido women | #8 |
| recurrence colon cancer | #8 |
| tamoxifeninduced hot flashes | #8 |
| evidence pharmacologic interventions | #8 |
| oral placebo | #8 |
| sdt1 | #8 |
| neuropathic symptoms | #8 |
| induced painful | #8 |
| prior chemotherapy exposure | #8 |
| neuropathy pain | #8 |
| severe hot flashes | #8 |
| treatment cinv | #8 |
| disease receive | #9 |
| cutaneous aged anesthetics | #9 |
| lymphedema hrqol | #9 |
| study treatment arm | #9 |
| vitality subscale | #9 |
| cancer patients cipn | #9 |
| acid amines | #9 |
| 5 nausea | #9 |
| oxaliplatin placebo | #9 |
| radiationinduced esophagitis | #9 |
| questionnaires syndrome | #9 |
| mucositis pain | #9 |
| relapse relapse prevention | #9 |
| trial paroxetine | #9 |
| genistein tumor growth | #9 |
| numbness fingers | #9 |
| letrozole day | #9 |
| hot flashes tamoxifen | #9 |
| neuropathic symptoms patients | #9 |
| lmwh injections | #9 |
| antiemetic properties | #9 |
| topical antimetabolites | #9 |
| flash control | #9 |
| incidence colorectal adenomas | #9 |
| cipn patients | #9 |
| sensory axonopathy | #9 |
| 43 trials | #9 |
| baseline week week | #9 |
| follow tests | #9 |
| medications evidence | #9 |
| lamotrigine pain | #9 |
| dose dfmo | #9 |
| flashes hot | #9 |
| ambulatory analgesics | #9 |
| disease recurrence recurrence | #9 |
| patients hot | #9 |
| appetite weight | #9 |
| apixaban lower rate | #9 |
| patients provided | #9 |
| lymphedema prevention | #9 |
| aged pilot | #9 |
| mometasone furoate placebo | #9 |
| surgical year | #9 |
| incurable disease | #9 |
| skindex16 scores | #9 |
| fosaprepitant | #9 |
| fatigue methylphenidate | #9 |
| prevention vomiting | #9 |
| nonhormonal treatment | #10 |
| qol anemia | #10 |
| aprepitant treatment | #10 |
| patients treatment period | #10 |
| gabapentin | #10 |
| differences 5 years | #10 |
| scrambler therapy patients | #10 |
| life topic reproducibility | #10 |
| life dietary supplements | #10 |
| phase iii | #10 |
| flash data | #10 |
| combination therapy relapse | #10 |
| frequency hot flashes | #10 |
| ecog kps | #10 |
| chemotherapy‐induced | #10 |
| oxaliplatin peripheral | #10 |
| recommendations general population | #10 |
| patients neurotoxic chemotherapy | #10 |
| minocycline reduction | #10 |
| 40 arm | #10 |
| doses citalopram | #10 |
| δ − | #10 |
| randomized placebo | #10 |
| factes | #10 |
| trials demonstrated | #10 |
| cognitive chemotherapy | #10 |
| qol total | #10 |
| shark cartilage | #10 |
| sensitivity cancer | #10 |
| anorexia cachexia | #10 |
| asco guideline | #10 |
| oxaliplatin trpa1 | #10 |
| neoplasms neuralgia | #10 |
| incidence stomatitis | #10 |
| antineoplastic agents humans | #10 |
| humans megestrol | #10 |
| cancerrelated fatigue fatigue | #10 |
| venlafaxine arm | #10 |
| adult cancers | #10 |
| cancerassociated anemia | #10 |
| folfox 5fu | #10 |
| controlled randomized | #10 |
| nonhormonal therapies | #10 |
| data relatedness | #10 |
| megestrol acetate quality | #10 |
| vaginal dryness | #10 |
| ctcae grades | #10 |
| inhibit cyp2d6 | #10 |
| symptomatic malignant ascites | #10 |
| physical consequences | #10 |
| pain medications patients | #10 |
| advanced cancer life | #10 |
| curve assay | #11 |
| melt curve | #11 |
| efficacy black cohosh | #11 |
| olanzapine chemotherapy | #11 |
| reported incidences | #11 |
| differences study arms | #11 |
| translational component | #11 |
| vomiting cancer patients | #11 |
| hydrazine sulfate | #11 |
| erythropoietic response | #11 |
| fsfi female | #11 |
| anastrozole 10 | #11 |
| physicians increased risk | #11 |
| diphenhydramine lidocaine | #11 |
| gbu | #11 |
| ginseng placebo | #11 |
| cancer undergoing | #11 |
| ativan | #11 |
| combination treated | #11 |
| prevalence neuropathic pain | #11 |
| electroanalgesia | #11 |
| qol uniscale | #11 |
| institutional guideline | #11 |
| difficulty patients | #11 |
| dalteparin major bleeding | #11 |
| antiemetic guidelines | #11 |
| sensory neurotoxicity | #11 |
| flashes | #11 |
| nicotine patch therapy | #11 |
| promising data | #11 |
| toxicities groups | #12 |
| patients cipn symptoms | #12 |
| hb response | #12 |
| adjuvant communication decision | #12 |
| breast cancer letrozole | #12 |
| oxaliplatin induced | #12 |
| cycles drugs | #12 |
| hot flashes 95 | #12 |
| reported peripheral | #12 |
| pilot trial levetiracetam | #12 |
| individuals advanced adenomas | #12 |
| pluronic lecithin organogel | #12 |
| ctpm | #12 |
| apixaban dalteparin | #12 |
| venlafaxine women | #12 |
| probability prospective studies | #12 |
| recurrence comparisons | #12 |
| cachexia clinical trials | #12 |
| decreased libido | #12 |
| leptin cck8 | #12 |
| valerian placebo | #12 |
| cipn development | #12 |
| −307 | #12 |
| rash quality | #12 |
| capsaicin cream | #12 |
| irox folfox | #12 |
| completed daily | #12 |
| gait testing | #12 |
| neurotoxic chemotherapy | #12 |
| toxicity 4 weeks | #12 |
| venlafaxine hydrochloride | #12 |
| months smoking | #13 |
| adenomas aspirin | #13 |
| autonomic scale | #13 |
| bmd 1 year | #13 |
| patients diphenhydramine | #13 |
| andropause | #13 |
| flashes day | #13 |
| venlafaxine paroxetine | #13 |
| trial support | #13 |
| therapy benefits | #13 |
| ncctg | #13 |
| life investigation | #13 |
| nausea patients | #13 |
| valerian sleep | #13 |
| median hb | #13 |
| severity hot flashes | #13 |
| education clinical practice | #13 |
| improve cancer | #13 |
| treatment advanced cancer | #13 |
| 40 points 95 | #13 |
| abh gel | #13 |
| anemia life | #13 |
| weight cachexia | #13 |
| initial 3 months | #13 |
| 2000 update | #13 |
| patients breakthrough cinv | #13 |
| adjuvant benefit | #13 |
| venlafaxine life | #13 |
| incident exposure | #13 |
| newer antidepressants placebo | #13 |
| life neoplasm recurrence | #13 |
| hot flashes baseline | #13 |
| oral anesthetics | #13 |
| troublesome symptoms | #13 |
| paroxetine hot flashes | #13 |
| neuropathic pain surgery | #13 |
| rs3213619 | #13 |
| patients advancedstage cancer | #13 |
| troubling | #13 |
| neuropathy outcome | #13 |
| ais women | #13 |
| estimates prognosis | #13 |
| megestrol acetate therapy | #13 |
| 10 range | #13 |
| acute treatment vte | #13 |
| common toxicity | #13 |
| adjuvant colon cancer | #13 |
| major bleeding doac | #13 |
| marked toxicity | #14 |
| palliate | #14 |
| genital symptoms | #14 |
| diagnosis localized disease | #14 |
| 5fu surgery | #14 |
| prophylactic agent | #14 |
| phase 3 months | #14 |
| oral iron | #14 |
| recurrences patients | #14 |
| benefit toxicity | #14 |
| stool dna | #14 |
| flash activity | #14 |
| life anemia | #14 |
| provided data | #14 |
| oxaliplatin vivo | #14 |
| fluoxymesterone | #14 |
| smokers placebo | #14 |
| based topical | #14 |
| patients pain scores | #14 |
| biomarkers bone formation | #14 |
| folfox irox | #15 |
| advanced malignant disease | #15 |
| life life survivors | #15 |
| week darbepoetin | #15 |
| acceptability device | #15 |
| monoclonal carcinoma antibodies | #15 |
| prognosis quality life | #15 |
| lidocaine patch | #15 |
| grade age | #15 |
| evidence treatment options | #15 |
| bfq | #15 |
| acute diarrhea patients | #15 |
| aes treatment | #15 |
| mastectomy irradiation | #15 |
| advanced cancer methods | #15 |
| academic oncologists | #15 |
| therapy nicotine | #15 |
| clinician perception | #15 |
| duloxetine cipn | #15 |
| treatment weeks patients | #15 |
| trials gabapentin | #15 |
| 16–28 | #15 |
| suggestion guideline | #15 |
| vaginal dryness dyspareunia | #15 |
| sternal skin conductance | #15 |
| week baseline | #15 |
| adjuvant aromatase | #15 |
| oxaliplatininduced neurotoxicity | #15 |
| taste alterations | #15 |
| agents life | #15 |
| androgen ablation therapy | #15 |
| highly emetogenic | #15 |
| triazoles zoledronic | #15 |
| persistent incisional pain | #15 |
| syndromes peripheral | #15 |
| randomized trial aspirin | #16 |
| diarrhoea time | #16 |
| patch therapy | #16 |
| rash pruritus | #16 |
| advancedstage cancer patients | #16 |
| treatment cancer vte | #16 |
| product time | #16 |
| induced hot | #16 |
| premenopausal women chemotherapy | #16 |
| venlafaxine patients | #16 |
| loss appetite | #16 |
| symptoms numbness | #16 |
| findings education | #16 |
| stool dna test | #16 |
| paclitaxel oxaliplatin | #16 |
| mfsi | #16 |
| dalteparin 95 | #16 |
| antiemetic agent | #16 |
| female cancer survivors | #16 |
| tingling pain | #16 |
| vte apixaban | #16 |
| measurable evaluable disease | #16 |
| breast gynecologic cancer | #16 |
| endpoints baseline | #16 |
| patients venlafaxine | #16 |
| arthralgias | #17 |
| breast cancer oestrogen | #17 |
| 18 months women | #17 |
| vaginal symptoms | #17 |
| adenomas 1 | #17 |
| oxaliplatin doses | #17 |
| screen detection | #17 |
| inadequate control | #17 |
| arhgef10 | #17 |
| oxaliplatin treated | #17 |
| device women | #17 |
| crc patients patients | #17 |
| recommendation suggestion | #17 |
| fractional co2 | #17 |
| reduction fatigue | #17 |
| study tetracycline | #17 |
| 786 patients | #17 |
| dfs folfox | #17 |
| cancer menopause | #17 |
| rs11849538 | #17 |
| flashes tamoxifen | #17 |
| leptin concentrations groups | #17 |
| women metastatic | #17 |
| venlafaxine | #17 |
| institute common | #17 |
| leap study | #17 |
| receiving head | #18 |
| intervention guidelines | #18 |
| severity cipn | #18 |
| menopausal problems | #18 |
| secondary endpoint analysis | #18 |
| standard prognostic | #18 |
| postmenopausal women letrozole | #18 |
| 120000 | #18 |
| 5 adjuvant | #18 |
| oncology providers patients | #18 |
| mri mastectomy | #18 |
| prophylactic antiemetic therapy | #18 |
| placebo 04 | #18 |
| subsets age | #18 |
| symptoms hormone | #18 |
| patients overview | #18 |
| randomized trials women | #18 |
| data followup | #18 |
| sigmoidoscopy tomography | #18 |
| oral dronabinol | #18 |
| patients hb | #18 |
| flash frequencies | #18 |
| patients informed decisions | #18 |
| baseline 4 | #18 |
| severity hot | #18 |
| patients irox | #18 |
| treatment osteopenia | #18 |
| sternal skin | #18 |
| induced mucositis | #19 |
| patients based chemotherapy | #19 |
| double blinded | #19 |
| oxaliplatin neurotoxicity | #19 |
| 95 46 | #19 |
| neoplasms peripheral | #19 |
| n6 n5 | #19 |
| physician reported | #19 |
| minimal adverse effects | #19 |
| rs7349683 | #19 |
| flash reduction | #19 |
| acute cancer | #19 |
| mastectomy methotrexate | #19 |
| 7 outcomes | #19 |
| groups infliximab | #19 |
| unpleasant taste | #19 |
| evidence status | #19 |
| life gabapentin | #19 |
| oxaliplatin carboplatin | #19 |
| folfox fluorouracil | #19 |
| bmd neoplasms chemotherapy | #19 |
| previous colorectal | #19 |
| panax quinquefolius | #19 |
| ncdf | #19 |
| treatment mastectomy | #19 |
| advanced cancer study | #20 |
| surveillance protocol | #20 |
| major bleeding treatment | #20 |
| reducing pain | #20 |
| placebo smokers | #20 |
| numbness | #20 |
| fecal occult | #20 |
| placebo cream | #20 |
| pilot trials | #20 |
| diseases randomized | #20 |
| emetogenic chemotherapy | #20 |
| moderate pain patients | #20 |
| progestational agents | #20 |
| appetite nutritional status | #20 |
| palliating | #20 |
| life skindex16 | #20 |
| cancer cancer therapy | #20 |
| receiving pelvic | #20 |
| study ginseng | #20 |
| revisitation | #20 |
| baseline week | #20 |
| fatigue 4 | #20 |
| therapeutic options treatment | #20 |
| trial 12 months | #21 |
| oral mucositis pain | #21 |
| acetate patients | #21 |
| radiationinduced dermatitis | #21 |
| chemotherapy agents | #21 |
| routine test | #21 |
| crossover analysis | #21 |
| therapy adverse effects | #21 |
| treatment options women | #21 |
| female menopause | #21 |
| receptorpositive breast cancer | #21 |
| substantial problem | #21 |
| management cachexia | #21 |
| cipn symptoms | #21 |
| refractory cachexia | #21 |
| studies methylphenidate | #21 |
| metastatic breast carcinoma | #21 |
| cancer starting | #21 |
| scores ≤ | #22 |
| 150 groups | #22 |
| location stage | #22 |
| patients testosterone | #22 |
| subcutaneous testosterone | #22 |
| npy leptin | #22 |
| median time initiation | #22 |
| n9741 | #22 |
| crossover phase | #22 |
| optumlabs | #22 |
| severity adverse events | #22 |
| asco panel | #22 |
| candidate single | #22 |
| guideline intervention | #22 |
| pharmacokinetics infliximab | #22 |
| doc time | #22 |
| patients 5 weeks | #22 |
| projects quality | #22 |
| emetogenic | #22 |
| gain patients | #22 |
| mascc isoo | #23 |
| mcf7 cells genistein | #23 |
| stool dna testing | #23 |
| sucralfate patients | #23 |
| fsdsr | #23 |
| followup tests | #23 |
| decision adjuvant | #23 |
| aes qol | #23 |
| versus delayed | #23 |
| acetate middle | #23 |
| acupuncture hot | #23 |
| life ascites | #23 |
| potential toxicities | #23 |
| 5 pounds | #23 |
| detecting recurrence | #23 |
| hrt survival | #24 |
| weeks primary | #24 |
| prevention chemotherapy | #24 |
| randomized 1 | #24 |
| design rcts | #24 |
| aged amines | #24 |
| aged anorexia | #24 |
| adjuvant decision making | #24 |
| apixaban treatment | #24 |
| replacement testosterone | #24 |
| female hot | #24 |
| tamoxifen octreotide | #24 |
| n56 | #24 |
| day chemotherapy | #24 |
| topic design severity | #24 |
| pilot clinical | #24 |
| abstract5fluorouracil | #24 |
| ortho biotech | #24 |
| mirtazapine patients | #24 |
| every3 | #24 |
| lymphedema incidence | #25 |
| severe nausea vomiting | #25 |
| trial pilot | #25 |
| placebo arm treatment | #25 |
| prevention nausea | #25 |
| nausea olanzapine | #25 |
| cco guideline | #25 |
| women adjuvant tamoxifen | #25 |
| recommendations basis | #25 |
| doses schedules | #25 |
| vte trial | #25 |
| criteria adverse | #25 |
| qol tools | #25 |
| institutional guidelines | #25 |
| cancerassociated weight loss | #25 |
| mmf placebo | #25 |
| antiepileptic agent | #25 |
| neoplasia screening | #25 |
| bpisf | #25 |
| 2005 update | #26 |
| trial evaluate | #26 |
| joints muscles | #26 |
| nci ctc | #26 |
| treatment arms | #26 |
| regional breast | #26 |
| induced musculoskeletal | #26 |
| dose gabapentin | #26 |
| combination weight loss | #26 |
| clinical trials chemotherapy | #26 |
| aiinduced | #26 |
| irradiation mastectomy | #26 |
| cachexia carcinoma | #26 |
| colorectal adenomas patients | #26 |
| prior week | #26 |
| undergoing adjuvant | #26 |
| neoplasms estrogens | #26 |
| receiving oxaliplatin | #26 |
| oncology journals | #26 |
| agents prevention | #26 |
| syndrome menopause | #26 |
| mfsisf | #26 |
| antiemetic | #27 |
| hot flashes hf | #27 |
| adjuvant 5fu | #27 |
| recommendations trials | #27 |
| valerian | #27 |
| neuropathy symptoms | #27 |
| lymphedema arm | #27 |
| smoking bupropion | #27 |
| lmwh survival | #27 |
| events ctcae | #27 |
| fubased | #27 |
| patients short term | #27 |
| nurse survey | #27 |
| series trials | #27 |
| prophylactic antiemetic | #27 |
| muscles joints | #28 |
| primary endpoint proportion | #28 |
| treatment hot flushes | #28 |
| chest rays | #28 |
| fluoxetine citalopram | #28 |
| describers | #28 |
| prevent colorectal adenomas | #28 |
| matched general population | #28 |
| newer | #28 |
| standard prognostic factors | #28 |
| intractable palliative | #28 |
| alliance | #28 |
| gynecologic cancer survivors | #28 |
| lidocaine patches | #28 |
| mastectomy rate | #28 |
| definitively | #28 |
| biological predictors | #29 |
| citalopram placebo | #29 |
| mucositis study | #29 |
| pain cancer survivors | #29 |
| feet hands | #29 |
| difluoromethylornithine dfmo | #29 |
| vitamin incidence | #29 |
| statistical controversies | #29 |
| asco guideline update | #29 |
| points study | #29 |
| blood screening | #29 |
| placebo arm | #29 |
| paclitaxel cipn | #29 |
| taxanebased chemotherapy | #29 |
| smokers bupropion | #29 |
| chemotherapy cipn | #29 |
| patients paclitaxel | #29 |
| efficacy venlafaxine | #29 |
| survival arms | #29 |
| postmenopause predictive | #30 |
| management oral mucositis | #30 |
| mild nausea | #30 |
| phase iii comparison | #30 |
| loss postmenopausal | #30 |
| contralateral axillary | #30 |
| benadryl | #30 |
| small pilot | #30 |
| middle aged postmenopause | #30 |
| alfa darbepoetin | #30 |
| anthrapyrazoles | #30 |
| development cipn | #30 |
| month duration | #30 |
| usual oncology | #30 |
| pain oral | #30 |
| cipn pain | #30 |
| twoyear followup | #30 |
| diseases peripheral | #30 |
| term rectal | #31 |
| benefit dfs | #31 |
| patients races | #31 |
| patients secondary analysis | #31 |
| pain quality life | #31 |
| ixabepilone patients | #31 |
| prevention oral mucositis | #31 |
| symptomatic ascites | #31 |
| middle aged perimenopause | #31 |
| mastectomy mri | #31 |
| management menopausal symptoms | #31 |
| calcium magnesium | #31 |
| treatment acute vte | #31 |
| arms placebo | #31 |
| sixtysix patients | #31 |
| treatment paclitaxel | #31 |
| efficacy methylphenidate | #31 |
| rash severity | #32 |
| female services | #32 |
| evidencebased guidance | #32 |
| guideline endorsement | #32 |
| women lymphedema | #32 |
| doubleblind trial | #32 |
| breast cancer symptoms | #32 |
| camg | #32 |
| oncologist patients | #32 |
| receiving highly | #32 |
| vera gel | #32 |
| delayed chemotherapy | #32 |
| survival advanced cancer | #33 |
| aloe vera gel | #33 |
| toxicity breast | #33 |
| acupuncture hot flashes | #33 |
| pursuant | #33 |
| isoo | #33 |
| 4week followup | #33 |
| chemotherapeutic regimens | #33 |
| neoplasms carboplatin | #33 |
| therapy bupropion | #33 |
| dose megestrol | #33 |
| patients cinv | #33 |
| fingers hands | #33 |
| breast neoplasms life | #33 |
| hands feet | #33 |
| blind manner | #33 |
| week treatment | #33 |
| neuropathy patients | #33 |
| sensitivity polyps | #33 |
| patients taxol | #33 |
| increased difficulty | #33 |
| painful cipn | #33 |
| instruments life | #33 |
| questionnaires total | #33 |
| smokers randomized | #33 |
| continuation study | #34 |
| patients acitretin | #34 |
| chemotherapy hec | #34 |
| toxicity fluorouracil | #34 |
| patients nausea | #34 |
| moderatetosevere patients | #35 |
| stomatitis | #35 |
| prevention chemotherapyinduced nausea | #35 |
| dawley statistics | #35 |
| trial designed | #35 |
| inhibitors venlafaxine | #35 |
| levels week | #35 |
| major bleeding lmwh | #35 |
| primary outcomes trials | #35 |
| treating cancer | #35 |
| formal consensus process | #35 |
| cipn severity | #35 |
| cancer international society | #35 |
| 4 week | #35 |
| united states hrqol | #35 |
| carcinoembryonic antigen levels | #35 |
| patients tools | #35 |
| tnfα study | #36 |
| nk1ras | #36 |
| secondary prevention measures | #36 |
| lymphedema treatment | #36 |
| pyrexia patients | #36 |
| stages colorectal cancer | #36 |
| doxepin | #36 |
| mometasone placebo | #36 |
| head neck radiotherapy | #36 |
| pain pilot | #36 |
| cohosh | #36 |
| myalgias | #36 |
| symptoms cancer | #37 |
| early integrated | #37 |
| alleviation | #37 |
| ctcae | #37 |
| cancerrelated fatigue | #37 |
| survival supportive | #37 |
| mc5 | #37 |
| planned sample size | #37 |
| global impression | #37 |
| topic stomatitis | #37 |
| chronic nausea | #37 |
| topic humans life | #37 |
| nausea neoplasms | #37 |
| p00052 | #37 |
| study intravenous | #37 |
| patients taxanes | #38 |
| fluorouracil based | #38 |
| individual item | #38 |
| tests controlled trials | #38 |
| trial conducted | #38 |
| 5ht3ras | #38 |
| oncology providers | #38 |
| relationships populations | #38 |
| patients highdose melphalan | #38 |
| women metastatic disease | #38 |
| illness purpose | #38 |
| sensitization nociceptors | #38 |
| qol clinical trials | #39 |
| cohort type | #39 |
| grade 2 toxicity | #39 |
| trials oncology | #39 |
| treatment breakthrough | #39 |
| crushed ice | #39 |
| chi2 tests | #39 |
| acids drug | #39 |
| blind crossover | #39 |
| study double | #39 |
| 3 agents | #39 |
| menopause gsm | #39 |
| arm placebo | #39 |
| arm difference | #39 |
| european organisation cancer | #39 |
| prevent colorectal | #40 |
| terminology criteria | #40 |
| topic reproducibility surveys | #40 |
| mastectomy chemotherapy | #40 |
| patients lamotrigine | #40 |
| arthralgia breast | #40 |
| single dose placebo | #40 |
| method fatigue | #40 |
| appetite patients | #40 |
| initial mastectomy | #40 |
| difluoromethylornithine | #40 |
| treatment analyses | #40 |
| cachexia clinical | #40 |
| gabapentin placebo | #41 |
| trial performed | #41 |
| bupropion smokers | #41 |
| drug evaluation studies | #41 |
| symptoms 12 months | #41 |
| united states guidelines | #41 |
| treatment period | #41 |
| relapse 3 months | #41 |
| smokers weight | #41 |
| undergoing androgen | #41 |
| zoledronic acid bmd | #41 |
| cure recurrence | #41 |
| treating institution | #42 |
| appetite body | #42 |
| patients incurable | #42 |
| nortriptyline placebo | #42 |
| chemotherapy day | #42 |
| randomized doubleblind trial | #42 |
| location age | #42 |
| placebo venlafaxine | #42 |
| transdermal gel | #42 |
| oral gabapentin | #42 |
| neuronal protection | #42 |
| patients completed | #42 |
| sex location | #43 |
| baseline fatigue | #43 |
| highdose interferon | #43 |
| dietary supplements life | #43 |
| 5 induced | #43 |
| postsurgical | #43 |
| preliminary insights | #43 |
| desipramine patients | #43 |
| median weight | #43 |
| surveillance united states | #44 |
| sensory symptoms | #44 |
| nonpain | #44 |
| trial benefit | #44 |
| pain reduction patients | #44 |
| risk cipn | #44 |
| weeks efficacy | #44 |
| chemotherapyinduced nausea vomiting | #44 |
| outcome gamma | #44 |
| collaborative effort | #44 |
| disagreement | #44 |
| bupropion placebo | #44 |
| vaginal moisturizer | #44 |
| acute pain patients | #45 |
| fisher tests | #45 |
| ginseng panax quinquefolius | #45 |
| objective tumor regression | #45 |
| rash grade | #45 |
| piroxantrone | #45 |
| historic controls | #45 |
| survivors colorectal cancer | #45 |
| humans peripheral | #45 |
| 5 years incidence | #45 |
| menogaril | #45 |
| genitourinary syndrome menopause | #45 |
| conclusion trial | #45 |
| chemotherapy antineoplastic | #46 |
| longitudinal methods | #46 |
| factor prognostic | #46 |
| iii colon cancer | #46 |
| acute skin toxicity | #46 |
| radiotherapy randomized | #46 |
| nonpharmacological therapy | #46 |
| patients advanced adenomas | #46 |
| vaccines melanoma | #46 |
| middle aged patient | #46 |
| cisplatin neuropathy | #46 |
| phase iii life | #46 |
| clinical problem | #46 |
| putative mechanism | #46 |
| adverse symptoms | #46 |
| item measures | #46 |
| radiationinduced oral mucositis | #46 |
| epoetin alfa placebo | #46 |
| current manuscript | #46 |
| study gaba | #46 |
| randomized comparison | #46 |
| megestrol acetate treatment | #46 |
| genetic predictors | #47 |
| dose paclitaxel | #47 |
| average pain | #47 |
| screening setting | #47 |
| differences pros | #47 |
| cachexia female | #47 |
| aged mometasone | #47 |
| bipn | #47 |
| twopart | #47 |
| neoplasms parenteral nutrition | #47 |
| darbepoetin alfa patients | #47 |
| mascc | #47 |
| stratification factor | #48 |
| placebo gabapentin | #48 |
| qol female humans | #48 |
| physical examinations | #48 |
| neck radiotherapy | #48 |
| nausea day | #48 |
| oxybutynin | #48 |
| genitourinary symptoms | #48 |
| menopause life | #48 |
| sham arm | #49 |
| chemotherapy nausea | #49 |
| flie | #49 |
| female cancer | #49 |
| patientclinician communication | #49 |
| receiving androgen | #50 |
| antiserotonergic | #50 |
| mastectomy pain | #50 |
| pain numbness | #50 |
| time conclusions | #50 |
| cancer survivors fatigue | #50 |
| replens | #50 |
| placebos randomized | #50 |
| cachexia | #50 |
| models stage | #50 |
| hot flashes hfs | #50 |
| effective treating | #51 |
| vomiting chemotherapy | #51 |
| cisplatin humans | #51 |
| blinded placebo | #51 |
| patients cancer pain | #51 |
| patients 8 weeks | #51 |
| transdermal testosterone | #51 |
| genitourinary syndrome | #51 |
| regional hypothermia | #51 |
| treatment adt | #52 |
| management chemotherapy | #52 |
| trastuzumab orr | #52 |
| differences treatment arms | #52 |
| risk bone loss | #52 |
| metaanalysis incidence | #52 |
| 80k | #52 |
| aged orchiectomy | #52 |
| black cohosh | #52 |
| receiving radiotherapy | #53 |
| purposepatients | #53 |
| toxicity time | #53 |
| nervous peripheral | #53 |
| tamoxifen antineoplastic agents | #53 |
| cancer venous | #53 |
| control nausea | #53 |
| potential adjuvant | #53 |
| 20 data | #54 |
| blood testing | #54 |
| severe hot | #54 |
| standard placebo | #54 |
| pilot trial | #54 |
| life topic humans | #54 |
| treatment months | #54 |
| double‐blind trial | #54 |
| recurrent disease | #54 |
| levetiracetam treatment | #54 |
| antiemetics antineoplastic | #54 |
| acupuncture cancer | #55 |
| scalp cooling | #55 |
| serial levels | #55 |
| cancerdirected therapy | #55 |
| bupropion treatment | #55 |
| symptoms therapy | #55 |
| cachexia therapy | #55 |
| treatment tobacco dependence | #55 |
| fatigue inventory | #55 |
| undergoing chemotherapy | #56 |
| adjuvant endocrine treatment | #56 |
| symptoms hot | #56 |
| carboplatin female humans | #56 |
| time placebo | #56 |
| diseases antineoplastic | #56 |
| xaliproden | #56 |
| 12 courses | #57 |
| benefit scale | #57 |
| recurrence symptoms | #57 |
| adjuvant colon | #57 |
| common terminology | #57 |
| placebo solution | #57 |
| quality life questionnaire | #58 |
| cachexia weight loss | #58 |
| compared oral | #58 |
| pain peripheral | #58 |
| skin dermatitis | #58 |
| topical gel | #58 |
| major bleeding enoxaparin | #58 |
| points placebo | #58 |
| ferric gluconate | #58 |
| limited degree | #58 |
| completion adjuvant chemotherapy | #58 |
| undergoing treatment | #58 |
| coprescription | #59 |
| weight appetite | #59 |
| ocular irritation | #59 |
| placebo citalopram | #59 |
| safety rivaroxaban | #59 |
| chemotherapyinduced nausea | #59 |
| data understanding | #59 |
| osteopaenia | #59 |
| patients hec | #59 |
| chemotherapy cognitive | #59 |
| study medication | #60 |
| anticonvulsants antidepressive | #60 |
| serotonergic effects | #60 |
| patients mirtazapine | #60 |
| hb baseline | #60 |
| colonoscopically | #60 |
| cancer patients study | #61 |
| 3 randomized | #61 |
| bleomycin patients | #61 |
| standard dosing | #61 |
| emla cream | #61 |
| 1 week treatment | #61 |
| doubleblind | #61 |
| tamoxifen metabolism | #61 |
| lymphedema women | #61 |
| topic surveys life | #61 |
| paroxetine fluoxetine | #61 |
| sensitivity individuals | #61 |
| pipn | #61 |
| caregivers pain | #61 |
| dermatological toxicities | #62 |
| pain bleeding | #62 |
| efficacy fluoxetine | #62 |
| induced taste | #62 |
| ocular toxicity | #62 |
| recurrent disease patients | #62 |
| chemotherapy dose | #62 |
| venlafaxine placebo | #62 |
| fluorouracil induced | #62 |
| alpha weight | #62 |
| integrative oncology | #63 |
| patients disease recurrence | #63 |
| ncictc | #63 |
| anorexia patients | #63 |
| antibodies monoclonal carcinoma | #63 |
| prior chemotherapy regimen | #63 |
| 105 months | #63 |
| aged placebos | #63 |
| lessen | #63 |
| alleviate | #64 |
| rivaroxaban enoxaparin | #64 |
| treatment chemotherapy | #64 |
| cyclohexanols | #64 |
| versus placebo | #64 |
| carboplatin oxaliplatin | #64 |
| cyproheptadine | #64 |
| bupropion nicotine | #64 |
| incidence rash | #64 |
| patients cancer types | #64 |
| improvement sexual function | #64 |
| painful peripheral neuropathy | #64 |
| aged nausea | #64 |
| allelic variability | #64 |
| survivorship issues | #65 |
| appetite weight loss | #65 |
| administration paclitaxel | #65 |
| patients comparisons | #65 |
| efficacy toxicity | #65 |
| patients minocycline | #65 |
| validated patient | #65 |
| 75 daily | #65 |
| dalteparin treatment | #65 |
| agents double | #65 |
| 4 weeks week | #65 |
| acetate therapy | #66 |
| placebo months | #66 |
| study gabapentin | #66 |
| oncology clinical | #66 |
| nicotine nasal | #66 |
| food intake patients | #66 |
| diseases neoplasms | #66 |
| life topic | #67 |
| clinician training | #67 |
| qol fatigue | #67 |
| target doses | #67 |
| estrogen suppression | #67 |
| baseline study | #68 |
| subcutaneous dalteparin | #68 |
| hormonal therapies | #68 |
| prevention smoking | #68 |
| induced dermatitis | #68 |
| pilocarpine treatment | #68 |
| cachexia weight | #68 |
| patients randomized | #68 |
| 46 95 | #68 |
| hec | #68 |
| vasomotor symptoms women | #69 |
| skin surveys | #69 |
| ongoing loss | #69 |
| fsfi score | #69 |
| debilitating | #69 |
| gained weight | #69 |
| surgery cancer | #70 |
| multifactorial syndrome | #70 |
| item score | #70 |
| nonsignificant trends | #70 |
| induced ovarian | #70 |
| women ais | #70 |
| chemotherapy anemia | #70 |
| development severity | #70 |
| incidence severity | #71 |
| major bleeding apixaban | #71 |
| life referral | #71 |
| anthrapyrazole | #71 |
| infliximab combination | #71 |
| weight compared | #71 |
| week percentage | #71 |
| humans lignans | #72 |
| cisplatin treated | #72 |
| effects ginseng | #72 |
| systemic retinoids | #72 |
| trials planning | #72 |
| patients pilot | #72 |
| oral drug administration | #72 |
| placebo patches | #72 |
| prospective pilot trial | #73 |
| chemotherapy supportive | #73 |
| placebo | #73 |
| chemoprevention trial | #73 |
| stage primary | #73 |
| weeks placebo | #73 |
| ginseng treatment | #73 |
| ergotamines | #73 |
| trial evaluating | #74 |
| anemia antineoplastic | #74 |
| fractional co2 laser | #74 |
| women estrogen therapy | #74 |
| qli | #74 |
| receiving chemotherapy | #74 |
| rcts systematic reviews | #74 |
| dronabinol | #74 |
| rash | #74 |
| cancerrelated fatigue crf | #75 |
| 353 patients | #75 |
| prevention | #75 |
| nervous diseases | #75 |
| acid supplement | #75 |
| weekly arm | #76 |
| cycles cycle | #76 |
| acute skin | #76 |
| inhibitors tamoxifen | #76 |
| blind clinical | #76 |
| tamoxifen postmenopausal | #77 |
| anorexia weight loss | #77 |
| hospice staff | #77 |
| breast cancer paclitaxel | #77 |
| cancer randomized | #77 |
| alliance patients | #77 |
| anemia darbepoetin | #77 |
| 95 01 | #77 |
| dose 90 | #77 |
| week p005 | #77 |
| 3 arm | #78 |
| tamoxifen postmenopausal women | #78 |
| female humans insurance | #78 |
| patients zoledronic acid | #78 |
| values data | #78 |
| symptoms sensitivity | #79 |
| pain syndrome | #79 |
| therapy antineoplastic | #79 |
| vte recurrence | #79 |
| surgery year | #79 |
| serum concentrations infliximab | #79 |
| patients darbepoetin alfa | #79 |
| efficacy lamotrigine | #79 |
| week schedule | #79 |
| isoflavone supplements | #80 |
| foot syndrome | #80 |
| zoledronic acid treatment | #80 |
| time mastectomy | #80 |
| vomiting antiemetics | #80 |
| week 4 | #80 |
| life phase iii | #80 |
| oral oncology | #81 |
| study march | #81 |
| period crossover | #81 |
| patients treatment arms | #81 |
| guideline recommendation | #81 |
| lowmolecular weight heparin | #81 |
| patient qol | #81 |
| paroxetine patients | #82 |
| greater weight gain | #82 |
| bupropion smoking | #82 |
| backgroundchemotherapy | #82 |
| standard clinical | #82 |
| suggestion | #82 |
| recommendations article | #83 |
| trpv1 trpa1 | #83 |
| day weeks | #83 |
| orbital stability | #83 |
| patients participating | #83 |
| trpm8 trpa1 | #84 |
| cinv patients | #84 |
| method female | #84 |
| zinc sulfate | #84 |
| cancer weight | #85 |
| neoplasm metastasis neoplasms | #85 |
| systematic reviews rcts | #85 |
| ice pack | #85 |
| mayo clinic | #86 |
| receiving placebo | #86 |
| cryotherapy patients | #86 |
| treatment nicotine dependence | #86 |
| ttf survival | #86 |
| serum hepcidin levels | #87 |
| week 5 | #87 |
| therapyinduced | #87 |
| life cachexia | #87 |
| baseline arms | #87 |
| incidence osteoporosis | #87 |
| methodspatients | #87 |
| nicotine nasal spray | #87 |
| primary symptom | #87 |
| frequency severity | #87 |
| pilot study safety | #87 |
| acp documentation | #88 |
| anecdotal reports | #88 |
| integrative therapies | #88 |
| iu daily | #89 |
| cancer vte | #89 |
| putative mediator | #89 |
| treatment fatigue | #89 |
| outcome venlafaxine | #90 |
| clinical oncology asco | #90 |
| morphine pharmacokinetics | #90 |
| male chemotherapy | #90 |
| iii efficacy | #91 |
| delayed cinv | #91 |
| arm treatment | #91 |
| symptoms including | #91 |
| tolerated patients | #91 |
| endoxifen concentrations | #91 |
| scores placebo | #91 |
| ncorp | #91 |
| patients paroxetine | #92 |
| nerve pain | #92 |
| completion chemotherapy | #92 |
| patients upfront | #92 |
| trials treatment | #92 |
| cisplatin oxaliplatin | #92 |
| ameliorating | #93 |
| apixaban dose | #94 |
| quiet stance | #94 |
| 1 primary | #94 |
| neoplasms quality life | #94 |
| arm 3 | #94 |
| anemic patients | #94 |
| mometasone | #94 |
| questionnaires survival | #94 |
| breast cancer survivors | #94 |
| duloxetine hydrochloride | #94 |
| patients appetite | #95 |
| cancerrelated pain | #95 |
| common symptoms | #95 |
| alfa patients | #95 |
| 0 10 | #96 |
| patients completion | #96 |
| udi | #96 |
| prevention management | #96 |
| hlaa2 patients | #96 |
| mayo clinic rochester | #96 |
| failure chemotherapy | #96 |
| ccop | #96 |
| pyrexia | #97 |
| oral mucositis patients | #97 |
| adjuvant therapy survival | #97 |
| paclitaxel patient | #97 |
| acute vte | #97 |
| alleviating | #98 |
| painful area | #98 |
| treatment tolerability | #98 |
| crnmb | #98 |
| preliminary data | #98 |
| text review | #98 |
| completed study | #98 |
| identical placebo | #98 |
| 15 points | #98 |
| agents paclitaxel | #98 |
| topic cyclophosphamide | #99 |
| difference incidence | #99 |
| fatigue insomnia | #99 |
| 5fluorouracil oxaliplatin | #99 |
| patient medical | #99 |
| pregnadienediols | #99 |
| 5fu leucovorin | #99 |
| bcca | #99 |
| 4 weeks baseline | #99 |
| patient questionnaires | #99 |
| induced esophagitis | #99 |
| clinician communication | #100 |
| 10 doses | #100 |
| survival nsclc | #100 |
| male sex factors | #100 |
| oncology outpatients | #100 |
| qlq | #100 |
| antineoplastic agents life | #101 |
| lung cancer chemoprevention | #101 |
| postresection | #101 |
| 5 based | #101 |
| 275 patients | #101 |
| humans life | #101 |
| nortriptyline | #101 |
| lidocaine lidocaine | #101 |
| oncology clinicians | #101 |
| oncology asco | #101 |
| methods trial | #102 |
| placebo 1 year | #102 |
| reported effects | #103 |
| variance clinical trials | #103 |
| quality life data | #104 |
| purposeprevious | #104 |
| patients anorexia | #104 |
| 3106 | #104 |
| races ethnicities | #104 |
| diseases treatment | #105 |
| 12 24 months | #105 |
| phytogenic clinical trials | #105 |
| leap | #105 |
| chemotherapy cycle | #105 |
| patients 150 | #105 |
| infusion site | #106 |
| months relapse | #106 |
| dalteparin patients | #106 |
| compounds oxaliplatin | #106 |
| trial studies | #106 |
| dfmo | #106 |
| nutritional determinants | #106 |
| stool samples patients | #106 |
| neuropathy | #106 |
| versus dexamethasone | #107 |
| pain intensity ratings | #107 |
| humans menopause | #107 |
| cycle cycles | #107 |
| valeriana officinalis | #107 |
| urogenital diseases | #107 |
| anastrozole letrozole | #107 |
| epoetin alfa patients | #107 |
| breast cancer tamoxifen | #108 |
| week study | #108 |
| life topic severity | #108 |
| relapse prevention | #108 |
| time toxicity | #108 |
| women experience | #108 |
| mouthwash | #109 |
| patients guideline | #109 |
| treatment cancer pain | #109 |
| women vasomotor symptoms | #109 |
| levocarnitine | #109 |
| female urogenital | #109 |
| strong prognostic factor | #109 |
| oxaliplatin therapy | #110 |
| clinic rochester | #110 |
| patients cancer treatment | #110 |
| combined paclitaxel | #110 |
| life adverse events | #110 |
| vomiting adult | #111 |
| egfr inhibitor | #111 |
| cmf chemotherapy | #111 |
| prevention bone loss | #111 |
| dosing schedules | #112 |
| function suppression | #112 |
| insomnia pain | #112 |
| treatment arms patients | #113 |
| colorectal neoplasia | #113 |
| –iii | #113 |
| vaginal diseases | #113 |
| agents hormonal | #113 |
| reassess | #113 |
| vestibulitis | #113 |
| patients arms | #113 |
| adverse events ctcae | #113 |
| functional iron deficiency | #113 |
| visits patient | #113 |
| diseases breast | #114 |
| cachexia humans | #114 |
| single nucleotide variants | #114 |
| acitretin | #114 |
| patients olanzapine | #114 |
| alopecia patients | #114 |
| months 3 | #114 |
| hfsd | #114 |
| qol patient | #114 |
| therapy induced | #114 |
| dietary lignans | #114 |
| laser therapy lasers | #115 |
| letrozole tamoxifen | #115 |
| combination nicotine | #115 |
| patients anthracycline | #115 |
| crci | #115 |
| rivaroxaban venous | #115 |
| studies randomized | #115 |
| placebo postmenopausal women | #116 |
| treatment arm | #116 |
| 2007 guidelines | #117 |
| nk1 receptor antagonist | #117 |
| oral factor | #117 |
| symptoms chemotherapy | #117 |
| patients peripheral neuropathy | #117 |
| induction ornithine decarboxylase | #117 |
| appetite stimulant | #118 |
| oral antineoplastic agents | #118 |
| recurrence diagnosis | #118 |
| diseases pain | #119 |
| trpa1 trpv1 | #119 |
| preventive therapies | #119 |
| trials conducted | #119 |
| noradrenaline reuptake | #119 |
| 3915 | #119 |
| patients weekly paclitaxel | #119 |
| original report | #120 |
| participants arms | #120 |
| resultswhile | #120 |
| olanzapine placebo | #120 |
| 750 day | #120 |
| treatment weeks | #120 |
| clinical histories | #120 |
| definition classification | #120 |
| placebo double | #121 |
| induced ocular | #121 |
| fullerton | #121 |
| untoward | #121 |
| patients cancers | #121 |
| hormonal agents | #121 |
| postmenopausal postmenopause | #121 |
| oxaliplatin folfox | #122 |
| cancer multiple | #122 |
| nervous agents | #122 |
| stable dose | #123 |
| skin pain | #123 |
| objective review | #123 |
| rolapitant | #123 |
| netupitant | #123 |
| surgery analysis | #123 |
| acute oral | #123 |
| weeks 4 | #123 |
| cancer quality | #123 |
| pros baseline | #124 |
| patients diploid tumors | #124 |
| isoflavones genistein | #124 |
| treatment letrozole | #124 |
| rivaroxaban compared | #124 |
| survivors breast cancer | #124 |
| neuropathic pain patients | #124 |
| 1 month patients | #125 |
| week dose | #125 |
| 90 dose | #125 |
| factors odds | #126 |
| neurotoxic agents | #126 |
| resultsfour | #126 |
| recurrent adenomas | #127 |
| fsfi | #127 |
| diagnosis metastatic disease | #127 |
| patients physicians | #127 |
| promising agents | #127 |
| hormonal breast | #127 |
| anorexia | #127 |
| genetic quality | #127 |
| alfa erythropoietin | #128 |
| belladonna | #128 |
| weight concerns | #128 |
| arms patients | #128 |
| cancerassociated vte | #128 |
| uncommon variants | #128 |
| resultsforty | #129 |
| postural instability | #129 |
| 5 leucovorin | #129 |
| clinical trial patients | #129 |
| neoplasms quality | #129 |
| agents neoplasms | #129 |
| vomiting cinv | #129 |
| problem patients | #130 |
| control arms | #130 |
| patientreported outcome | #130 |
| serum baseline | #130 |
| bmd tscore | #131 |
| 150 iu | #131 |
| function fsfi | #131 |
| treatment toxicities | #131 |
| prognostic variables | #131 |
| cancer fatigue | #131 |
| pilot data | #132 |
| cancerrelated symptoms | #132 |
| onycholysis | #132 |
| efficacy vitamin | #132 |
| neurotoxicity syndromes | #132 |
| relapse smoking | #132 |
| assessable | #133 |
| topical treatment | #133 |
| progress report | #133 |
| cachexia patients | #133 |
| ganglion block | #134 |
| endodermal sinus tumor | #134 |
| ginseng panax | #134 |
| symptom control | #134 |
| 5 placebo | #134 |
| cold hyperalgesia | #135 |
| bmd postmenopausal women | #135 |
| common adverse effects | #135 |
| cancers patients | #135 |
| toxt | #135 |
| 150 women | #135 |
| agents generation | #135 |
| chemotherapy 5 | #135 |
| symptomatic benefit | #136 |
| npy levels | #136 |
| weekly therapy | #136 |
| patientlevel pooled analysis | #136 |
| bothersome | #136 |
| painful neuropathy | #136 |
| poor qol | #137 |
| percentage reduction | #137 |
| life physical function | #137 |
| study trials | #137 |
| intrapatient | #137 |
| agents bortezomib | #137 |
| substantial benefit | #137 |
| stage cancer | #137 |
| severe fatigue | #137 |
| grade stage | #138 |
| zoledronic | #138 |
| accrued | #138 |
| hfs patients | #138 |
| advanced lung | #139 |
| underwent mastectomy | #139 |
| therapy breast | #139 |
| chemoprevention studies | #139 |
| factbr | #139 |
| incurable cancer | #139 |
| breast chest wall | #140 |
| patients advanced cancer | #140 |
| liquid suspension | #140 |
| oxaliplatin chemotherapy | #141 |
| paclitaxel weekly | #141 |
| patients placebo | #141 |
| financial concerns | #142 |
| disclose | #142 |
| patients levetiracetam | #142 |
| tamoxifen placebo | #142 |
| protocols breast | #143 |
| fluorouracil 5 | #143 |
| medicine clinical | #143 |
| snv | #144 |
| european organisation | #144 |
| preoperative magnetic | #144 |
| allopurinol placebo | #144 |
| eortc qlq | #145 |
| fluorouracil humans | #145 |
| debilitating condition | #145 |
| evidence loe | #145 |
| agents bone | #145 |
| vaginal cytology | #145 |
| eligible women | #146 |
| surgery type | #146 |
| dietary counselling | #148 |
| backgroundwomen | #148 |
| volatile plants | #148 |
| oral olanzapine | #148 |
| numeracy | #149 |
| desipramine treatment | #149 |
| adjuvant systemic | #150 |
| n201 | #150 |
| predict recurrence | #150 |
| venlafaxine treatment | #150 |
| prior chemotherapy regimens | #151 |
| response rate survival | #151 |
| patients receive | #151 |
| intravenous access | #151 |
| methodologic | #151 |
| women estrogen | #151 |
| multinational association | #151 |
| daily diaries | #151 |
| balance impairments | #152 |
| ovarian function suppression | #152 |
| tumor recurrence patients | #152 |
| groups symptoms | #152 |
| oral mucositis | #152 |
| caa patients | #152 |
| 14 week | #152 |
| cramping | #153 |
| 80 dose | #154 |
| carboplatin trastuzumab | #154 |
| cindices | #155 |
| adjuvant systemic therapy | #155 |
| dermatomes | #155 |
| integrated palliative | #156 |
| combination chemotherapy cisplatin | #156 |
| infliximab 5 | #156 |
| fsds | #156 |
| methods randomized | #156 |
| mangafodipir | #156 |
| vinblastine bleomycin | #156 |
| life randomized | #156 |
| hyperalimentation | #156 |
| racially diverse | #157 |
| gait stability | #157 |
| women breast carcinoma | #157 |
| breast cancer trastuzumab | #157 |
| common terminology criteria | #157 |
| oncology study | #158 |
| study initiation | #158 |
| arm versus | #158 |
| vomiting nausea | #158 |
| physicians patients | #159 |
| iii clinical | #159 |
| survivors colorectal | #159 |
| weekly doses | #159 |
| induced nausea | #159 |
| chemotherapy breast cancer | #159 |
| chemotherapy quality | #160 |
| paclitaxel taxol | #160 |
| cancer pain patients | #160 |
| stellate ganglion | #160 |
| european organisation treatment | #160 |
| treatment postmenopausal women | #160 |
| major problem | #160 |
| estrogen depletion | #161 |
| validity life | #161 |
| women hormone therapy | #161 |
| risk infertility | #161 |
| data efficacy | #163 |
| efficacy women | #164 |
| neoplasms pain | #164 |
| cisplatin vinblastine | #165 |
| mometasone furoate | #165 |
| current project | #165 |
| pharmacokinetic analyses | #166 |
| patients 1 month | #166 |
| skeletal events | #166 |
| illness surveys questionnaires | #167 |
| osteoporosis prevention | #167 |
| life topic surveys | #167 |
| anthracycline | #168 |
| chemotherapy‐induced nausea | #168 |
| chemotherapy groups | #168 |
| direct inhibitors | #168 |
| dosing patients | #169 |
| patients adenomas | #169 |
| menopause symptoms | #169 |
| 432 patients | #169 |
| patients data | #169 |
| ixabepilone | #170 |
| management chronic pain | #170 |
| prospective clinical trials | #171 |
| rochester | #171 |
| daily placebo | #171 |
| global quality | #171 |
| disease cmt | #171 |
| prestudy | #172 |
| chemotherapy completion | #172 |
| label pilot | #173 |
| hot flushes | #173 |
| placebos | #173 |
| judicious | #173 |
| lamotrigine placebo | #173 |
| impaired balance | #173 |
| 1 year therapy | #173 |
| pilot feasibility study | #174 |
| prospective evaluation | #174 |
| phase iii trial | #174 |
| diarrhoea patients | #174 |
| methylphenidate placebo | #174 |
| cancer cancer treatment | #175 |
| physician order | #175 |
| male breast cancer | #175 |
| decreased quality | #175 |
| arthralgia | #175 |
| baseline weight | #176 |
| life assessments | #177 |
| weeks women | #177 |
| treatment 14 | #177 |
| thirty percent | #178 |
| bodyweights | #178 |
| life baseline | #179 |
| expected benefits | #179 |
| treatmentrelated toxicity | #179 |
| bolus fluorouracil | #179 |
| bothered | #179 |
| sufferer | #180 |
| phase evaluation | #181 |
| darbepoetin | #182 |
| escalations | #182 |
| gain weight | #182 |
| oxaliplatin 5fluorouracil | #182 |
| ginseng | #182 |
| toxicity criteria | #183 |
| organisation treatment | #183 |
| peri postmenopausal women | #183 |
| infliximab antibodies | #184 |
| acetyll | #184 |
| prognostic criteria | #184 |
| tube primary | #184 |
| biostatisticians | #184 |
| received oral | #184 |
| effects chemotherapy | #184 |
| acute pain | #184 |
| white smokers | #184 |
| reported sexual | #185 |
| additional chemotherapy | #185 |
| outcome measures life | #185 |
| arm volume | #186 |
| cinv | #187 |
| treating | #187 |
| delayed nausea | #187 |
| patients drug | #187 |
| treatment 4 weeks | #187 |
| troublesome | #188 |
| strong prognostic | #188 |
| week follow | #188 |
| tamoxifen letrozole | #188 |
| reduction therapy | #188 |
| management breast cancer | #188 |
| adjuvant decision | #188 |
| lessened | #188 |
| neoplasia female humans | #189 |
| aching | #189 |
| oxaliplatin dose | #189 |
| placebo study | #190 |
| week 1 | #190 |
| protocol therapy | #190 |
| survivors breast | #190 |
| antiemetic regimens | #190 |
| aged nitriles | #190 |
| cancer cancer survivors | #191 |
| twentyfive patients | #191 |
| completed baseline | #191 |
| patients increases | #192 |
| toxicity patients | #192 |
| aches | #192 |
| aspirin incidence | #192 |
| fortysix patients | #192 |
| chronic lymphedema | #192 |
| treatment cancer patients | #192 |
| manuscript | #192 |
| humans isoflavones | #193 |
| cimicifuga racemosa | #193 |
| assigned receive | #193 |
| 25 women | #194 |
| effective agents | #194 |
| weekly trastuzumab | #194 |
| ornithine decarboxylase activity | #195 |
| 3 fatty | #195 |
| pain breast | #195 |
| weight loss patients | #195 |
| acids double | #196 |
| resultsdata | #196 |
| trial designs | #197 |
| pituitaryadrenal axis | #197 |
| palonosetron dexamethasone | #197 |
| postmenopausal patients | #198 |
| surveillance strategy | #198 |
| toxicity profiles | #198 |
| resultstwo | #198 |
| nicotine patch | #199 |
| culminates | #199 |
| organization treatment | #199 |
| women menopause | #199 |
| delayed emesis | #199 |
| patients letrozole | #199 |
| accent | #199 |
| percent reduction | #200 |
| adjuvant interferon | #200 |
| oral glutamine | #201 |
| menopause premature | #201 |
| imiquimod | #202 |
| greater 5 | #202 |
| treatment bmd | #202 |
| treatment week | #202 |
| item responses | #202 |
| primary goal | #202 |
| cancer anemia | #203 |
| bmd postmenopausal | #203 |
| hormonal treatments | #203 |
| plo | #204 |
| treated placebo | #204 |
| composition cachexia | #204 |
| pelvic radiation therapy | #204 |
| induced oral | #205 |
| udi6 | #206 |
| chemotherapy drugs | #206 |
| unwilling | #206 |
| dalteparin | #206 |
| placebo 8 | #206 |
| leucovorin patients | #206 |
| heat hyperalgesia | #207 |
| pharmacologic interventions | #207 |
| mice cisplatin | #207 |
| 4 8 weeks | #208 |
| humans leucovorin | #208 |
| reduced food intake | #208 |
| incurable | #208 |
| hands patients | #209 |
| 5 daily | #209 |
| chemotherapy | #209 |
| estrogen receptor modulators | #210 |
| lamotrigine | #210 |
| controlled evaluation | #210 |
| methotrexate 5 | #210 |
| gel application | #211 |
| initials | #212 |
| diagnosis recurrence | #212 |
| regionally advanced | #212 |
| methodsthis | #212 |
| vomiting patients | #212 |
| docetaxel cyclophosphamide | #213 |
| trial vitamin | #213 |
| charcotmarietooth disease | #213 |
| placebo 6 weeks | #214 |
| patient weight | #214 |
| dexamethasone control | #214 |
| oncology practices | #214 |
| december patients | #215 |
| oxaliplatin | #215 |
| 15 minutes | #215 |
| antiemetic therapy | #215 |
| olanzapine 5 | #215 |
| neoplasms cross | #216 |
| prostate cancer survivors | #216 |
| women tamoxifen | #217 |
| patients duloxetine | #217 |
| gabapentin humans | #217 |
| tamoxifen users | #217 |
| women breast cancer | #217 |
| hot | #218 |
| current management | #218 |
| 10 daily | #218 |
| placebo weeks | #218 |
| aprepitant | #218 |
| —reply | #218 |
| nonmajor | #218 |
| purposethe purpose | #218 |
| transdermal fentanyl | #219 |
| palliative oncology | #219 |
| life humans | #219 |
| nmscs | #219 |
| nonabsorbable | #220 |
| sublingual administration | #220 |
| sexual symptoms | #220 |
| moderate pain | #221 |
| painful peripheral | #221 |
| ornithine decarboxylase odc | #221 |
| society clinical oncology | #221 |
| pregabalin patients | #221 |
| neoplasms palliative | #222 |
| methylphenidate modafinil | #222 |
| lymphedema patients | #222 |
| treatment postmenopausal | #222 |
| primary breast cancer | #222 |
| prospective study women | #222 |
| ginkgo biloba egb | #222 |
| relieving | #222 |
| furoate | #223 |
| randomized doubleblind study | #223 |
| prevention patients | #224 |
| quinquefolius | #225 |
| 99 months | #225 |
| computerized physician | #225 |
| vaginal estrogen | #226 |
| agent patients | #226 |
| partial mastectomy | #226 |
| turmoil | #227 |
| bupropion | #227 |
| pain presence | #227 |
| clinical situation | #228 |
| trial | #228 |
| secondary endpoint | #229 |
| 200 iu | #229 |
| nondiploid | #229 |
| editorials | #230 |
| anthracycline cardiotoxicity | #230 |
| akt inhibitor | #230 |
| hospice patients | #230 |
| physicians quality | #230 |
| antidepressive | #230 |
| cancer recommendations | #230 |
| placebo 10 | #230 |
| eating disorders humans | #230 |
| rashes | #231 |
| vitamin effects | #231 |
| based adjuvant | #231 |
| lightheadedness | #232 |
| conclusionsthe | #232 |
| cachexia cytokines | #232 |
| time study | #232 |
| handfoot syndrome | #232 |
| fluoxetine paroxetine | #233 |
| nonpharmacologic | #233 |
| women hot | #234 |
| 4 doses | #234 |
| acute symptoms | #234 |
| thirty women | #234 |
| treatment vte | #234 |
| day response | #235 |
| relieve | #235 |
| tamoxifen neoplasms chemotherapy | #235 |
| sucralfate | #235 |
| arm 95 | #235 |
| 375 day | #235 |
| effective treatments | #236 |
| placebo gel | #237 |
| premenopausal patients | #237 |
| postoperative monitoring | #238 |
| survivors treatment | #238 |
| letrozole patients | #238 |
| incidence grade | #238 |
| antiemetics | #238 |
| flash | #238 |
| chemotherapy placebo | #239 |
| overexpressing metastatic | #239 |
| adjuvant 5 | #239 |
| oncology clinic | #239 |
| nonpharmacologic interventions | #239 |
| methodswomen | #239 |
| menopause middle | #239 |
| improved bioavailability | #239 |
| cachexia syndrome | #240 |
| treatment breast cancer | #240 |
| neoadjuvant therapy surgery | #240 |
| oral complications | #240 |
| independent tests | #241 |
| participants randomized | #242 |
| stinging | #242 |
| small doses | #243 |
| aged paclitaxel | #243 |
| tetracycline | #244 |
| epoetin alfa | #245 |
| 3 arms | #245 |
| appetite stimulants | #246 |
| common practice | #246 |
| adjuvant oxaliplatin | #246 |
| efficacy placebo | #247 |
| mouthwashes | #248 |
| cachexia cancer | #248 |
| 800 iu | #249 |
| dysgeusia | #249 |
| item scores | #250 |
| randomized sham | #250 |
| loss bmd | #250 |
| survivors adult | #250 |
| 689 | #251 |
| major problems | #251 |
| patients physical | #251 |
| coasting | #252 |
| topic vitamin | #252 |
| menopause women | #252 |
| primary point | #253 |
| armodafinil | #253 |
| randomised studies | #253 |
| moderate degree | #254 |
| average intensity | #254 |
| nasal spray | #254 |
| recurrence registries | #255 |
| chemotherapy breast | #255 |
| longitudinal followup | #256 |
| prospective clinical | #256 |
| cancer treatment | #257 |
| therapy women | #257 |
| neoplasms randomized | #257 |
| antidepressant | #257 |
| women treated | #258 |
| new therapeutic approaches | #258 |
| pretreatment levels | #258 |
| dyspareunia | #258 |
| hydrochloride | #259 |
| rigors | #259 |
| inhibitors treatment | #260 |
| opioid doseresponse relationship | #260 |
| tube cancer | #260 |
| common problem | #261 |
| 1 baseline | #261 |
| repeated measures | #261 |
| patients cancer | #261 |
| patients ovarian cancer | #262 |
| citalopram treatment | #262 |
| chronic post | #262 |
| dosage levels | #263 |
| decision framework | #263 |
| months treatment | #263 |
| management options | #263 |
| hematinics | #264 |
| treatment oxaliplatin | #264 |
| duloxetine placebo | #264 |
| phytogenic | #264 |
| recommendations quality | #265 |
| outcome administration | #265 |
| treatmentrelated deaths | #266 |
| preoperative mri | #266 |
| substantiation | #267 |
| surgery adjuvant | #267 |
| individual items | #267 |
| placebo 8 weeks | #267 |
| treatment cancer | #267 |
| paresthesia | #267 |
| impact quality | #268 |
| adult cancer survivors | #268 |
| 208 patients | #269 |
| patients rash | #270 |
| nausea | #270 |
| signaled | #270 |
| ginkgo biloba | #270 |
| estrogen antagonists | #271 |
| moderate correlations | #271 |
| 80 90 | #271 |
| patients octreotide | #271 |
| performance status patients | #272 |
| control trials | #272 |
| treatment 95 | #272 |
| weekly | #272 |
| score baseline | #272 |
| bridged ring | #272 |
| distressing | #272 |
| dna test | #272 |
| abstinence rates | #273 |
| placebo‐controlled trial | #273 |
| sham treatment | #274 |
| dryness | #274 |
| oncology clinical trials | #274 |
| valeriana | #275 |
| induced cisplatin | #275 |
| gross disease | #275 |
| patients caa | #276 |
| chemoprevention trials | #277 |
| treatment breast | #278 |
| perspiration | #278 |
| prominent | #279 |
| cimicifuga | #279 |
| therapeutic options | #279 |
| biomarkers disease humans | #279 |
| patients hospice | #279 |
| patients symptoms | #279 |
| patients frequency | #280 |
| breast cancer outcomes | #280 |
| cartilage patients | #280 |
| individual patient | #280 |
| cholinergic antagonists | #280 |
| doxorubicin cyclophosphamide | #281 |
| zoledronic acid patients | #281 |
| psychometric testing | #281 |
| antidepressive agents | #282 |
| chamomile | #282 |
| stage colon | #282 |
| women effects | #284 |
| greater severity | #284 |
| completed questionnaires | #284 |
| gabapentin treatment | #285 |
| smoking abstinence | #285 |
| fatigue crf | #286 |
| early discontinuation | #286 |
| paps | #287 |
| acid adult | #287 |
| weeks patients | #287 |
| symptoms function | #287 |
| colorectal lung | #287 |
| function quality | #287 |
| female hormone | #287 |
| hot flush | #288 |
| aromatase inhibitor therapy | #288 |
| life survival | #290 |
| eligible patients | #291 |
| common symptom | #292 |
| qualitative approach | #292 |
| treatment target | #292 |
| discouraged | #292 |
| clinical trial participation | #292 |
| mucositis oral | #293 |
| cbdca | #294 |
| pain symptoms | #294 |
| 1636 | #294 |
| weight gain patients | #294 |
| vinca alkaloids | #295 |
| monographs | #295 |
| citalopram | #295 |
| bone loss patients | #295 |
| testosterone supplementation | #295 |
| toxicity evaluation | #296 |
| primary peritoneal cancer | #297 |
| patients entered | #298 |
| aspirin placebo | #298 |
| questionnaires treatment | #298 |
| neoplasms cyclophosphamide | #299 |
| feet | #299 |
| peripheral nervous | #299 |
| hypothetical scenarios | #300 |
| radiation dermatitis | #300 |
| inhibitors ais | #300 |
| treated combination | #301 |
| shooting | #301 |
| octreotide | #302 |
| survival trials | #302 |
| nogalamycin | #302 |
| acute neurotoxicity | #303 |
| treatment serum | #303 |
| stage grade | #303 |
| subscale scores | #304 |
| nausea vomiting | #304 |
| symptoms pain | #304 |
| prime time | #305 |
| schedule female | #305 |
| complementary therapies | #305 |
| placebo groups | #305 |
| prospective clinical trial | #305 |
| global quality life | #306 |
| factg | #306 |
| shortread | #307 |
| placebo treatment | #307 |
| aromatase inhibitor | #307 |
| inflammatory breast cancer | #307 |
| prochlorperazine | #307 |
| drug embryo | #308 |
| apixaban | #308 |
| aged cancer | #308 |
| neoplasms chemotherapy | #308 |
| darbepoetin alfa | #309 |
| studies double | #310 |
| zoledronic acid | #310 |
| cancer receiving | #311 |
| riskstratification | #311 |
| individual subject | #311 |
| lung docetaxel | #311 |
| advanced cancer | #311 |
| epoetin | #312 |
| testosterone placebo | #312 |
| placebo‐controlled | #312 |
| musculoskeletal symptoms | #313 |
| patients cycle | #313 |
| or10 | #314 |
| cancer adjuvant | #314 |
| syndrome aps | #314 |
| new primary | #315 |
| operative chemotherapy | #315 |
| article evidence | #316 |
| organoplatinum | #316 |
| symptoms breast | #317 |
| blinded | #317 |
| ambulatory patients | #317 |
| sesame oil | #317 |
| bfi | #317 |
| double‐blind | #317 |
| rivaroxaban patients | #318 |
| irox | #319 |
| efficacy treatment | #319 |
| informed decisions | #321 |
| dietary counseling | #322 |
| life differences | #322 |
| thromboembolism anticoagulants | #323 |
| glutamine humans | #324 |
| monthly intervals | #324 |
| smokers nicotine | #324 |
| preventing | #325 |
| nsclc chemotherapy | #326 |
| breast radiotherapy | #326 |
| compared baseline | #327 |
| titrate | #327 |
| patients ductal carcinoma | #327 |
| continuation phase | #328 |
| lymphedema | #329 |
| conducted evaluate | #329 |
| patients resected | #329 |
| vte cancer patients | #329 |
| oral nutritional supplements | #329 |
| antagonists female | #329 |
| treatment 1 year | #329 |
| potential efficacy | #330 |
| patients nasal | #330 |
| arms | #330 |
| future clinical trials | #330 |
| controlled clinical | #330 |
| polymerase inhibitor | #331 |
| diagnosed primary | #332 |
| lozenge | #332 |
| cancer ontario | #332 |
| placebo patients | #334 |
| patients daily | #334 |
| 80 anemia | #334 |
| time disease | #335 |
| paclitaxel therapy | #336 |
| ongoing clinical | #336 |
| relative benefits | #336 |
| pain scale | #336 |
| 128 patients | #336 |
| sublingual | #337 |
| 5 fluorouracil | #337 |
| adjuvant letrozole | #337 |
| surveillance guidelines | #338 |
| survival 5 years | #338 |
| discernible | #339 |
| order entry | #340 |
| flutamide | #340 |
| eligible participants | #341 |
| treatment proportion | #341 |
| patients 4 weeks | #341 |
| mastectomy radiotherapy | #341 |
| fallopian tube cancer | #342 |
| cancer cachexia | #342 |
| osteopenia osteoporosis | #342 |
| society clinical | #343 |
| tooth disease | #343 |
| diseases quality | #343 |
| pilot randomized | #344 |
| clinicians patients | #345 |
| skeletal neoplasms | #345 |
| epha5 | #345 |
| mk2206 | #346 |
| clinical problems | #346 |
| accruing | #346 |
| coumarin | #347 |
| adverse events groups | #347 |
| therapy pain | #347 |
| mucositis patients | #348 |
| antineoplastic therapy | #349 |
| sham acupuncture | #349 |
| adjuvant folfox | #350 |
| induced acute | #350 |
| vast majority | #350 |
| baseline quality | #350 |
| dose schedule | #351 |
| treatment citalopram | #351 |
| dehydroepiandrosterone dhea | #351 |
| study therapy | #352 |
| endodermal sinus | #353 |
| response letter | #353 |
| patientreported outcomes | #353 |
| paclitaxel | #353 |
| letrozole | #355 |
| cancer life | #355 |
| risedronate | #355 |
| pain baseline | #356 |
| vomiting | #359 |
| skin toxicities | #359 |
| adjuvant colonic | #359 |
| ductal situ carcinoma | #360 |
| clin oncol | #360 |
| wellknown | #360 |
| potential benefit | #360 |
| cryotherapy | #360 |
| diaries | #361 |
| began | #361 |
| pelvic radiation | #362 |
| direct oral | #362 |
| nonpharmacological | #363 |
| calculators | #363 |
| ovarian suppression | #363 |
| pain measures | #363 |
| cancer surveillance | #363 |
| flaxseed | #363 |
| local prognosis receptor | #365 |
| cddp | #365 |
| ovarian fallopian | #365 |
| docetaxel paclitaxel | #365 |
| completing | #365 |
| bioavailable testosterone | #366 |
| optimal frequency | #366 |
| pain cancer | #366 |
| patients delayed | #366 |
| management cancer | #366 |
| scalp | #367 |
| 5‐year | #368 |
| weeks study | #368 |
| scale 0 | #368 |
| scheduled | #369 |
| aged neoplasms | #369 |
| hrt risk | #370 |
| cancer received | #371 |
| skeletalrelated events | #371 |
| orally daily | #372 |
| gamma aminobutyric acid | #372 |
| 5fluorouracil 5fu | #373 |
| symptoms patients | #373 |
| skin toxicity | #373 |
| ovarian failure | #374 |
| ecogps | #374 |
| paclitaxel dose | #374 |
| irreversible damage | #374 |
| resected stage | #374 |
| clinical oncology | #374 |
| −005 | #375 |
| therapy based | #376 |
| women breast | #376 |
| decreasing | #376 |
| medroxyprogesterone acetate | #377 |
| blood test | #377 |
| assessable patients | #378 |
| polyneuropathy | #378 |
| week patients | #378 |
| drowsiness | #378 |
| humans specificity | #378 |
| nociceptors | #379 |
| national cancer institute | #380 |
| fura | #381 |
| loss skeletal | #381 |
| telerehabilitation | #381 |
| 4 treatment | #382 |
| organoplatinum compounds | #383 |
| unacceptable toxicity | #383 |
| leucovorin | #383 |
| disputes | #384 |
| function pain | #384 |
| target dose | #384 |
| adverse event | #384 |
| trials involving | #384 |
| patients capecitabine | #384 |
| 402 | #384 |
| leptin patients | #385 |
| conservation agents | #385 |
| 5fluorouracil leucovorin | #385 |
| fourths | #386 |
| density conservation | #386 |
| 2 treatment | #388 |
| androgendeprivation therapy | #389 |
| glutathione gsh | #390 |
| treatment women | #390 |
| advanced adenomas | #391 |
| sexual desire | #392 |
| aromatase inhibitors ais | #392 |
| adjuvant trials | #394 |
| dying patients | #394 |
| 4 weeks | #394 |
| early palliative | #395 |
| life breast | #396 |
| discontinuation rates | #396 |
| ring compounds | #397 |
| cytotoxics | #397 |
| humans mastectomy | #397 |
| performance score | #397 |
| olanzapine | #397 |
| paired tests | #398 |
| 1280 | #398 |
| patients randomly | #398 |
| life data | #399 |
| withdrew | #400 |
| chemotherapy colorectal | #400 |
| questionnaires treatment outcome | #400 |
| fatty acid supplementation | #400 |
| peripheral neurotoxicity | #400 |
| intramuscular | #400 |
| 8090 | #401 |
| 3 cohorts | #401 |
| estrogen receptors biomarkers | #401 |
| assigned | #401 |
| loe | #402 |
| entered | #402 |
| evidencebased | #402 |
| sadenosyllmethionine | #403 |
| acid female | #403 |
| female humans life | #403 |
| 5 weeks | #405 |
| female fluorouracil | #406 |
| baseline demographics | #406 |
| responding patients | #408 |
| cisplatin induced | #409 |
| keratolytic | #410 |
| patients 5fu | #411 |
| life aged | #411 |
| female hemorrhage humans | #412 |
| topic neoplasms | #412 |
| regimens patients | #414 |
| ornithine decarboxylase | #414 |
| pain qol | #415 |
| placebo 2 | #415 |
| based chemotherapy | #415 |
| oxaliplatin based | #415 |
| acetate | #415 |
| patient factors | #416 |
| carboplatin patients | #416 |
| oncology neoplasms | #416 |
| platinum agents | #417 |
| gabapentinoids | #417 |
| delayed | #417 |
| prospective pilot | #417 |
| receiving | #418 |
| nighttime sleep | #419 |
| adjuvant hormonal therapy | #419 |
| metastatic breast cancer | #419 |
| case series patients | #419 |
| 0 4 | #419 |
| antiemetic prophylaxis | #420 |
| tamoxifen women | #421 |
| controlled pilot | #421 |
| study entry | #421 |
| cancer purpose | #421 |
| tcl1a | #421 |
| fourth week | #422 |
| directed therapy | #422 |
| severities | #422 |
| selfreported symptoms | #422 |
| adequately | #423 |
| pyridones | #423 |
| arm 2 | #423 |
| 5 trials | #423 |
| neurophysiologic | #424 |
| tamoxifen | #425 |
| androgen ablation | #425 |
| anastrozole | #425 |
| ongoing clinical trials | #426 |
| complementary alternative | #426 |
| prevention vte | #427 |
| baseline 6 weeks | #427 |
| treating patients | #428 |
| gain adult | #428 |
| primary peritoneal | #428 |
| creatine | #429 |
| greater percentage | #429 |
| adjectives | #430 |
| desipramine | #430 |
| glycitein | #431 |
| detection colorectal | #431 |
| laser therapy | #431 |
| contraindicated | #431 |
| hgb | #431 |
| methodsa | #431 |
| fatigue humans | #431 |
| symptom management | #432 |
| diploid tumors | #432 |
| sunscreen | #433 |
| joint symptoms | #433 |
| antiseizure | #433 |
| resultsone | #434 |
| 115 patients | #434 |
| purpose objectives | #434 |
| cancer tamoxifen | #434 |
| oral calcium | #435 |
| nutrition cancer | #436 |
| olanzapine treatment | #436 |
| topic treatment | #436 |
| pains | #436 |
| 1157 | #436 |
| absolute terms | #438 |
| anthracyclinebased chemotherapy | #438 |
| clinical cancer | #438 |
| nodenegative breast cancer | #439 |
| administration cutaneous | #440 |
| postoperative follow | #440 |
| expected survival | #441 |
| neoplasms cancer | #441 |
| diminish | #441 |
| yoga | #442 |
| vasomotor | #442 |
| baseline 1 month | #444 |
| hgpin | #444 |
| preoperative breast | #445 |
| doxorubicin drug administration | #445 |
| receive | #445 |
| life efficacy | #445 |
| screening colorectal | #445 |
| loss aged | #445 |
| marie | #446 |
| agents antineoplastic | #446 |
| acid aged | #447 |
| treatment regimen | #447 |
| day dexamethasone | #447 |
| 2 months | #448 |
| patients qol | #448 |
| patients weight | #448 |
| european organization | #448 |
| estrogen therapy | #449 |
| climacteric | #449 |
| baseline patient | #450 |
| premature discontinuation | #451 |
| baseline 4 weeks | #452 |
| cancer symptoms | #452 |
| outline | #453 |
| study feasibility | #453 |
| arms arm | #454 |
| nodepositive breast cancer | #454 |
| postmenopause | #455 |
| dhea | #455 |
| geranium | #456 |
| 5fu patients | #456 |
| axillary metastases | #457 |
| diphenhydramine | #458 |
| evaluate efficacy | #459 |
| mucositis | #460 |
| patients venous thromboembolism | #461 |
| questionnaires terminology | #461 |
| enforced | #461 |
| cytokines patients | #462 |
| patients baseline | #462 |
| helpful | #462 |
| 6 weeks | #462 |
| increased weight | #463 |
| potential interventions | #463 |
| therapy stage | #464 |
| clin | #468 |
| cancer institute | #468 |
| asco | #468 |
| referral centers | #469 |
| lung humans | #469 |
| radiation enteritis | #469 |
| sexual distress | #470 |
| consensus guideline | #470 |
| treatment options patients | #471 |
| esophagitis patients | #471 |
| purposethis | #471 |
| chemotherapy regimens | #472 |
| new treatment | #473 |
| subscale | #474 |
| 432 | #474 |
| pilocarpine | #474 |
| symptoms menopause | #475 |
| hormonal replacement therapy | #475 |
| groups 6 months | #475 |
| uncertain | #476 |
| single item | #477 |
| preliminary studies | #477 |
| appears | #477 |
| clinical decision making | #478 |
| placebo 24 weeks | #478 |
| onco | #479 |
| doubleblind study | #479 |
| variables age | #479 |
| 95 placebo | #479 |
| iii colon | #479 |
| enrollment patients | #480 |
| vitamin placebo | #480 |
| alopecia | #480 |
| osteoporosis osteopenia | #481 |
| crc 95 | #482 |
| moderatetosevere | #482 |
| higher dose | #483 |
| reluctance | #484 |
| adjuvant therapy | #484 |
| endpoints included | #485 |
| locoregional disease | #485 |
| tpn | #485 |
| neurotoxicity patients | #485 |
| 655 | #486 |
| cure | #486 |
| taqman pcr | #488 |
| blind | #488 |
| induced neuropathic | #489 |
| estrogen deprivation | #491 |
| pain scores | #491 |
| doselimiting toxicity | #491 |
| cancer cardiovascular disease | #492 |
| combined modality treatment | #493 |
| plant preparations | #493 |
| primary breast | #493 |
| narcotics | #494 |
| patients stage disease | #495 |
| decarboxylase activity | #498 |
| dropout rates | #499 |
| patients breast cancer | #500 |
| fentanyl humans | #500 |
| “ ” | #501 |
| received placebo | #501 |
| life questionnaires survivors | #502 |
| placebo‐controlled study | #502 |
| kps | #502 |
| pilot studies | #502 |
| metastatic cancer | #503 |
| loss patients | #504 |
| mesonephroma | #504 |
| chest ray | #505 |
| awaited | #506 |
| survival chemotherapy | #509 |
| pain inventory | #510 |
| smoking nicotine | #511 |
| placebo trial | #511 |
| preventative | #512 |
| breast diseases | #513 |
| therapy aged | #513 |
| trials data | #513 |
| flic | #514 |
| advance planning acp | #514 |
| nonmetastatic breast cancer | #514 |
| evidencebased interventions | #515 |
| women receiving | #516 |
| premature menopause | #516 |
| letrozole treatment | #516 |
| outcome antineoplastic | #517 |
| serum albumin levels | #517 |
| acute diarrhea | #519 |
| pain medications | #520 |
| achievements | #520 |
| cbcs | #521 |
| eflornithine | #521 |
| pharmaceutic | #522 |
| gamma aminobutyric | #522 |
| poorer quality life | #523 |
| mastectomy middle | #525 |
| symptoms fatigue | #525 |
| chills | #525 |
| resultsto | #527 |
| adverse events placebo | #528 |
| prophylactic therapy | #528 |
| controlled crossover | #528 |
| patients clinical trial | #529 |
| abt888 | #529 |
| phytogenic area | #529 |
| cmf | #529 |
| therapy prostate | #530 |
| oncologists | #531 |
| pregabalin | #531 |
| radiodermatitis | #531 |
| centrally | #531 |
| patients vitamin | #532 |
| iii trial | #533 |
| 30 minutes | #534 |
| genitourinary | #535 |
| medications treatment | #536 |
| patients evaluated | #536 |
| antineoplastic agents | #537 |
| study week | #538 |
| agents chemotherapy | #538 |
| weeks therapy | #538 |
| superficial bladder | #538 |
| patients clinical trials | #539 |
| terminally | #540 |
| patients assigned | #541 |
| pharmacologic | #542 |
| pain patients | #543 |
| dehydroepiandrosterone | #543 |
| topic severity | #543 |
| week 6 | #544 |
| risedronic | #544 |
| pain score | #544 |
| 329 | #545 |
| 592 | #546 |
| peripheral | #548 |
| patients scheduled | #548 |
| unable | #549 |
| bmd baseline | #550 |
| receiving adjuvant | #550 |
| differences study | #551 |
| dabrafenib trametinib | #552 |
| 3 95 | #552 |
| hypesthesia | #553 |
| axonal transport | #553 |
| adenomas patients | #554 |
| leucovorin oxaliplatin | #555 |
| evaluable | #556 |
| co2 laser | #556 |
| dysplastic lesions | #556 |
| neoplasms drug | #556 |
| regular aspirin | #556 |
| abh | #557 |
| 300 day | #557 |
| vasomotor symptoms | #559 |
| 80000 | #560 |
| emesis | #560 |
| rbc transfusions | #560 |
| reported outcomes | #560 |
| methylphenidate | #561 |
| day treatment | #561 |
| moisturizer | #561 |
| mesna | #562 |
| lmwh patients | #564 |
| hands | #564 |
| time detection | #565 |
| method drug | #565 |
| induced cold | #565 |
| treatment periods | #566 |
| trial data | #566 |
| 4 8 | #567 |
| supportive cancer | #567 |
| survival stage | #567 |
| 11 months | #568 |
| scientifically | #569 |
| calgb | #569 |
| therapy primary | #569 |
| adjuvant clinical trials | #569 |
| topic treatment outcome | #571 |
| decarboxylase odc | #571 |
| lower dose | #571 |
| bibliometric analysis | #572 |
| paclitaxel patients | #573 |
| fluorouracil oxaliplatin | #578 |
| topical capsaicin | #578 |
| patients candidates | #580 |
| refute | #580 |
| methods systematic review | #580 |
| hwe | #581 |
| treatment phase | #581 |
| paced | #583 |
| breakthrough pain | #583 |
| life questionnaire | #584 |
| paracentesis | #584 |
| desvenlafaxine | #585 |
| moderate correlation | #585 |
| drug toxicity | #587 |
| neoplasms nutritional | #587 |
| paclitaxel carboplatin | #588 |
| limited efficacy | #589 |
| multiple cancers | #589 |
| emotional functioning | #589 |
| oxaliplatin patients | #589 |
| muscle cramps | #589 |
| aged occult | #589 |
| osteopenia | #590 |
| taxane chemotherapy | #590 |
| aminobutyric | #590 |
| acrin | #591 |
| ablation therapy | #592 |
| median time progression | #592 |
| crossover trial | #592 |
| platinum drugs | #593 |
| chemotherapy benefit | #595 |
| pentoxifylline | #596 |
| compounded | #596 |
| exanthema | #597 |
| radiotherapy breast | #597 |
| sst2 | #597 |
| fatigue female | #597 |
| multisite | #598 |
| topic depressive disorder | #598 |
| patients mastectomy | #599 |
| publication administration | #599 |
| initial surgery | #599 |
| effects breast | #600 |
| patients etanercept | #600 |
| thromboembolism vte | #600 |
| 1093 | #601 |
| patient decision | #601 |
| statistically differences | #601 |
| health providers | #601 |
| discretion | #601 |
| oral solution | #601 |
| prevention measures | #602 |
| vte cancer | #602 |
| cfibers | #603 |
| cancer survivors | #604 |
| anthracycline based | #604 |
| exposed patients | #604 |
| toxicity profile | #605 |
| endoxifen | #607 |
| toes | #608 |
| 16 women | #608 |
| chemotherapy administration | #608 |
| iron supplementation | #609 |
| agents antidepressive | #609 |
| management symptoms | #609 |
| agents tricyclic | #611 |
| topic reproducibility | #612 |
| 2 95 | #613 |
| pilot | #613 |
| updated analysis | #614 |
| montanide | #615 |
| animal data | #616 |
| qol baseline | #616 |
| humans quality | #617 |
| 118 patients | #617 |
| commonly | #618 |
| antacid | #620 |
| appetite | #620 |
| persistent symptoms | #621 |
| urinary frequency | #621 |
| aic | #621 |
| follow median | #622 |
| itching | #625 |
| analyzable | #626 |
| gangliosides humans | #626 |
| cisplatin etoposide | #627 |
| life quality | #630 |
| 1 month | #631 |
| iii patients | #632 |
| authors knowledge | #633 |
| mistletoe | #634 |
| biological targets | #634 |
| month patients | #637 |
| female sexual function | #638 |
| assessment cancer | #640 |
| serum hepcidin | #640 |
| dose placebo | #640 |
| eligible | #641 |
| poorer quality | #642 |
| hormonal aromatase | #643 |
| inhibitors breast | #643 |
| prostatic intraepithelial | #644 |
| placebo time | #645 |
| multiple studies | #646 |
| nasal symptoms | #647 |
| palliative quality | #647 |
| 300 patients | #648 |
| malignant melanomas | #648 |
| syndrome acute | #649 |
| symptoms | #649 |
| method humans | #651 |
| doses patients | #651 |
| sores | #651 |
| flushes | #651 |
| appeared | #652 |
| dose limiting | #653 |
| opioid analgesic | #653 |
| limiting toxicity | #653 |
| patients 16 | #655 |
| poms | #657 |
| prior chemotherapy | #658 |
| complete response patients | #659 |
| grade glioma | #660 |
| twentysix patients | #661 |
| patients chemotherapy | #662 |
| colorectal adenocarcinoma | #662 |
| 62 months | #663 |
| 95 − | #665 |
| cancer prospective | #666 |
| alternative treatments | #666 |
| neoplasms patient | #666 |
| active agent | #666 |
| nonparametric surveys | #667 |
| life radiotherapy | #667 |
| levetiracetam | #668 |
| cancer treatments | #668 |
| treatment trials | #669 |
| women chemotherapy | #670 |
| marie tooth | #671 |
| paclitaxel docetaxel | #671 |
| axonopathy | #674 |
| pain adult | #674 |
| 1822 | #674 |
| p00004 | #674 |
| maintenance disorders | #675 |
| pharmacologic management | #675 |
| induced cognitive | #676 |
| racially | #676 |
| 5 consecutive | #678 |
| patients standard | #678 |
| controlled study | #679 |
| routine follow | #680 |
| diethylstilbestrol | #681 |
| reported outcome | #681 |
| purpose report | #682 |
| study samples | #684 |
| oncology practice | #685 |
| popularly | #685 |
| highdose melphalan | #685 |
| deprivation therapy | #686 |
| fluorouracil leucovorin | #687 |
| therapy cancer | #687 |
| practice settings | #688 |
| charcot marie | #688 |
| neurologic injury | #688 |
| sulindac | #688 |
| pharmacological targeting | #692 |
| life survivors | #692 |
| rescue medication | #693 |
| guideline update | #693 |
| phlebitis | #694 |
| administration schedule | #694 |
| randomized treatment | #695 |
| based testing | #698 |
| potential benefits | #699 |
| desmethyl | #699 |
| descriptive statistics | #700 |
| versa | #701 |
| appearing | #702 |
| postmenopausal | #704 |
| chemopreventive agent | #704 |
| v30 | #705 |
| medical oncologists | #706 |
| effective interventions | #707 |
| tens | #709 |
| locoregionally advanced | #710 |
| capecitabine patients | #711 |
| 160 | #712 |
| randomized studies | #712 |
| erythropoiesis stimulating | #712 |
| tube neoplasms | #714 |
| newer agents | #714 |
| prevention cancer | #715 |
| breast magnetic | #716 |
| lowmolecularweight heparin | #717 |
| inflammatory breast | #717 |
| convened | #719 |
| endorsement | #719 |
| ameliorate | #720 |
| erythropoietin female | #722 |
| data baseline | #722 |
| 6 months 95 | #725 |
| humans neoplasms | #725 |
| palliative medicine | #725 |
| cyclophosphamide methotrexate | #725 |
| therapeutic equivalency | #727 |
| 4 hours | #728 |
| physicians predictive | #728 |
| joint pain | #729 |
| patients radiation therapy | #730 |
| odc activity | #731 |
| induced human | #731 |
| study treatment | #731 |
| charcotmarietooth | #732 |
| women undergoing | #733 |
| nucleotide variants | #734 |
| vinca | #735 |
| medroxyprogesterone | #735 |
| adjuvant clinical | #736 |
| secondary prevention | #737 |
| induced neurotoxicity | #738 |
| chemotherapy women | #738 |
| opd | #739 |
| mirtazapine | #741 |
| prescribing practices | #742 |
| locoregional therapy | #742 |
| 4 weeks patients | #742 |
| fist | #744 |
| women placebo | #745 |
| baseline 1 year | #745 |
| armamentarium | #745 |
| patients breast | #747 |
| bone loss | #748 |
| ecog | #748 |
| chemotherapy initiation | #749 |
| trials patients | #749 |
| alfa | #750 |
| superficial bladder cancer | #750 |
| 271 | #750 |
| psychostimulant | #750 |
| rand | #752 |
| cervical dysplasia | #752 |
| compared placebo | #753 |
| complementary medicine | #753 |
| radiation skin | #754 |
| oct2 | #754 |
| 4·2 | #754 |
| antigen levels | #754 |
| secondary points | #755 |
| 46 | #755 |
| trouble | #755 |
| paclitaxel chemotherapy | #755 |
| patients insomnia | #756 |
| metastatic breast | #757 |
| hepcidin levels | #758 |
| local anesthetics | #759 |
| reduction pain | #759 |
| rifngamma | #759 |
| prostate adenocarcinoma | #760 |
| sulfasalazine | #760 |
| additional data | #762 |
| pain quality | #763 |
| ambulatory setting | #765 |
| occult blood | #766 |
| seventy patients | #766 |
| 81 patients | #766 |
| acid 4 | #768 |
| neoplasms prospective | #768 |
| medroxyprogesterone acetate mpa | #768 |
| humans imidazoles | #769 |
| baseline pain | #769 |
| activity breast | #770 |
| actual | #770 |
| sensory neuropathy | #771 |
| modified radical mastectomy | #772 |
| sweating | #772 |
| breast carcinoma ductal | #772 |
| relatedness | #772 |
| primary endpoint | #773 |
| women enrolled | #773 |
| keratinocyte growth factor | #773 |
| premenopausal women | #773 |
| 10 day | #774 |
| neoplasms breast | #774 |
| emla | #774 |
| patients colon | #774 |
| fifty patients | #774 |
| aged peripheral | #775 |
| acupuncture therapy | #776 |
| octreotide treatment | #776 |
| 257 | #777 |
| oral administration | #777 |
| gsm | #778 |
| p00002 | #778 |
| charcot | #778 |
| 137 patients | #781 |
| severity patients | #782 |
| menopausal symptoms | #783 |
| agents phytogenic | #784 |
| cutaneous administration | #785 |
| skin conductance | #785 |
| benefits patients | #785 |
| prognostic survival | #787 |
| management | #788 |
| enoxaparin | #788 |
| symptom experience | #791 |
| anesthetics local | #792 |
| subsequent cycles | #793 |
| women reported | #793 |
| colon rectal cancer | #796 |
| baseline period | #797 |
| estrogen levels | #798 |
| potential treatments | #798 |
| life outcomes | #801 |
| clinical questions | #801 |
| neuralgia pain | #801 |
| erythropoiesisstimulating agents | #802 |
| osteoporosis women | #802 |
| randomized phase trial | #804 |
| lack efficacy | #804 |
| day 3 | #804 |
| primary points | #805 |
| glutathione | #805 |
| effects patients | #806 |
| double | #806 |
| 894 | #807 |
| opioid analgesia | #807 |
| continue | #808 |
| 80 antineoplastic | #808 |
| 3 day | #808 |
| etoposide cisplatin | #808 |
| placebotreated patients | #808 |
| 0025 | #809 |
| complete response | #811 |
| odc | #812 |
| abrogate | #812 |
| previous reports | #816 |
| mild symptoms | #817 |
| disease genes | #818 |
| lorazepam | #819 |
| agents clinical | #820 |
| eastern cooperative | #820 |
| etoposide patients | #823 |
| randomly | #824 |
| tolerated | #826 |
| statisticians | #826 |
| 148 patients | #827 |
| cancer control | #828 |
| rasch model | #828 |
| cancer phase | #830 |
| administration oral | #830 |
| placebo 6 months | #830 |
| suggestive | #830 |
| neoplasms bone | #832 |
| dabrafenib | #832 |
| humans medical | #833 |
| subset analysis | #833 |
| similarities differences | #835 |
| 366 | #836 |
| advanced malignancies | #836 |
| mandelic | #837 |
| prognosis quality | #837 |
| numeric | #838 |
| eventual | #844 |
| breast neoplasms | #845 |
| adverse events aes | #846 |
| herbal products | #846 |
| p006 | #847 |
| 142 patients | #848 |
| global qol | #848 |
| detection rates | #849 |
| toxicities | #850 |
| eortc | #850 |
| taxol | #851 |
| prostate cancer patients | #852 |
| n55 | #853 |
| oncotype | #853 |
| stage ovarian | #853 |
| palliative services | #855 |
| daily dosing | #858 |
| vaginal bleeding | #859 |
| taxoids | #859 |
| assessment management | #859 |
| stratification patients | #860 |
| published data | #860 |
| strongest | #864 |
| etidronic | #866 |
| unacceptable | #868 |
| patients trial | #868 |
| placebo baseline | #868 |
| jellies | #873 |
| efficacious | #873 |
| peritoneal cancer | #874 |
| treatment completion | #875 |
| timepoints | #878 |
| 5ht3 | #879 |
| nonpharmacological interventions | #880 |
| symptomatic women | #880 |
| phytogenic carcinoma | #880 |
| midlife women | #881 |
| antineoplastic | #883 |
| 450 | #883 |
| study placebo | #883 |
| monoclonal antineoplastic agents | #885 |
| neurotoxic | #889 |
| mitigates | #889 |
| topic female | #890 |
| monoclonal female humans | #891 |
| data article | #892 |
| concomitant chemotherapy | #893 |
| caa | #894 |
| cancer guidelines | #894 |
| control arm | #896 |
| completed | #900 |
| oxy | #901 |
| neoplasms hormone | #901 |
| women hormone | #902 |
| inconvenience | #903 |
| nodal status | #903 |
| percent | #903 |
| nmsc | #904 |
| survival surgery | #905 |
| provided | #905 |
| chemotherapy response | #905 |
| 00006 | #905 |
| hospices | #909 |
| increased risk death | #910 |
| chemotherapeutic | #910 |
| cancer studies | #913 |
| weight maintenance | #914 |
| national cancer | #914 |
| norepinephrine reuptake | #915 |
| paroxetine | #916 |
| life cancer patients | #916 |
| gynecomastia | #918 |
| prospective pilot study | #919 |
| cycle chemotherapy | #920 |
| advanced cancer patients | #921 |
| mouth mucosa | #921 |
| evidence practice | #923 |
| manuscripts | #924 |
| population cohort | #924 |
| illness female humans | #925 |
| primary objectives | #926 |
| chemotherapy study | #927 |
| upper extremities | #929 |
| oral dosing | #929 |
| lasa | #930 |
| oncol | #931 |
| starting | #932 |
| fluoxetine | #933 |
| minocycline | #935 |
| cytotoxic therapy | #937 |
| day placebo | #938 |
| serotonin uptake | #939 |
| electronic health record | #939 |
| treatment symptoms | #940 |
| visual analogue | #940 |
| 138 patients | #942 |
| advanced adenoma | #943 |
| uptake inhibitors | #943 |
| high‐risk | #943 |
| colorectal adenomas | #944 |
| letter editor | #944 |
| patient population | #944 |
| beckman | #945 |
| gp100 | #945 |
| iii topic | #945 |
| 1year survival | #946 |
| fluorouracil | #948 |
| arm patients | #949 |
| natural menopause | #951 |
| recurrence score | #952 |
| compare | #953 |
| jci | #954 |
| orally | #954 |
| participating centers | #955 |
| evaluating | #955 |
| cooperative oncology | #957 |
| hfs | #958 |
| adjuvant therapies | #958 |
| rheumatologic | #958 |
| aloe vera | #958 |
| leukopenia | #959 |
| erythropoietic | #959 |
| moderately | #961 |
| monoclonal carcinoma | #962 |
| pjnk | #963 |
| trpm8 | #963 |
| received adjuvant | #964 |
| serum cytokine | #966 |
| menopause | #968 |
| 1160 | #969 |
| mart1 | #970 |
| earlystage disease | #972 |
| table | #972 |
| randomized pilot | #973 |
| gluconate | #976 |
| olmsted county | #977 |
| restarted | #977 |
| hypercalcemia | #978 |
| 1 10 | #978 |
| mechanical allodynia | #980 |
| 1month | #980 |
| 2700 | #982 |
| 150 | #984 |
| 1 week | #984 |
| antidotes | #984 |
| threequarters | #989 |
| patients venous | #989 |
| adjuvant | #992 |
| pain reduction | #993 |
| multiple logistic regression | #997 |
| analyses data | #998 |
| bother | #1003 |
| mayo | #1003 |
| cancer chemoprevention | #1005 |
| publication analgesics | #1007 |
| 71 | #1010 |
| continued | #1014 |
| patients metastatic disease | #1015 |
| organ systems | #1016 |
| neurocutaneous | #1018 |
| anthraquinones | #1019 |
| patients mri | #1020 |
| reported pain | #1021 |
| life symptoms | #1023 |
| trial participation | #1026 |
| 145 patients | #1027 |
| enteritis | #1028 |
| fatigue patients | #1028 |
| urogenital | #1030 |
| delayed treatment | #1031 |
| alternative treatment | #1031 |
| pill | #1037 |
| evidence treatment | #1037 |
| ” “ | #1038 |
| androgen deprivation therapy | #1042 |
| validity responsiveness | #1043 |
| prx | #1044 |
| postural control | #1044 |
| randomized trial patients | #1046 |
| colorectal tumor | #1047 |
| patients safety | #1047 |
| prevention intervention | #1047 |
| substantial | #1050 |
| frey | #1051 |
| nutritional supplementation | #1051 |
| life | #1053 |
| 30 40 | #1053 |
| postchemotherapy | #1056 |
| doxorubicin female humans | #1056 |
| minority | #1057 |
| primary analysis | #1059 |
| osteoporosis treatment | #1059 |
| feeding eating | #1059 |
| 10 weeks | #1060 |
| day study | #1061 |
| tricyclic | #1061 |
| prospective validation | #1063 |
| fruitful | #1063 |
| oncologist | #1063 |
| 347 | #1064 |
| endocrine resistance | #1064 |
| loss weight | #1066 |
| ongoing studies | #1066 |
| suggested | #1069 |
| disappointing | #1069 |
| therapy | #1069 |
| metastatic lung | #1070 |
| practical guidance | #1070 |
| descriptive | #1073 |
| tobacco dependence | #1075 |
| concurrent chemotherapy | #1078 |
| nccn | #1078 |
| monoclonal humans | #1078 |
| women treatment | #1079 |
| placebo day | #1080 |
| patients bone metastases | #1081 |
| women received | #1083 |
| advance planning | #1084 |
| placebo participants | #1085 |
| prompted | #1089 |
| breast cancer recurrence | #1089 |
| duloxetine | #1089 |
| patients adjuvant therapy | #1090 |
| low intermediate | #1091 |
| prospective multicenter study | #1092 |
| progestogens | #1094 |
| palonosetron | #1095 |
| postoperative surveillance | #1095 |
| adult breast | #1097 |
| 25 day | #1098 |
| favor | #1099 |
| intravenous iron | #1099 |
| functional ability | #1100 |
| agents treatment | #1100 |
| previous chemotherapy | #1100 |
| 54 | #1103 |
| phytoestrogens | #1103 |
| prospective trial | #1106 |
| peripheral neuropathies | #1108 |
| acknowledged | #1110 |
| 3 6 months | #1112 |
| transdermal | #1114 |
| randomized | #1115 |
| 1 year treatment | #1116 |
| prevention trials | #1119 |
| treatment life | #1121 |
| life death | #1122 |
| inhaler | #1124 |
| interprofessional relations | #1126 |
| cancer trials | #1126 |
| unpleasant | #1127 |
| dmc | #1127 |
| prilocaine | #1127 |
| based evidence | #1128 |
| mexiletine | #1129 |
| participants received | #1131 |
| clinician | #1133 |
| patients versus | #1133 |
| sunscreening | #1136 |
| lecithins | #1137 |
| opioid therapy | #1139 |
| 25 micrograms | #1139 |
| hormonal therapy | #1140 |
| practice guideline | #1140 |
| cancer | #1141 |
| purposeto | #1144 |
| inhibit | #1144 |
| egb | #1146 |
| cancer pain | #1146 |
| randomized crossover | #1146 |
| locoregionally | #1147 |
| illness surveys | #1148 |
| taste disorders | #1149 |
| purpose determine | #1150 |
| shark | #1150 |
| premature ovarian failure | #1150 |
| nervousness | #1153 |
| 730 | #1153 |
| smoking prevention | #1154 |
| detrimental | #1154 |
| hormonal | #1154 |
| flecainide | #1157 |
| 325 | #1159 |
| 481 | #1161 |
| rinse | #1162 |
| 22 | #1162 |
| doac | #1163 |
| educate | #1164 |
| purposethis study | #1167 |
| toxicity assessment | #1167 |
| comparative efficacy | #1172 |
| ceramides | #1173 |
| therapy estrogens | #1174 |
| painful | #1174 |
| intervention trials | #1175 |
| receptor modulators | #1176 |
| patients syndrome | #1177 |
| clinical trial | #1178 |
| inadequately | #1179 |
| projects | #1180 |
| lowest risk | #1181 |
| chemotherapy regimen | #1182 |
| chose | #1184 |
| aged prostatic | #1185 |
| growing population | #1186 |
| physician patient | #1187 |
| electrostimulation | #1188 |
| international consensus | #1189 |
| prior treatment | #1189 |
| acetate treatment | #1190 |
| mastectomy breast | #1190 |
| usage | #1193 |
| gained | #1196 |
| olmsted | #1197 |
| diary | #1197 |
| estrogen replacement therapy | #1197 |
| experiencing | #1198 |
| alternative therapies | #1200 |
| caregivers patients | #1202 |
| male smokers | #1204 |
| partial responses | #1204 |
| 552 | #1204 |
| panax | #1205 |
| clinical trials patients | #1207 |
| magnesium | #1208 |
| satisfied | #1212 |
| breast cancer | #1212 |
| induced skin | #1213 |
| patients pts | #1215 |
| 611 | #1215 |
| communication skills | #1215 |
| likert | #1217 |
| adjuvant endocrine | #1218 |
| secondary endpoints | #1219 |
| sexuality | #1219 |
| precludes | #1219 |
| 8 week | #1221 |
| phase clinical trial | #1223 |
| higher numbers | #1223 |
| limiting | #1224 |
| thighs | #1227 |
| editor | #1227 |
| participants reported | #1229 |
| organogel | #1230 |
| primary melanomas | #1232 |
| 8 weeks | #1232 |
| 52 | #1233 |
| n54 | #1234 |
| discontinue | #1235 |
| randomized phase | #1235 |
| tricyclic antidepressants | #1241 |
| clinical syndrome | #1241 |
| baseline values | #1245 |
| symptoms diagnosis | #1248 |
| review data | #1248 |
| day 2 | #1248 |
| decided | #1249 |
| female sexual | #1250 |
| etiologies | #1250 |
| postmenopausal women | #1252 |
| bedtime | #1252 |
| il1β tnfα | #1253 |
| estrogens female | #1255 |
| diarrhea patients | #1257 |
| diphosphonates | #1258 |
| combination docetaxel | #1258 |
| thromboembolism patients | #1258 |
| trametinib | #1259 |
| patients 4 | #1259 |
| hypochromic | #1259 |
| kidney dysfunction | #1260 |
| rasch | #1260 |
| pain medication | #1261 |
| doubts | #1263 |
| neurologic humans | #1263 |
| tumor promotion | #1265 |
| dna ploidy | #1265 |
| esophagitis | #1266 |
| sae | #1266 |
| protocols chemotherapy | #1268 |
| magnesium oxide | #1270 |
| phytotherapy | #1271 |
| drug double | #1272 |
| qol scores | #1272 |
| short form36 | #1273 |
| situ carcinoma ductal | #1273 |
| patients families | #1274 |
| preoperative chemotherapy | #1274 |
| preclude | #1276 |
| cutaneous melanomas | #1278 |
| tamoxifen patients | #1279 |
| taxanes | #1279 |
| median ttp | #1280 |
| dosing interval | #1281 |
| heparin lmwh | #1282 |
| label trial | #1284 |
| male medication adherence | #1285 |
| medical oncology | #1286 |
| adjuvant tamoxifen | #1287 |
| opposed | #1289 |
| adjuvant therapy patients | #1289 |
| cyclophosphamide doxorubicin | #1289 |
| folfox | #1291 |
| 109 patients | #1292 |
| acupuncture treatment | #1294 |
| cochran | #1294 |
| data clinical | #1296 |
| prevalence severity | #1296 |
| antimetabolites antineoplastic | #1297 |
| neurosensory | #1298 |
| neoplasms disease | #1300 |
| emetic | #1301 |
| women cancer | #1303 |
| abstinent | #1307 |
| 8 cycles | #1307 |
| stimulating agents | #1309 |
| survival 5 | #1310 |
| motion rom | #1310 |
| critical review | #1312 |
| sportdiscus | #1313 |
| gynecologic cancers | #1314 |
| gsh | #1315 |
| biotech | #1315 |
| melanoma antigen | #1315 |
| breast biopsy | #1317 |
| durations | #1318 |
| contacted | #1318 |
| health‐related quality | #1320 |
| etanercept | #1320 |
| chemotherapeutic agents | #1321 |
| controlled | #1321 |
| investigative | #1321 |
| oncology patients | #1321 |
| pain interference | #1322 |
| primary outcome measure | #1322 |
| patients quality | #1322 |
| ointments | #1323 |
| nerve damage | #1326 |
| appetite loss | #1327 |
| patient physician | #1328 |
| life scores | #1328 |
| agents colorectal | #1329 |
| cardiac toxicity | #1329 |
| life surveys | #1337 |
| adjuvant breast | #1339 |
| 375 | #1340 |
| published reports | #1341 |
| evenly | #1342 |
| 2 week | #1345 |
| ambulatory monitoring | #1346 |
| platinum compounds | #1347 |
| breast cancer women | #1347 |
| experienced | #1350 |
| colonoscopic | #1350 |
| tibolone | #1351 |
| karnofsky | #1352 |
| benefit patients | #1353 |
| cancer experience | #1353 |
| malignant ascites | #1354 |
| carcinoembryonic | #1356 |
| period patients | #1358 |
| eligibility criteria | #1359 |
| wks | #1360 |
| agents cancer | #1367 |
| effects treatment | #1368 |
| attribution | #1369 |
| postural balance | #1372 |
| continues | #1376 |
| combination female humans | #1377 |
| hopes | #1379 |
| titrated | #1381 |
| n32 | #1382 |
| n29 | #1382 |
| patients colon cancer | #1382 |
| duplicates | #1386 |
| mastectomy | #1387 |
| hydrazines | #1387 |
| snvs | #1388 |
| patients 40 | #1391 |
| femoral neck bmd | #1396 |
| medical literature | #1397 |
| ajcc | #1399 |
| cancer adult | #1400 |
| cancer therapies | #1403 |
| pain neuropathic | #1404 |
| somnolence | #1406 |
| rifn | #1407 |
| polyneuropathies | #1407 |
| replete | #1408 |
| physical activity level | #1410 |
| treats | #1411 |
| integrative medicine | #1412 |
| fisher test | #1415 |
| wilcoxon | #1416 |
| viscum | #1416 |
| combination chemotherapy | #1417 |
| cessation treatment | #1418 |
| quality life | #1420 |
| treatment recommendations | #1423 |
| subjective symptoms | #1424 |
| noncompliance | #1424 |
| sleep initiation | #1424 |
| biloba | #1425 |
| methodsdata | #1426 |
| therapy initiation | #1426 |
| prevent | #1427 |
| cancer quality life | #1427 |
| cytotoxic chemotherapy | #1428 |
| aromatase | #1431 |
| hormonal treatment | #1431 |
| and or | #1432 |
| 5fu | #1433 |
| weight heparin | #1433 |
| radiation injuries | #1434 |
| statistically difference | #1434 |
| daily intake | #1435 |
| primary objective | #1437 |
| caloric intake | #1439 |
| adults cancer | #1440 |
| female humans illness | #1442 |
| proctitis | #1445 |
| goserelin | #1445 |
| aminobutyric acid | #1446 |
| ehrs | #1447 |
| postacute | #1447 |
| cancer clinical trials | #1449 |
| incidences | #1449 |
| assigning | #1450 |
| coulter | #1453 |
| treatment pain | #1454 |
| nccn guidelines | #1454 |
| patients ovarian | #1454 |
| infliximab | #1455 |
| cognitive testing | #1456 |
| bruising | #1457 |
| hrqol | #1458 |
| 63 | #1459 |
| individual patients | #1461 |
| effective management | #1461 |
| dna testing | #1461 |
| adjuvant treatment | #1463 |
| aged quality | #1466 |
| life cancer | #1466 |
| haloperidol humans | #1467 |
| discrepancies | #1467 |
| network meta | #1467 |
| crossover | #1468 |
| nutritional support | #1469 |
| locally advanced head | #1469 |
| physical activity patients | #1470 |
| recurrent vte | #1475 |
| life treatment | #1477 |
| hormone dependent | #1477 |
| resultsa | #1479 |
| substantial proportion | #1479 |
| lower extremities | #1483 |
| tumor promoter | #1484 |
| oral aged | #1484 |
| pik3ca mutation | #1485 |
| aromatase inhibitors | #1492 |
| nrs | #1493 |
| cancer society | #1494 |
| ongoing | #1495 |
| systemic chemotherapy | #1498 |
| mood states | #1499 |
| planned | #1500 |
| paclitaxel cisplatin | #1501 |
| resultsafter | #1501 |
| mpa | #1509 |
| colon cancer patients | #1510 |
| anti anxiety | #1510 |
| perimenopause | #1513 |
| gynecologic cancer | #1513 |
| premalignant | #1514 |
| neuropeptide npy | #1518 |
| bowel function | #1520 |
| efficacy | #1523 |
| hair loss | #1523 |
| biweekly | #1523 |
| diagnosed cancer | #1525 |
| p0024 | #1525 |
| root ganglion | #1526 |
| oncology | #1526 |
| 3 weeks | #1528 |
| interfered | #1530 |
| balanced | #1532 |
| gastrointestinal toxicity | #1533 |
| cck8 | #1537 |
| cytotoxic agents | #1537 |
| survivors | #1538 |
| physical examination | #1542 |
| cycle patients | #1546 |
| warranted | #1548 |
| guideline recommendations | #1549 |
| tamoxifen treatment | #1550 |
| treatment induced | #1556 |
| adult cancer | #1560 |
| male breast | #1562 |
| blind randomized | #1562 |
| pounds | #1567 |
| transfusion requirements | #1568 |
| design considerations | #1569 |
| response rates | #1572 |
| or1 | #1574 |
| pharmacologic treatment | #1576 |
| iii disease | #1576 |
| 5 day | #1579 |
| bibliographies | #1580 |
| crushed | #1583 |
| rivaroxaban | #1583 |
| patients small | #1583 |
| rate survival | #1584 |
| vaginal | #1587 |
| prospective trials | #1588 |
| postmenopausal breast | #1589 |
| updates | #1590 |
| image body | #1593 |
| dissent | #1593 |
| phase iii study | #1595 |
| localized disease | #1599 |
| stratification | #1600 |
| trpa1 | #1600 |
| therapy cyclophosphamide | #1602 |
| completion | #1603 |
| aged cross | #1603 |
| advanced colorectal cancer | #1604 |
| disagreements | #1605 |
| modafinil | #1606 |
| allopurinol | #1608 |
| ≥70 | #1611 |
| bid | #1612 |
| dosing | #1619 |
| aged antineoplastic | #1620 |
| accrual | #1623 |
| 970 | #1624 |
| oncology nursing | #1624 |
| dna markers | #1626 |
| cream | #1627 |
| 176 | #1628 |
| prophylactic treatment | #1629 |
| tumor type | #1633 |
| 227 | #1634 |
| vte | #1636 |
| upfront | #1637 |
| potential channels | #1642 |
| respiratory depression | #1643 |
| combined modality therapy | #1649 |
| cardiovascular toxicity | #1650 |
| 49 | #1651 |
| controlled phase | #1652 |
| 2003 | #1652 |
| monthly | #1656 |
| cancer stage | #1660 |
| current treatment | #1661 |
| limited data | #1663 |
| pelvic radiotherapy | #1664 |
| referencing | #1666 |
| populationbased cohort | #1667 |
| breast cancer patients | #1667 |
| evaluation female | #1670 |
| treated breast | #1676 |
| patient preference | #1679 |
| therapy hrt | #1680 |
| ovid medline | #1682 |
| hb | #1683 |
| agents carcinoma | #1687 |
| blood tests | #1689 |
| publication attitude | #1691 |
| neoplasms practice | #1693 |
| anticancer therapy | #1693 |
| weight patients | #1694 |
| stopping | #1695 |
| percent patients | #1695 |
| methyldopa | #1696 |
| ≤2 | #1696 |
| nootropic | #1698 |
| randomization | #1698 |
| patients bone | #1698 |
| morpholines | #1700 |
| patients control | #1701 |
| symptom distress | #1701 |
| endpoint | #1703 |
| enrolled patients | #1705 |
| glutamine | #1705 |
| reported symptoms | #1706 |
| study groups | #1707 |
| chisquare | #1708 |
| chemotherapy patients | #1709 |
| 595 | #1709 |
| endocrine treatment | #1711 |
| incorrectly | #1714 |
| inhibitor therapy | #1715 |
| crossover study | #1716 |
| hyperalgesia male | #1717 |
| antineoplastic agents carcinoma | #1719 |
| interventions patients | #1720 |
| human epidermal | #1726 |
| effects cancer | #1726 |
| selective estrogen | #1728 |
| referral consultation | #1728 |
| 652 | #1729 |
| testosterone treatment | #1729 |
| nineteen | #1730 |
| neuropathic pain | #1731 |
| orchiectomy | #1731 |
| lmwh | #1738 |
| paucity | #1740 |
| life questionnaires | #1741 |
| topical | #1746 |
| p450 cyp2d6 | #1746 |
| ≥10 | #1749 |
| oxcarbazepine | #1749 |
| scores patients | #1751 |
| fifty | #1752 |
| recommendations patients | #1753 |
| neoplasms early | #1754 |
| unique challenges | #1754 |
| greater reduction | #1762 |
| insufficient evidence | #1762 |
| treatment data | #1762 |
| cramps | #1764 |
| fall risk | #1765 |
| grade 2 | #1766 |
| massage | #1766 |
| progression survival | #1770 |
| anticoagulants doacs | #1772 |
| urinary symptoms | #1775 |
| performance status | #1779 |
| 95 0 | #1781 |
| clinical endpoints | #1781 |
| objective responses | #1784 |
| fingers | #1784 |
| behavioral interventions | #1785 |
| lignans | #1785 |
| pros | #1787 |
| dizziness | #1789 |
| facts | #1790 |
| anorectic | #1791 |
| life assessment | #1791 |
| survival outcomes patients | #1791 |
| drug therapy | #1792 |
| rbc transfusion | #1794 |
| transient receptor | #1795 |
| alternative medicine | #1796 |
| primary therapy | #1796 |
| descriptive analysis | #1798 |
| decision aids | #1800 |
| investigator | #1802 |
| treatment cycles | #1803 |
| acetylcarnitine | #1803 |
| median survival time | #1804 |
| severe toxicity | #1804 |
| supporting | #1805 |
| premenopause | #1807 |
| adjunct | #1808 |
| analgesic efficacy | #1811 |
| topic | #1812 |
| agents female | #1813 |
| 16 patients | #1813 |
| breast surgery | #1816 |
| evidencebased recommendations | #1818 |
| trpm | #1818 |
| ql | #1821 |
| receptor potential | #1822 |
| cancer women | #1823 |
| 327 | #1823 |
| evaluable patients | #1825 |
| effective therapy | #1825 |
| anxiety agents | #1827 |
| ganglion neurons | #1831 |
| humans neoplasm | #1831 |
| longterm survival patients | #1835 |
| neoplasms prognosis | #1835 |
| suffering | #1836 |
| menopausal transition | #1837 |
| administration topical | #1849 |
| active cancer | #1850 |
| months 12 | #1851 |
| comprehensive cancer | #1851 |
| patients prognosis | #1853 |
| neuropathic | #1853 |
| dermatological | #1853 |
| 23 months | #1853 |
| providers patients | #1857 |
| aged postmenopause | #1858 |
| initial dose | #1858 |
| cancer types | #1858 |
| rationale design | #1863 |
| antimitotic | #1864 |
| univariate analyses | #1867 |
| antimetabolites | #1871 |
| europe female humans | #1873 |
| humans pain | #1873 |
| secondary objective | #1876 |
| continuing | #1877 |
| vice | #1878 |
| induced pain | #1879 |
| resultsa total | #1879 |
| antigen colorectal | #1881 |
| analysis adult | #1881 |
| musculoskeletal pain | #1881 |
| leucovorin male | #1886 |
| galvanic | #1887 |
| weeks | #1888 |
| 15 weeks | #1890 |
| questionnaires time | #1891 |
| schedules | #1891 |
| keratinocyte | #1891 |
| mainstay | #1892 |
| sexual functioning | #1893 |
| hospice | #1896 |
| triazoles | #1897 |
| sensory motor | #1898 |
| problematic | #1899 |
| stellate | #1899 |
| psqi | #1903 |
| topic surveys | #1910 |
| treatment modality | #1911 |
| neuropeptide | #1913 |
| evidence recommendations | #1918 |
| serum cortisol | #1922 |
| creams | #1924 |
| unwanted | #1928 |
| symptoms women | #1933 |
| pain | #1940 |
| health personnel attitude | #1946 |
| prematurely | #1946 |
| patients prostate cancer | #1949 |
| 5year followup | #1950 |
| treatment trial | #1951 |
| peritoneal neoplasms | #1952 |
| imidazoles | #1953 |
| cancer survivorship | #1955 |
| diagnosed breast | #1956 |
| cannabidiol | #1964 |
| signed | #1966 |
| nipple | #1969 |
| primary aim | #1971 |
| iii breast | #1971 |
| warrant | #1972 |
| surveillance colonoscopy | #1974 |
| articles | #1974 |
| initiating | #1975 |
| estrogen replacement | #1978 |
| clinical patients | #1978 |
| hand foot | #1979 |
| intravaginal | #1982 |
| collaborative | #1982 |
| dose melphalan | #1983 |
| controlled trial | #1985 |
| wasting syndrome | #1989 |
| androgen antagonists | #1994 |
| cancer patient | #1994 |
| current treatments | #2002 |
| stool samples | #2004 |
| patients dose | #2005 |
| effective therapies | #2011 |
| dose reductions | #2012 |
| gastrointestinal neoplasms | #2017 |
| phytotherapy plant | #2018 |
| form36 | #2018 |
| fallopian tube | #2019 |
| topic clinical trials | #2022 |
| steroidal aspirin | #2023 |
| critics | #2025 |
| perimenopausal | #2025 |
| neuromuscular diseases | #2026 |
| cardiotoxicity | #2029 |
| testing patients | #2031 |
| patients arm | #2032 |
| outpatient visits | #2034 |
| doses | #2036 |
| eortc qlqc30 | #2038 |
| transcutaneous | #2041 |
| exercise interventions | #2042 |
| recurrence survival | #2044 |
| dnr | #2045 |
| functional impairment | #2046 |
| breast cancer treatment | #2047 |
| evidence base | #2056 |
| status patients | #2056 |
| concentration time | #2058 |
| doxorubicin female | #2059 |
| 35 patients | #2063 |
| antibodies monoclonal antibodies | #2064 |
| head neck cancers | #2065 |
| chest | #2066 |
| cancer population | #2069 |
| relaxation therapy | #2069 |
| 120 patients | #2070 |
| contention | #2073 |
| inhibitor treatment | #2074 |
| hb level | #2075 |
| daily | #2075 |
| safety pharmacokinetics | #2075 |
| 50 reduction | #2076 |
| vinblastine | #2076 |
| nk1 | #2077 |
| benefit | #2080 |
| methysergide | #2081 |
| 20 day | #2082 |
| iii | #2087 |
| younger women | #2087 |
| patients caregivers | #2088 |
| advanced cancers | #2090 |
| antidote | #2090 |
| nursing practice | #2090 |
| major bleeding | #2094 |
| cco | #2094 |
| 66 years | #2097 |
| weekly paclitaxel | #2097 |
| anticonvulsants | #2102 |
| density bone | #2103 |
| mcg | #2104 |
| mitomycins | #2107 |
| therapy chemotherapy | #2109 |
| eicosapentaenoic acid | #2110 |
| tmt | #2111 |
| orally administered | #2111 |
| menopausal status | #2113 |
| day 1 | #2114 |
| 65 | #2115 |
| bmd lumbar spine | #2121 |
| ≥2 | #2121 |
| 5fluorouracil | #2122 |
| 96 patients | #2124 |
| treatment study | #2124 |
| journals | #2125 |
| mildly | #2126 |
| hb levels | #2126 |
| ttr | #2127 |
| bpi | #2128 |
| hormone concentrations | #2129 |
| hepcidins | #2130 |
| neoplasms clinical | #2133 |
| osteolytic | #2135 |
| secondary objectives | #2136 |
| 525 | #2136 |
| egfr inhibitors | #2136 |
| concerned | #2136 |
| aggressive disease | #2140 |
| qol | #2142 |
| levamisole | #2150 |
| tolerable | #2153 |
| carcinoembryonic antigen | #2154 |
| regimens | #2157 |
| item | #2158 |
| prt | #2160 |
| preventive strategies | #2161 |
| baseline | #2166 |
| evidence efficacy | #2166 |
| treatment acute | #2169 |
| anemic | #2169 |
| aloe | #2175 |
| women | #2177 |
| worst | #2179 |
| album | #2179 |
| pain syndromes | #2179 |
| tosyl | #2181 |
| physician | #2182 |
| detailed description | #2185 |
| fatigue pain | #2188 |
| 44 patients | #2195 |
| nervous | #2197 |
| severe symptoms | #2204 |
| questionnaires survivors | #2207 |
| dose intensity | #2208 |
| 455 | #2208 |
| prescription drugs | #2210 |
| age race | #2210 |
| female head | #2210 |
| 1 7 | #2212 |
| ensuing | #2213 |
| hypnosis | #2213 |
| weight loss | #2214 |
| 1–4 | #2220 |
| recurrences | #2220 |
| cmt | #2224 |
| adenosyl | #2225 |
| premenopausal | #2226 |
| myalgia | #2233 |
| osteonecrosis jaw | #2235 |
| 9 weeks | #2235 |
| 138 | #2242 |
| 60 minutes | #2243 |
| adrenal axis | #2247 |
| failed | #2247 |
| patient populations | #2251 |
| dermatologic | #2256 |
| life severity | #2257 |
| preliminary evidence | #2262 |
| summarized | #2265 |
| exercise female humans | #2266 |
| clinically meaningful | #2270 |
| patients metastatic melanoma | #2271 |
| 566 | #2272 |
| differences patients | #2273 |
| irritation | #2277 |
| bioelectrical impedance | #2284 |
| 1 year patients | #2285 |
| oophorectomy | #2285 |
| occult | #2288 |
| metastatic melanoma | #2290 |
| osteoporosis postmenopausal | #2291 |
| sloan | #2292 |
| gastrointestinal cancer | #2293 |
| likewise | #2298 |
| 800 | #2299 |
| therapy adt | #2301 |
| life illness | #2301 |
| regular | #2302 |
| dysfunction physiological | #2303 |
| incisional | #2308 |
| future trials | #2309 |
| conclusionthe | #2310 |
| polymerase inhibitors | #2310 |
| recommendation | #2311 |
| patch | #2311 |
| cramp | #2312 |
| genetic variations | #2314 |
| therapeutic strategies | #2320 |
| topic risk | #2326 |
| baclofen | #2327 |
| 74 | #2327 |
| weight breast | #2328 |
| worse | #2329 |
| mastectomy segmental | #2333 |
| 36 | #2333 |
| burning | #2333 |
| toxicity | #2334 |
| modest | #2334 |
| subcutaneously | #2335 |
| receptor positive | #2337 |
| exclusion criteria | #2338 |
| week | #2342 |
| opioid analgesics | #2347 |
| society | #2347 |
| improve quality | #2349 |
| androgen deprivation | #2349 |
| 46 patients | #2352 |
| curve analysis | #2352 |
| endorsed | #2357 |
| adult antineoplastic | #2359 |
| cyp2d6 | #2365 |
| density bmd | #2365 |
| increased risks | #2367 |
| baseline treatment | #2367 |
| nonrandomized | #2371 |
| 669 | #2373 |
| agent | #2374 |
| bibliometric | #2375 |
| rom | #2378 |
| health practice guidelines | #2379 |
| taste | #2389 |
| cancer clinical | #2390 |
| ornithine | #2391 |
| treatment duration | #2393 |
| difference 95 | #2396 |
| justification | #2397 |
| neoplasms survival | #2399 |
| neurological complications | #2400 |
| 266 | #2405 |
| counteract | #2405 |
| titles | #2406 |
| inadequate | #2407 |
| treatment baseline | #2407 |
| remaining patients | #2412 |
| postural | #2418 |
| poor performance | #2419 |
| rectal cancer patients | #2419 |
| ovid | #2420 |
| documenting | #2421 |
| advanced prostate cancer | #2425 |
| 5 patients | #2425 |
| symptom scores | #2426 |
| limited evidence | #2426 |
| debate | #2433 |
| 761 | #2436 |
| 71 patients | #2437 |
| practiced | #2437 |
| estrogen deficiency | #2439 |
| patients crc | #2439 |
| response evaluation | #2442 |
| acupuncture | #2442 |
| outpatient treatment | #2443 |
| phase trials | #2449 |
| 56 years | #2452 |
| chemotherapy adjuvant | #2453 |
| receptor antagonist | #2460 |
| common cancers | #2462 |
| iiic | #2463 |
| common adverse | #2464 |
| assessment scale | #2469 |
| factor inhibitors | #2469 |
| fallopian | #2474 |
| 207 | #2474 |
| patients quality life | #2477 |
| weight gain | #2478 |
| bleomycin | #2480 |
| guidelines patients | #2481 |
| practical approach | #2485 |
| network metaanalysis | #2491 |
| crossed | #2493 |
| approached | #2494 |
| melanomas | #2495 |
| raloxifene | #2496 |
| discontinuing | #2497 |
| 6 patients | #2502 |
| sexual function | #2507 |
| ginkgo | #2510 |
| locoregional | #2510 |
| 61 | #2510 |
| patients colorectal cancer | #2519 |
| children cancer | #2524 |
| topic clinical | #2526 |
| venous thromboembolism | #2527 |
| regimen | #2531 |
| cooperative | #2537 |
| asked | #2542 |
| amitriptyline | #2542 |
| radiation induced | #2544 |
| rescue | #2545 |
| 12 24 | #2556 |
| treatment methods | #2556 |
| carryover | #2557 |
| symptom | #2558 |
| galectin3 | #2562 |
| mandated | #2564 |
| randomised clinical trial | #2567 |
| telopeptide | #2567 |
| nitriles | #2568 |
| reuptake | #2570 |
| treatment selection | #2570 |
| earlystage breast cancer | #2573 |
| stage small | #2573 |
| conjunctivitis | #2574 |
| trials | #2592 |
| secondary analyses | #2592 |
| ideally | #2595 |
| carboplatin | #2597 |
| effects drugs | #2598 |
| 2 cycles | #2602 |
| erbb2 receptors | #2608 |
| parenteral | #2610 |
| arm | #2612 |
| pruritus | #2614 |
| patient education | #2617 |
| antineoplastic combined | #2624 |
| outcome united | #2624 |
| apr | #2626 |
| consented | #2626 |
| suspicious | #2627 |
| symptoms quality | #2629 |
| dorsal root | #2629 |
| life hrqol | #2631 |
| increased likelihood | #2639 |
| managing | #2642 |
| prefer | #2644 |
| remedy | #2648 |
| 55 | #2649 |
| races | #2657 |
| 0001 patients | #2657 |
| thromboembolism | #2657 |
| attenuate | #2662 |
| total parenteral nutrition | #2663 |
| scores | #2663 |
| lasted | #2667 |
| basal cell | #2670 |
| testosterone | #2672 |
| cancer outcomes | #2673 |
| imprecise | #2675 |
| comparable | #2676 |
| poorer survival | #2677 |
| symptoms treatment | #2685 |
| 817 | #2686 |
| prescribed | #2687 |
| prevention interventions | #2692 |
| statistically | #2696 |
| randomized controlled | #2699 |
| direct oral anticoagulants | #2701 |
| prevalence smoking | #2705 |
| impotence | #2707 |
| advanced colorectal | #2711 |
| data synthesis | #2713 |
| primary lung | #2717 |
| myelosuppression | #2724 |
| 1000 | #2735 |
| 01 | #2741 |
| chemotherapy protocols | #2745 |
| modestly | #2745 |
| thermal hyperalgesia | #2748 |
| acp | #2749 |
| multiple factors | #2749 |
| patients pain | #2750 |
| topic drug | #2752 |
| efficacies | #2753 |
| taxane | #2758 |
| advanced breast | #2760 |
| male medical | #2761 |
| ttf | #2762 |
| 250 | #2764 |
| neurotoxicity | #2769 |
| pyrazoles | #2774 |
| 1 4 | #2775 |
| male neoplasms | #2775 |
| 237 | #2776 |
| breast carcinoma | #2777 |
| convenience sample | #2780 |
| selfreport | #2781 |
| syndrome aged | #2788 |
| cryosurgery | #2789 |
| pooled data | #2790 |
| paraneoplastic syndromes | #2790 |
| neoplasia | #2791 |
| undergone | #2792 |
| adverse | #2793 |
| ascites | #2794 |
| isoflavones | #2794 |
| agents | #2797 |
| complete data | #2799 |
| nv | #2801 |
| thrice | #2801 |
| doacs | #2802 |
| acid epa | #2806 |
| cox model | #2812 |
| additional studies | #2813 |
| shortness | #2814 |
| continuous infusion | #2815 |
| preferred | #2817 |
| neurofeedback | #2823 |
| 750 | #2827 |
| breast | #2834 |
| sexual health | #2837 |
| muscle weakness | #2840 |
| 1 3 | #2842 |
| meeting | #2844 |
| opioids | #2844 |
| 38 | #2845 |
| primary outcomes | #2845 |
| cancer aged | #2854 |
| n31 | #2857 |
| cohen | #2857 |
| linseed | #2859 |
| breakthrough | #2859 |
| pharmacogenomic | #2860 |
| neoplasms | #2860 |
| sham | #2861 |
| statistical methods | #2866 |
| activity level | #2867 |
| breaths | #2867 |
| purposethe | #2869 |
| anticipate | #2869 |
| covariate | #2870 |
| fertility preservation | #2875 |
| surveillance patients | #2876 |
| task force | #2886 |
| 5 years patients | #2886 |
| ellipse | #2893 |
| survival dose | #2895 |
| p04 | #2895 |
| decarboxylase | #2912 |
| functional assessment | #2915 |
| endodermal | #2917 |
| packyears | #2918 |
| screening tests | #2920 |
| measurable | #2922 |
| p0002 | #2927 |
| placebo response | #2930 |
| prior | #2931 |
| condylomata | #2931 |
| phase clinical | #2933 |
| p008 | #2941 |
| topic design | #2945 |
| dosing regimens | #2949 |
| identifier | #2949 |
| review articles | #2949 |
| colonoscopy colorectal | #2951 |
| auc | #2954 |
| laser treatment | #2955 |
| utility | #2956 |
| week 12 | #2961 |
| 2 groups | #2962 |
| humans infusions | #2963 |
| hirsutism | #2966 |
| combined chemotherapy | #2969 |
| search terms | #2971 |
| curable | #2974 |
| chest wall | #2975 |
| intraepithelial neoplasia | #2977 |
| prophylactic | #2982 |
| placebo difference | #2983 |
| questionnaires | #2985 |
| eicosapentaenoic | #2986 |
| calculator | #2988 |
| testimony | #2989 |
| stopped | #2990 |
| started | #2991 |
| calories | #2991 |
| severity symptoms | #2995 |
| positive breast | #2998 |
| fatigue | #3000 |
| resected | #3004 |
| long acting | #3010 |
| objective response | #3012 |
| n5 | #3012 |
| topically | #3013 |
| time progression | #3014 |
| discomfort | #3014 |
| pathologic complete response | #3019 |
| patients 5 | #3022 |
| mianserin | #3026 |
| bone fractures | #3029 |
| ifosfamide | #3033 |
| nci | #3034 |
| skeletal muscle mass | #3038 |
| her2 status | #3041 |
| reuptake inhibitors | #3041 |
| dermatoses | #3042 |
| placebo week | #3052 |
| sided | #3053 |
| relief | #3058 |
| risk colorectal | #3058 |
| dukes | #3058 |
| tumor activity | #3066 |
| curve auc | #3067 |
| outcome measure | #3067 |
| 264 | #3068 |
| clonidine | #3069 |
| malignancy | #3071 |
| hyperhidrosis | #3072 |
| ctx | #3074 |
| sternal | #3076 |
| histograms | #3092 |
| sexual dysfunction | #3097 |
| nicotine dependence | #3098 |
| loss adult | #3099 |
| intergroup | #3103 |
| patients day | #3107 |
| tumor grade | #3108 |
| vera | #3111 |
| cancer female humans | #3111 |
| bmd | #3111 |
| 66 | #3116 |
| 26 | #3121 |
| neurokinin1 | #3121 |
| reversing | #3135 |
| cognitive dysfunction | #3139 |
| schedule | #3143 |
| 12 weeks | #3144 |
| treatment oral | #3146 |
| life measures | #3147 |
| clinical stage | #3150 |
| trpv1 | #3154 |
| infusions intravenous | #3155 |
| randomized controlled study | #3161 |
| χ2 | #3165 |
| subsequent development | #3166 |
| strongest association | #3168 |
| lifestyle factors | #3178 |
| phase 3 | #3180 |
| reasonable | #3181 |
| systematic literature search | #3183 |
| supportive | #3185 |
| current approaches | #3185 |
| leuprolide | #3186 |
| relevant articles | #3188 |
| 617 | #3189 |
| intravenous | #3190 |
| wore | #3192 |
| cannabinoids | #3193 |
| 64 | #3196 |
| podophyllotoxin | #3197 |
| abstracted | #3201 |
| menopausal | #3208 |
| case reports | #3210 |
| constellation | #3218 |
| 42 | #3222 |
| joint committee | #3225 |
| intervention trial | #3225 |
| 39 | #3226 |
| nonsmallcell lung cancer | #3226 |
| cochrane central register | #3231 |
| pain perception | #3235 |
| enrolled | #3238 |
| breathing | #3239 |
| medical record | #3240 |
| paraneoplastic | #3245 |
| itch | #3260 |
| therapy combination | #3260 |
| intervention patients | #3263 |
| oral mucosa | #3264 |
| designed | #3264 |
| 236 | #3266 |
| disagree | #3269 |
| prior studies | #3269 |
| treatment efficacy | #3270 |
| n30 | #3271 |
| 5 10 | #3272 |
| skin biopsies | #3278 |
| supplementary | #3279 |
| finished | #3282 |
| expert panel | #3284 |
| 2030 | #3287 |
| root ganglia | #3287 |
| 80 antibodies | #3288 |
| 885 | #3290 |
| lymphoma patients | #3290 |
| 695 | #3290 |
| previous analyses | #3291 |
| 576 | #3294 |
| understudied | #3296 |
| 0026 | #3303 |
| neuralgia | #3313 |
| suffer | #3314 |
| undertook | #3316 |
| resection colorectal | #3319 |
| treatment placebo | #3320 |
| impression | #3320 |
| electronic health | #3321 |
| chlorhexidine | #3322 |
| prostate cancer risk | #3328 |
| 171 | #3334 |
| acuminata | #3334 |
| risk vte | #3339 |
| systemically | #3350 |
| platinum based | #3352 |
| terminology | #3356 |
| erythema | #3358 |
| historic | #3360 |
| female breast | #3365 |
| breast prostate | #3368 |
| doubt | #3370 |
| bone metastases | #3370 |
| thirty | #3374 |
| preclinical studies | #3375 |
| relapse free | #3380 |
| chemoprevention | #3386 |
| acute chronic | #3392 |
| equivalency | #3395 |
| advanced prostate | #3396 |
| iii trials | #3399 |
| answers | #3400 |
| preceding | #3406 |
| oral | #3408 |
| lymph node excision | #3411 |
| prostatic neoplasms | #3415 |
| delaying | #3417 |
| anilides | #3418 |
| severity | #3422 |
| delineated | #3425 |
| axillary lymph | #3426 |
| administering | #3437 |
| npy | #3438 |
| higher scores | #3444 |
| screening methods | #3446 |
| 012 | #3446 |
| subsequent | #3452 |
| aminoquinolines | #3460 |
| utilizing | #3463 |
| 64 patients | #3463 |
| sprays | #3464 |
| survival benefits | #3468 |
| listed | #3468 |
| pts | #3468 |
| anthracyclines | #3471 |
| chemotherapy radiation | #3471 |
| multicenter randomized | #3473 |
| lidocaine | #3475 |
| lower rate | #3477 |
| mailed | #3479 |
| cross validation | #3480 |
| cessation smoking | #3481 |
| 3 6 | #3484 |
| attempt | #3489 |
| antidepressants | #3490 |
| intent | #3495 |
| reviewing | #3499 |
| ctc | #3500 |
| malignant disease | #3501 |
| — | #3505 |
| chemotherapeutic agent | #3512 |
| recommend | #3524 |
| allodynia | #3529 |
| carries | #3539 |
| metastatic disease | #3544 |
| points | #3545 |
| opiates | #3559 |
| stage breast | #3561 |
| 148 | #3565 |
| faced | #3566 |
| patients metastatic | #3574 |
| phase topic | #3583 |
| correlational | #3583 |
| survival women | #3583 |
| carboplatin paclitaxel | #3586 |
| 135 | #3586 |
| oestrogen | #3587 |
| chemotherapy cycles | #3588 |
| patients experiences | #3588 |
| treatment decisions | #3595 |
| 211 | #3596 |
| gold standard | #3607 |
| life qol | #3608 |
| objective measures | #3608 |
| periodically | #3610 |
| thiotepa | #3615 |
| stage iiia | #3618 |
| oral adult | #3619 |
| survival cancer | #3620 |
| ≥30 | #3620 |
| benefits risks | #3620 |
| therapeutic benefit | #3623 |
| improvement quality | #3629 |
| antacids | #3630 |
| 29 patients | #3631 |
| survivals | #3634 |
| racial differences | #3639 |
| complete responses | #3648 |
| patients adjuvant chemotherapy | #3650 |
| colon cancer | #3650 |
| ordinal | #3650 |
| adjuvant chemotherapy patients | #3652 |
| ≥18 years | #3655 |
| parp inhibitor | #3660 |
| bodymass | #3661 |
| 34 patients | #3666 |
| acid antagonists | #3674 |
| sigmoidoscopy | #3682 |
| 673 | #3682 |
| preceded | #3685 |
| 580 | #3686 |
| proportion | #3686 |
| aps | #3688 |
| thirty patients | #3689 |
| cardio | #3690 |
| chemotherapies | #3695 |
| redness | #3700 |
| moxibustion | #3702 |
| options | #3705 |
| electron rats | #3706 |
| relapsefree survival | #3707 |
| study evidence | #3708 |
| cancer chemotherapy | #3712 |
| annually | #3714 |
| instructed | #3716 |
| adjuvant chemotherapy | #3718 |
| 5000 | #3719 |
| exception | #3721 |
| 911 | #3725 |
| breast tissue | #3731 |
| impressive | #3738 |
| combination female | #3741 |
| foams | #3742 |
| randomized clinical trial | #3742 |
| practicing | #3743 |
| anabolic | #3746 |
| late effects | #3752 |
| lymphatic vessels | #3754 |
| weight status | #3758 |
| longterm survival | #3768 |
| menopausal women | #3774 |
| symptom severity | #3782 |
| vertigo | #3788 |
| adversely | #3789 |
| cancer drugs | #3795 |
| compassionate | #3800 |
| 567 | #3801 |
| hormone replacement therapy | #3804 |
| external beam | #3805 |
| sixth | #3806 |
| 600 | #3807 |
| hormone replacement | #3811 |
| terminal | #3811 |
| anesthetics | #3811 |
| colchicine | #3815 |
| phase trial | #3816 |
| centric | #3817 |
| etoposide | #3822 |
| pain control | #3825 |
| cancer prostate | #3830 |
| ploidies | #3831 |
| intramuscularly | #3834 |
| patients experienced | #3834 |
| 16 weeks | #3839 |
| 136 | #3839 |
| patients moderate | #3843 |
| cutaneous | #3846 |
| trpv | #3847 |
| contraindications | #3847 |
| seventy | #3854 |
| blinding | #3854 |
| patients grade | #3855 |
| sharks | #3855 |
| internally | #3858 |
| treatment metastatic | #3861 |
| 23 | #3861 |
| 04 | #3866 |
| futility | #3867 |
| 786 | #3875 |
| individually | #3880 |
| queried | #3882 |
| flushing | #3886 |
| midwestern | #3888 |
| adenomas | #3895 |
| compelling | #3897 |
| dfs survival | #3905 |
| modulators | #3906 |
| received chemotherapy | #3909 |
| sponsored | #3917 |
| bone turnover | #3919 |
| 24 weeks | #3921 |
| hyperactivation | #3922 |
| keywords | #3927 |
| vte patients | #3928 |
| therapies | #3933 |
| myoclonus | #3940 |
| publication clinical trials | #3940 |
| discontinued | #3942 |
| grade 1 | #3945 |
| 61 patients | #3947 |
| bf | #3950 |
| food drug administration | #3951 |
| difficulty | #3953 |
| colorectal | #3955 |
| inhibitors female | #3956 |
| prostate carcinoma | #3961 |
| capsaicin | #3969 |
| manifested | #3970 |
| study drug | #3973 |
| 25 | #3975 |
| accidental | #3976 |
| pain severity | #3977 |
| adenosine triphosphate | #3980 |
| pluronic | #3983 |
| 20 | #3988 |
| 30 years | #3991 |
| toxic effects | #3993 |
| 449 | #3994 |
| weight | #4002 |
| lasting | #4002 |
| 370 | #4004 |
| gait | #4005 |
| sideeffects | #4006 |
| 692 | #4008 |
| kras mutations | #4014 |
| surgery radiation | #4018 |
| estrogenic | #4023 |
| patients intervention | #4034 |
| audio | #4034 |
| year patients | #4039 |
| lumbar spine | #4044 |
| thirteen patients | #4047 |
| tid | #4052 |
| erythropoietin | #4062 |
| prostatic | #4062 |
| nonusers | #4066 |
| flax | #4068 |
| conjunction | #4069 |
| cancer therapy | #4069 |
| 516 | #4075 |
| intravenously | #4077 |
| extremities | #4084 |
| strong evidence | #4087 |
| meaningful | #4099 |
| revisions | #4102 |
| rose | #4108 |
| 2–4 | #4116 |
| iii study | #4120 |
| bone neoplasms | #4124 |
| dermatitis | #4125 |
| noninfiltrating | #4126 |
| favoring | #4126 |
| sphase | #4131 |
| documentation | #4132 |
| 7 months | #4134 |
| definitions | #4138 |
| tablets | #4138 |
| topic practice patterns | #4138 |
| malignant melanoma | #4139 |
| femoral neck | #4139 |
| 269 | #4143 |
| combination therapy | #4144 |
| mbc | #4157 |
| interleukin6 il6 | #4159 |
| 4 months | #4164 |
| 326 | #4175 |
| effective | #4194 |
| noxious | #4196 |
| 10 months | #4199 |
| calcium vitamin | #4201 |
| depressants | #4210 |
| cancer bone | #4210 |
| undertaken | #4211 |
| 2006 | #4220 |
| treatment option | #4223 |
| twothirds | #4232 |
| 18 months | #4236 |
| platinumbased chemotherapy | #4238 |
| drug response | #4250 |
| quinazolines | #4254 |
| anemia patients | #4256 |
| contraindication | #4258 |
| neoplasms colorectal | #4258 |
| serially | #4268 |
| treatment discontinuation | #4268 |
| cation channels | #4271 |
| 58 patients | #4278 |
| 2 4 | #4283 |
| bone density | #4284 |
| survival quality | #4284 |
| day | #4285 |
| utilized | #4289 |
| inconsistencies | #4289 |
| colorectal neoplasms | #4297 |
| rheumatism | #4301 |
| node negative | #4307 |
| aged breast | #4313 |
| bioavailable | #4314 |
| chemotherapy treatment | #4323 |
| reductions | #4326 |
| prednisolone | #4326 |
| vast | #4327 |
| bone diseases | #4330 |
| primary endpoints | #4331 |
| healthy women | #4331 |
| reply | #4340 |
| firstline chemotherapy | #4343 |
| treatment studies | #4355 |
| equally | #4357 |
| institute | #4359 |
| neoplasms combined | #4359 |
| participated | #4360 |
| detrimental effects | #4367 |
| outcome data | #4368 |
| 3 months | #4373 |
| sleeping | #4376 |
| discontinuation | #4381 |
| preliminary | #4385 |
| carcinoma ductal | #4389 |
| time surgery | #4393 |
| therapies patients | #4394 |
| judgment | #4395 |
| 12 week | #4396 |
| repeatedly | #4402 |
| drug combinations | #4402 |
| hyperalgesia | #4411 |
| grouping | #4414 |
| minnesota | #4415 |
| purpose | #4417 |
| “ | #4424 |
| evaluate | #4425 |
| 1015 | #4427 |
| 14 months | #4429 |
| balance | #4430 |
| 80 breast | #4431 |
| studies colorectal | #4431 |
| low doses | #4436 |
| drg neurons | #4437 |
| pain relief | #4438 |
| documented | #4440 |
| relevant studies | #4445 |
| day patients | #4446 |
| improve patient | #4446 |
| summarize | #4450 |
| clinical predictors | #4455 |
| clinical parameters | #4460 |
| humanized antineoplastic | #4464 |
| 80 | #4465 |
| pain measurement | #4465 |
| fecal | #4466 |
| clinical practice guidelines | #4490 |
| 05 | #4494 |
| risk breast cancer | #4499 |
| humans lymph | #4501 |
| received | #4504 |
| drug administration | #4505 |
| stimulants | #4510 |
| axillary | #4521 |
| daily activities | #4523 |
| 5 | #4523 |
| sedation | #4529 |
| gynecologic | #4530 |
| ductal breast | #4530 |
| ganglion | #4530 |
| disease recurrence | #4531 |
| cancer methods | #4534 |
| hematology | #4535 |
| disabling | #4536 |
| stimulant | #4536 |
| natural | #4537 |
| sphingolipids | #4537 |
| diarrhea | #4540 |
| drug effects | #4540 |
| journal | #4544 |
| impairments | #4546 |
| 3 4 | #4550 |
| ganglia spinal | #4552 |
| continuation | #4558 |
| outcome measures | #4561 |
| financial | #4562 |
| rescue therapy | #4564 |
| clinical | #4564 |
| 376 | #4567 |
| rbc | #4569 |
| 4 | #4575 |
| reliability validity | #4575 |
| successes | #4577 |
| single blind | #4583 |
| tumor regression | #4587 |
| explore | #4588 |
| risk bleeding | #4591 |
| hydroxytryptamine | #4591 |
| mmf | #4592 |
| cumulative | #4604 |
| tenderness | #4606 |
| 115 | #4609 |
| longer duration | #4612 |
| chemopreventive | #4617 |
| emphasizes | #4620 |
| neoplasms dna | #4626 |
| throat | #4633 |
| caf | #4636 |
| patients increase | #4642 |
| 6 12 | #4647 |
| neuropathies | #4647 |
| daily dose | #4647 |
| tumor recurrence | #4653 |
| 1 study | #4661 |
| data studies | #4662 |
| 96 | #4664 |
| adpribose | #4665 |
| dose chemotherapy | #4665 |
| increased incidence | #4669 |
| treatments | #4674 |
| qol patients | #4679 |
| vitality | #4683 |
| peaked | #4684 |
| hazards | #4689 |
| deprivation | #4691 |
| 29 | #4693 |
| secondary analysis | #4699 |
| treatment survival | #4701 |
| dose | #4704 |
| low dose | #4708 |
| dose reduction | #4712 |
| reference lists | #4722 |
| preliminary study | #4733 |
| ” | #4734 |
| mediastinum | #4734 |
| assessment tool | #4740 |
| phase 2 trial | #4741 |
| vigor | #4751 |
| percentage patients | #4752 |
| cgy | #4762 |
| efficacy tolerability | #4773 |
| analysis neoplasm | #4783 |
| recommended | #4785 |
| adt | #4790 |
| invasive breast cancer | #4792 |
| 353 | #4795 |
| proven | #4798 |
| 009 | #4806 |
| corticosteroid | #4806 |
| 538 | #4810 |
| tears | #4810 |
| evaluations | #4813 |
| circulating concentrations | #4817 |
| improved quality | #4818 |
| cancer compared | #4818 |
| acetylcysteine | #4821 |
| capecitabine | #4829 |
| musculoskeletal | #4830 |
| symptom burden | #4836 |
| multicenter | #4836 |
| carcinoma small | #4837 |
| bridged | #4837 |
| tubulin | #4841 |
| seer program | #4841 |
| aes | #4846 |
| 60 | #4848 |
| 55 patients | #4854 |
| receipt | #4857 |
| 381 | #4861 |
| patients recurrence | #4868 |
| patients prostate | #4870 |
| individual patient data | #4876 |
| amines | #4886 |
| neck neoplasms humans | #4890 |
| 048 | #4901 |
| receptor egfr | #4904 |
| fisher | #4910 |
| crc patients | #4911 |
| lastly | #4917 |
| systemic therapy | #4921 |
| harms | #4922 |
| platinum | #4924 |
| stage iiib | #4925 |
| abstinence | #4926 |
| unfavorable | #4927 |
| existed | #4928 |
| basal cell carcinoma | #4933 |
| ≥1 | #4937 |
| 727 | #4942 |
| coadministration | #4946 |
| screening tool | #4956 |
| sensitization | #4956 |
| 9 months | #4960 |
| plethora | #4970 |
| subsequently | #4974 |
| eligibility | #4975 |
| equivocal | #4980 |
| cancer background | #4981 |
| optimal management | #4983 |
| depot | #4989 |
| deep vein thrombosis | #4992 |
| cumulative dose | #4996 |
| recurrence free | #4997 |
| exercise intervention | #5003 |
| lessons | #5005 |
| metastatic prostate | #5016 |
| situ carcinoma | #5017 |
| based cohort | #5018 |
| combined treatment | #5027 |
| routine clinical | #5028 |
| biphasic | #5029 |
| multicenter trial | #5039 |
| initiate | #5045 |
| sedative | #5055 |
| actively | #5058 |
| missing data | #5060 |
| favorably | #5071 |
| osteoporosis | #5073 |
| physical symptoms | #5075 |
| 3 trials | #5076 |
| methotrexate | #5077 |
| karnofsky performance | #5084 |
| genistein | #5084 |
| study incidence | #5086 |
| phenobarbital | #5091 |
| 100 patients | #5098 |
| 342 | #5099 |
| version | #5104 |
| pyrimidinones | #5104 |
| bortezomib | #5105 |
| cisplatin treatment | #5106 |
| published | #5116 |
| skin neoplasms | #5121 |
| ntprobnp | #5124 |
| conventional chemotherapy | #5126 |
| physical therapy | #5131 |
| reducing | #5131 |
| 120 | #5141 |
| topical application | #5142 |
| indomethacin | #5143 |
| medicine humans | #5149 |
| higher rate | #5154 |
| women early | #5155 |
| lower rates | #5157 |
| bisphosphonates | #5165 |
| resolve | #5169 |
| prognostic | #5176 |
| analysis randomized | #5177 |
| compiled | #5181 |
| cycle | #5186 |
| antiinflammatory agents | #5187 |
| supplement | #5201 |
| thalidomide | #5207 |
| 30 patients | #5214 |
| references | #5218 |
| cisplatin | #5225 |
| april | #5231 |
| medications | #5239 |
| identical | #5243 |
| dying | #5243 |
| randomised controlled trial | #5244 |
| humans lung | #5249 |
| article | #5249 |
| insomnia | #5255 |
| conventionally | #5257 |
| patients time | #5257 |
| mitoxantrone | #5265 |
| progestins | #5266 |
| resectable | #5269 |
| low molecular | #5270 |
| caring | #5270 |
| negative impact | #5277 |
| health disparities | #5278 |
| sed | #5291 |
| undergo | #5306 |
| gynecology | #5309 |
| parenteral nutrition | #5310 |
| vaporizers | #5317 |
| cancer prevention | #5319 |
| conflicting | #5325 |
| pelvic | #5326 |
| ineligible | #5327 |
| 404 | #5333 |
| alkaloids | #5335 |
| anticipated | #5335 |
| administered | #5339 |
| methods design | #5344 |
| patient data | #5349 |
| monophenol | #5351 |
| sensation | #5359 |
| perceived | #5359 |
| current practice | #5361 |
| colorectal cancers | #5362 |
| answered | #5376 |
| neurologists | #5377 |
| 346 | #5385 |
| adenosylmethionine | #5393 |
| isotretinoin | #5394 |
| declining | #5396 |
| judged | #5403 |
| responding | #5412 |
| study women | #5421 |
| stage iii | #5423 |
| officinalis | #5423 |
| 33 | #5425 |
| colonic polyps | #5444 |
| axilla | #5468 |
| 57 | #5470 |
| manner | #5473 |
| p0006 | #5481 |
| minutes | #5482 |
| baseline characteristics | #5486 |
| health records | #5490 |
| pufas | #5492 |
| based interventions | #5496 |
| 167 | #5504 |
| preclinical models | #5506 |
| methylases | #5508 |
| ovary | #5512 |
| thromboembolic events | #5518 |
| patient demographics | #5521 |
| neoplasms humans | #5525 |
| 410 | #5535 |
| pooled | #5548 |
| medical conditions | #5556 |
| 03 | #5571 |
| cancer center | #5573 |
| ready | #5580 |
| acne | #5582 |
| routine clinical practice | #5583 |
| stage patients | #5590 |
| dropped | #5593 |
| 002 | #5594 |
| current literature | #5598 |
| patient quality | #5604 |
| woman | #5605 |
| 41 | #5611 |
| polyps | #5620 |
| carnitine | #5623 |
| enteral | #5633 |
| treatment approaches | #5638 |
| sensory | #5638 |
| new therapies | #5642 |
| lung carcinoma | #5642 |
| 0007 | #5648 |
| concurrent | #5672 |
| treatment regimens | #5676 |
| guideline | #5679 |
| constipation | #5683 |
| sf36 | #5684 |
| n6 | #5687 |
| standard chemotherapy | #5688 |
| neuromodulation | #5689 |
| 50 | #5693 |
| renewed | #5694 |
| dexamethasone | #5694 |
| desire | #5695 |
| preserve | #5696 |
| online | #5699 |
| patients therapy | #5701 |
| nonsignificant | #5703 |
| multiplied | #5704 |
| raise | #5705 |
| cancer type | #5708 |
| androgen | #5716 |
| trials rcts | #5722 |
| specialist | #5730 |
| complete | #5730 |
| dna content | #5733 |
| serial | #5736 |
| provider | #5761 |
| tumor breast | #5762 |
| tumor stage | #5762 |
| interruption | #5762 |
| total score | #5766 |
| impair | #5770 |
| versus | #5773 |
| chance | #5779 |
| carcinoma situ | #5783 |
| mucous | #5783 |
| nicotine | #5783 |
| exploratory study | #5790 |
| node excision | #5795 |
| 345 | #5805 |
| higher doses | #5806 |
| 395 | #5814 |
| vitamin | #5817 |
| systemic effects | #5827 |
| patients aspirin | #5828 |
| patient experience | #5830 |
| 4 5 | #5837 |
| cancer breast | #5842 |
| leukocyte count | #5850 |
| intermediate risk | #5852 |
| selfreported | #5855 |
| patients survival | #5857 |
| stools | #5858 |
| subgroups patients | #5873 |
| 405 | #5877 |
| interfere | #5877 |
| excitatory amino | #5883 |
| enrollment | #5886 |
| neoplasm recurrence | #5887 |
| exercises | #5888 |
| totally | #5898 |
| response relationship | #5899 |
| potential mechanisms | #5909 |
| 3 | #5910 |
| 0 1 | #5917 |
| trastuzumab | #5925 |
| alternating | #5926 |
| gel | #5930 |
| acids omega3 | #5935 |
| humans injections | #5940 |
| pooled analysis | #5946 |
| dysplastic | #5947 |
| questionnaires adult | #5952 |
| treatment toxicity | #5954 |
| previous | #5955 |
| treatment failure | #5964 |
| symptoms depression | #5967 |
| returned | #5979 |
| confounding | #5990 |
| analogue | #5995 |
| devoted | #5996 |
| 239 | #5997 |
| evaluation studies | #5997 |
| icd9 | #6000 |
| sectional survey | #6002 |
| validated | #6007 |
| serum patients | #6010 |
| 1977 | #6013 |
| insulinlike growth factor | #6013 |
| prognostic indicator | #6018 |
| minute | #6019 |
| descriptions | #6019 |
| worsened | #6026 |
| sentinel node | #6028 |
| 0013 | #6041 |
| chemotherapy radiotherapy | #6041 |
| grade 3 | #6042 |
| 243 | #6045 |
| new evidence | #6049 |
| month | #6052 |
| institutional | #6061 |
| syndrome | #6065 |
| protective agents | #6066 |
| caution | #6067 |
| stool | #6070 |
| 480 | #6082 |
| subscales | #6083 |
| approved | #6097 |
| aspect | #6098 |
| 20 years | #6102 |
| 43 | #6104 |
| hormone therapy | #6108 |
| increment | #6109 |
| tests prognosis | #6116 |
| spitzer | #6118 |
| conducted | #6120 |
| randomized controlled trial | #6125 |
| routes | #6128 |
| surviving | #6156 |
| antiepileptic | #6164 |
| kilogram | #6167 |
| endpoints | #6173 |
| inception | #6184 |
| skin diseases | #6188 |
| 241 | #6189 |
| omega3 | #6193 |
| selective serotonin | #6195 |
| boronic | #6199 |
| intraepithelial | #6204 |
| 16 | #6215 |
| 900 | #6218 |
| female | #6221 |
| central venous | #6229 |
| combination treatment | #6232 |
| 62 | #6234 |
| epa | #6239 |
| randomized clinical trials | #6242 |
| invasive breast | #6249 |
| patients colorectal | #6253 |
| treated mice | #6255 |
| exploratory | #6257 |
| 58 | #6258 |
| asymptomatic patients | #6260 |
| metastasis neoplasm | #6261 |
| receptors progesterone | #6265 |
| historically | #6269 |
| palliative | #6270 |
| protocols | #6275 |
| psychotropic drugs | #6280 |
| disclosure | #6280 |
| ease | #6282 |
| 2000 | #6283 |
| xerostomia | #6284 |
| followup patients | #6293 |
| innovations | #6299 |
| scopus | #6300 |
| benzhydryl | #6302 |
| insignificant | #6302 |
| survival female | #6312 |
| 328 | #6314 |
| chi2 | #6320 |
| prospective | #6330 |
| lobular | #6343 |
| counseling | #6344 |
| 59 | #6346 |
| rigorous | #6347 |
| clinically | #6350 |
| endocrine therapy | #6365 |
| aged | #6372 |
| fentanyl | #6372 |
| venous thromboembolism vte | #6385 |
| 2007 | #6385 |
| epidermal growth | #6393 |
| infusions | #6393 |
| breadth | #6395 |
| physicians | #6402 |
| cronbach | #6404 |
| narcotic | #6407 |
| vitro model | #6413 |
| early intervention | #6424 |
| sexes | #6425 |
| initial treatment | #6426 |
| endocrinology | #6432 |
| 2 3 | #6433 |
| pittsburgh | #6439 |
| psychotropic | #6439 |
| multinational | #6440 |
| entire | #6440 |
| 361 | #6445 |
| counts | #6446 |
| soybeans | #6449 |
| sex hormones | #6452 |
| logs | #6453 |
| congeners | #6455 |
| quality | #6458 |
| termed | #6470 |
| 75 | #6471 |
| intraluminal | #6471 |
| life health | #6478 |
| n16 | #6481 |
| treatment guidelines | #6482 |
| patients 2 | #6485 |
| time diagnosis | #6486 |
| mcf7 cells | #6496 |
| records | #6498 |
| abcb1 | #6499 |
| ≥18 | #6501 |
| usual patients | #6512 |
| disease stage | #6515 |
| adenoma | #6520 |
| complementary | #6521 |
| consultation | #6524 |
| guidance | #6531 |
| iu | #6533 |
| ranked | #6536 |
| developments | #6540 |
| transfusions | #6551 |
| 004 | #6552 |
| tumor location | #6554 |
| 86 | #6567 |
| 0004 | #6575 |
| analog | #6576 |
| 53 | #6591 |
| abstracts | #6593 |
| baseline patients | #6598 |
| initiated | #6602 |
| acting | #6604 |
| colonic neoplasms | #6605 |
| pyrazines | #6608 |
| l3 | #6612 |
| hemoglobins | #6612 |
| 287 | #6614 |
| decisions | #6614 |
| fourth | #6615 |
| phase | #6617 |
| 02 | #6618 |
| surveys questionnaires | #6621 |
| hrt | #6622 |
| curative resection | #6623 |
| familiar | #6641 |
| pellet | #6646 |
| guidelines | #6646 |
| crf | #6648 |
| patients health | #6651 |
| hormone receptor | #6651 |
| courses | #6664 |
| randomized controlled trials | #6666 |
| emerging evidence | #6681 |
| osseous | #6682 |
| physical health | #6683 |
| tools | #6685 |
| figure | #6689 |
| dex | #6691 |
| erectile dysfunction | #6694 |
| caloric | #6694 |
| develops | #6696 |
| neoplasm metastasis | #6699 |
| hypothesized | #6702 |
| radiotherapy chemotherapy | #6702 |
| ketamine | #6710 |
| colorectal cancer patients | #6717 |
| consecutive | #6717 |
| interprofessional | #6728 |
| detailed | #6731 |
| testicular cancer | #6743 |
| score | #6745 |
| 295 | #6750 |
| quit | #6751 |
| replacement therapy | #6751 |
| difference | #6763 |
| grade | #6770 |
| lower incidence | #6773 |
| true | #6776 |
| ocular | #6783 |
| prevents | #6784 |
| titration | #6787 |
| pain management | #6793 |
| longest | #6801 |
| search strategy | #6801 |
| frequently | #6801 |
| chart review | #6802 |
| rounds | #6804 |
| 344 | #6806 |
| hepcidin | #6809 |
| controlled studies | #6810 |
| fulfilled | #6810 |
| participating | #6811 |
| mice treated | #6818 |
| detect | #6826 |
| ovarian function | #6841 |
| treatment advanced | #6842 |
| integrative | #6851 |
| early treatment | #6853 |
| exercise therapy | #6861 |
| classification | #6874 |
| inventory | #6877 |
| narrative | #6879 |
| drg | #6883 |
| routinely | #6887 |
| new drugs | #6889 |
| secondary | #6891 |
| concerns | #6896 |
| strength muscle | #6898 |
| differ | #6903 |
| 277 | #6904 |
| serum concentrations | #6912 |
| tumor formation | #6917 |
| 5 ht | #6918 |
| controversial | #6930 |
| summarizes | #6932 |
| mass loss | #6941 |
| factors breast | #6942 |
| cbd | #6942 |
| iiib | #6944 |
| laparotomy | #6953 |
| diarrhoea | #6955 |
| tartrate | #6960 |
| quarter | #6970 |
| regressions | #6981 |
| skin temperature | #6981 |
| ais | #6986 |
| wearing | #6990 |
| calorie | #6990 |
| quiet | #6990 |
| definition | #6994 |
| 35 | #6994 |
| seer | #7001 |
| promise | #7002 |
| patients developed | #7006 |
| 1 year | #7011 |
| initially | #7015 |
| women study | #7019 |
| hemorrhage humans | #7020 |
| breast cancers | #7030 |
| 051 | #7045 |
| metaanalyses | #7049 |
| animal doseresponse relationship | #7050 |
| neoplasms risk | #7063 |
| interested | #7067 |
| patients 1 | #7067 |
| 50 patients | #7068 |
| 31 | #7083 |
| screening middle | #7089 |
| total | #7097 |
| overview | #7098 |
| asian patients | #7111 |
| neu | #7113 |
| approval | #7114 |
| 97 | #7121 |
| neoplasms treatment | #7122 |
| polyadp | #7124 |
| neoplasms female | #7130 |
| prostate cancer | #7130 |
| 261 | #7131 |
| female gastrointestinal | #7143 |
| strengthened | #7144 |
| neuroprotection | #7147 |
| 833 | #7154 |
| therapy humans | #7165 |
| estrogens | #7171 |
| appropriateness | #7179 |
| breast cancer risk | #7187 |
| expect | #7188 |
| pik3ca | #7201 |
| confirm | #7211 |
| uncontrolled | #7220 |
| estrogen | #7228 |
| entity | #7234 |
| discusses | #7238 |
| agents steroidal | #7255 |
| 203 | #7262 |
| questionnaire | #7264 |
| ameliorates | #7264 |
| chosen | #7266 |
| popularity | #7283 |
| additionally | #7295 |
| outpatients | #7296 |
| neoplasms primary | #7296 |
| cinahl | #7333 |
| node biopsy | #7334 |
| increased survival | #7336 |
| 10 | #7340 |
| aged anti | #7343 |
| stages | #7347 |
| superficial | #7353 |
| evaluates | #7353 |
| radiotherapy adjuvant | #7358 |
| prognosis prospective | #7361 |
| firstline therapy | #7376 |
| epo | #7378 |
| eating | #7379 |
| short | #7384 |
| square distribution | #7390 |
| 47 | #7393 |
| noradrenergic | #7407 |
| rfs | #7416 |
| curative | #7416 |
| esr1 | #7417 |
| radiotherapy | #7433 |
| genital | #7435 |
| emphasis | #7436 |
| confirmatory | #7436 |
| receptor agonists | #7436 |
| naphthalenes | #7437 |
| cancer treated | #7438 |
| established | #7449 |
| 25 patients | #7456 |
| clinical evaluation | #7467 |
| 199 | #7478 |
| 1st | #7482 |
| 058 | #7484 |
| wasting | #7488 |
| prognosis proportional | #7488 |
| treatment strategy | #7489 |
| bolus | #7496 |
| genetic factors | #7499 |
| metastatic colorectal | #7501 |
| gonadotropin | #7504 |
| 259 | #7507 |
| november | #7509 |
| dysplasia | #7523 |
| transaminases | #7524 |
| objectively | #7526 |
| melanoma patients | #7528 |
| cancer vaccines | #7531 |
| infertility | #7534 |
| investigators | #7534 |
| october | #7539 |
| tumor colorectal | #7541 |
| local neoplasm | #7543 |
| 315 | #7558 |
| primary treatment | #7559 |
| adequacy | #7564 |
| concurrently | #7578 |
| kaplanmeier method | #7583 |
| intraductal | #7586 |
| 00001 | #7589 |
| patients head | #7594 |
| grades | #7605 |
| single dose | #7607 |
| tretinoin | #7608 |
| discussions | #7609 |
| chronic pain | #7615 |
| coumarins | #7616 |
| gain | #7620 |
| opinions | #7621 |
| interval | #7624 |
| ploidy | #7624 |
| receptor antagonists | #7632 |
| receptor erbb2 | #7633 |
| pharmacists | #7641 |
| local neoplasms | #7642 |
| sequelae | #7645 |
| metastatic colorectal cancer | #7656 |
| clinical benefit | #7666 |
| retinoids | #7678 |
| corticosteroids | #7684 |
| visits | #7691 |
| longterm effects | #7695 |
| evident | #7696 |
| 1 day | #7699 |
| monitored | #7699 |
| 026 | #7710 |
| publication biomarkers | #7713 |
| surveys | #7725 |
| 021 | #7725 |
| recurrence | #7726 |
| risk breast | #7728 |
| thrombophilia | #7734 |
| washout | #7744 |
| administration | #7744 |
| onethird | #7749 |
| nicotinic | #7751 |
| rank | #7758 |
| cancer recurrence | #7763 |
| independent predictors | #7776 |
| omega3 fatty | #7779 |
| treatment time | #7780 |
| serotonergic | #7785 |
| pathophysiology | #7796 |
| negative effects | #7805 |
| 14 | #7807 |
| ovarian neoplasms | #7811 |
| erectile | #7812 |
| clinicians | #7820 |
| gonadal | #7839 |
| 12 months | #7842 |
| swallowing | #7843 |
| subcutaneous | #7855 |
| pain intensity | #7856 |
| patient centered | #7866 |
| thiophenes | #7869 |
| 0 | #7876 |
| hemoglobins humans | #7892 |
| statistic | #7900 |
| physical function | #7917 |
| ago | #7927 |
| impacted | #7927 |
| 40 | #7933 |
| dysfunctions | #7950 |
| androgens | #7955 |
| comparing | #7956 |
| 5year survival | #7956 |
| advanced | #7957 |
| generally | #7963 |
| 305 | #7965 |
| ductal carcinoma | #7968 |
| ≤ | #7972 |
| actuarial | #7973 |
| 055 | #7975 |
| individualized | #7981 |
| collect | #7982 |
| situation | #7983 |
| female genital | #7985 |
| 062 | #8006 |
| 278 | #8020 |
| noninferiority | #8032 |
| powered | #8051 |
| preclinical | #8062 |
| genders | #8063 |
| intractable | #8063 |
| colorectal cancer crc | #8064 |
| 45 | #8065 |
| 208 | #8069 |
| 105 | #8086 |
| sixteen | #8088 |
| humans longitudinal | #8090 |
| relating | #8096 |
| expand | #8099 |
| resultant | #8100 |
| trial background | #8102 |
| occurred | #8107 |
| irrespective | #8127 |
| analgesics opioid | #8128 |
| 5 years | #8132 |
| reduce | #8141 |
| receptors estrogen | #8142 |
| methodswe | #8150 |
| entering | #8154 |
| translational | #8164 |
| facilitating | #8173 |
| dose escalation | #8185 |
| specific antigen | #8189 |
| edetic | #8191 |
| ondansetron | #8204 |
| withdrawal | #8206 |
| tnf alpha | #8213 |
| cancer detection | #8218 |
| popular | #8220 |
| b4 | #8224 |
| mild | #8234 |
| spearman | #8242 |
| patients adult | #8249 |
| regard | #8249 |
| committees | #8252 |
| stage | #8255 |
| parp | #8258 |
| dietary supplements | #8265 |
| treated | #8266 |
| modalities | #8269 |
| tobramycin | #8285 |
| antitumor activity | #8287 |
| neoplasms male | #8289 |
| patient groups | #8315 |
| 201 | #8324 |
| estradiol | #8325 |
| risk cancer | #8327 |
| triazines | #8331 |
| wellbeing | #8341 |
| sertraline | #8344 |
| concern | #8345 |
| cell lung | #8349 |
| pubmed | #8352 |
| patient treatment | #8362 |
| year follow | #8372 |
| pharmacogenetics | #8372 |
| calcium | #8389 |
| clinical activity | #8395 |
| choose | #8397 |
| 6 cycles | #8403 |
| predisposing | #8405 |
| costly | #8417 |
| preparations | #8422 |
| undergoing | #8422 |
| neck neoplasms | #8435 |
| expense | #8447 |
| married | #8448 |
| detecting | #8460 |
| testing | #8465 |
| underestimate | #8466 |
| composition body | #8478 |
| 37 | #8482 |
| 3 trial | #8482 |
| eruptions | #8486 |
| oncologic | #8488 |
| neuromuscular | #8489 |
| clinical experience | #8509 |
| 39 patients | #8527 |
| respond | #8553 |
| cyclophosphamide | #8562 |
| 253 | #8570 |
| average | #8576 |
| 020 | #8587 |
| stratified | #8596 |
| exists | #8598 |
| ttp | #8610 |
| standard therapy | #8620 |
| 81 | #8624 |
| 015 | #8629 |
| morphine | #8637 |
| estrogen receptors | #8637 |
| cancer female | #8639 |
| remain | #8643 |
| fda | #8646 |
| legs | #8657 |
| initial | #8658 |
| relative risks | #8659 |
| practitioners | #8676 |
| functional status | #8679 |
| syndrome patients | #8684 |
| 6 months | #8685 |
| egfr | #8692 |
| grip | #8695 |
| notable | #8700 |
| single nucleotide polymorphisms | #8700 |
| molecular markers | #8705 |
| threatening | #8705 |
| loss | #8714 |
| aged 80 | #8715 |
| selfreports | #8722 |
| leptin | #8728 |
| 32 patients | #8731 |
| colorectal cancer | #8743 |
| drug | #8748 |
| perspectives | #8751 |
| majority | #8756 |
| illustrates | #8757 |
| inhibitors | #8764 |
| repeated | #8765 |
| 123 | #8769 |
| 2001 | #8774 |
| survivorship | #8779 |
| 066 | #8786 |
| aged models | #8792 |
| real | #8800 |
| mouth | #8800 |
| prospective randomized | #8808 |
| providers | #8813 |
| question | #8814 |
| advanced stage | #8823 |
| accumulating | #8842 |
| groups patients | #8847 |
| ferric | #8858 |
| uremic | #8865 |
| concomitant | #8886 |
| highrisk | #8893 |
| enteral nutrition | #8908 |
| publication aged aged | #8919 |
| predefined | #8929 |
| supplemental | #8938 |
| negatively | #8961 |
| 017 | #8966 |
| 145 | #8971 |
| ovaries | #8984 |
| demographics | #8989 |
| ribose | #8990 |
| 28 patients | #8996 |
| 2 study | #9000 |
| acceptability | #9006 |
| dna neoplasm | #9008 |
| 304 | #9013 |
| lung neoplasms | #9014 |
| analyses | #9017 |
| bivariate | #9019 |
| longer | #9020 |
| favored | #9020 |
| 300 | #9035 |
| 18 | #9037 |
| literature | #9043 |
| 223 | #9060 |
| vagina | #9062 |
| analgesics | #9073 |
| women risk | #9074 |
| 116 | #9084 |
| venous | #9089 |
| 275 | #9107 |
| consisted | #9112 |
| medical treatment | #9114 |
| 70 | #9117 |
| instability | #9124 |
| oral anticoagulants | #9131 |
| referred | #9132 |
| 286 | #9133 |
| gene expression profiling | #9135 |
| rated | #9162 |
| 232 | #9167 |
| 1987 | #9170 |
| 103 | #9180 |
| germ cell | #9183 |
| erbb receptors | #9195 |
| feeling | #9196 |
| moderate | #9197 |
| embryonal | #9202 |
| erythropoiesis | #9216 |
| 12 patients | #9228 |
| predict | #9230 |
| approaches | #9232 |
| 320 | #9249 |
| psycinfo | #9250 |
| update | #9253 |
| incidence | #9265 |
| eighteen | #9277 |
| stimulate | #9281 |
| manifestation | #9291 |
| primary | #9292 |
| administrative | #9293 |
| greater risk | #9301 |
| favorable | #9308 |
| hypnotics | #9310 |
| systematic literature | #9317 |
| 94 | #9317 |
| possess | #9332 |
| 15 | #9332 |
| participant | #9336 |
| grip strength | #9341 |
| metastatic | #9361 |
| lives | #9367 |
| cycles | #9371 |
| acceptable | #9383 |
| mechanisms action | #9383 |
| ambulatory | #9385 |
| drug female | #9385 |
| postulated | #9389 |
| 177 | #9431 |
| 82 | #9435 |
| 28 | #9436 |
| consisting | #9437 |
| neurologic | #9443 |
| partial response | #9454 |
| definitive | #9454 |
| abdomen | #9468 |
| 3 groups | #9499 |
| death patients | #9509 |
| ophthalmic | #9514 |
| recurrence patients | #9518 |
| serving | #9539 |
| 500 | #9542 |
| cancer crc | #9542 |
| 006 | #9545 |
| 065 | #9547 |
| jaw | #9565 |
| decisionmaking | #9568 |
| imbalance | #9575 |
| melphalan | #9579 |
| similarities | #9580 |
| add | #9583 |
| sentinel lymph | #9619 |
| 68 | #9624 |
| progesterone receptor | #9627 |
| addressed | #9641 |
| oral cavity | #9657 |
| prednisone | #9662 |
| electroacupuncture | #9668 |
| publications | #9669 |
| referrals | #9677 |
| items | #9695 |
| p0004 | #9696 |
| fell | #9698 |
| 149 | #9702 |
| nerve injury | #9707 |
| adenocarcinoma aged | #9733 |
| logistic regression analysis | #9737 |
| smokers | #9746 |
| cope | #9749 |
| erbb | #9762 |
| experts | #9767 |
| carcinoma patients | #9777 |
| sleep disorders | #9784 |
| food intake | #9785 |
| priority | #9791 |
| monoclonal humanized | #9791 |
| 0002 | #9797 |
| remission induction | #9812 |
| exercise female | #9831 |
| trends | #9835 |
| 7 | #9836 |
| patient age | #9855 |
| saponins | #9856 |
| palliation | #9857 |
| neuroprotective agents | #9871 |
| avoid | #9872 |
| clinical outcomes patients | #9872 |
| 95ci | #9875 |
| goals | #9882 |
| bleeding | #9884 |
| axonal | #9897 |
| illness | #9909 |
| 89 | #9921 |
| injections | #9941 |
| zinc | #9942 |
| mitigate | #9952 |
| provision | #9954 |
| variety | #9963 |
| telephone | #9968 |
| recurrence rates | #9969 |
| education topic | #9980 |
| 88 | #9985 |
| behavioral therapy | #9988 |
| ethics | #9991 |
| 400 | #9997 |
| growing | #9999 |
| square | #10005 |
| prescribing | #10007 |
| reactions female | #10007 |
| advanced disease | #10009 |
| dosedependent manner | #10013 |
| exist | #10016 |
| art | #10020 |
| bone resorption | #10023 |
| progressed | #10053 |
| women health | #10061 |
| autonomic | #10070 |
| ortho | #10071 |
| reason | #10076 |
| percentages | #10095 |
| candidates | #10096 |
| exceptions | #10097 |
| 76 | #10099 |
| node dissection | #10100 |
| il1β | #10101 |
| criterion | #10109 |
| disease adult | #10113 |
| 56 | #10120 |
| predictive factors | #10154 |
| preference | #10168 |
| micronutrients | #10188 |
| categorized | #10215 |
| measures | #10218 |
| monoamine | #10221 |
| 12 | #10224 |
| 40 patients | #10233 |
| demonstrate | #10251 |
| lack | #10261 |
| curve | #10266 |
| guideline adherence | #10267 |
| 256 | #10271 |
| developed | #10274 |
| achieving | #10279 |
| caused | #10317 |
| higher incidence | #10325 |
| sarcomas | #10341 |
| epidermal | #10345 |
| variables | #10354 |
| bone mineral density | #10369 |
| anemia | #10385 |
| cell transplant | #10386 |
| morning | #10392 |
| survival dfs | #10400 |
| changed | #10400 |
| 3 5 | #10407 |
| 142 | #10413 |
| 141 | #10436 |
| smoking cessation | #10437 |
| chart | #10440 |
| 041 | #10450 |
| revised | #10485 |
| 24 hours | #10489 |
| lvef | #10497 |
| masked | #10500 |
| syndromes | #10508 |
| longitudinal studies | #10522 |
| mineral density | #10522 |
| effort | #10550 |
| instruments | #10555 |
| 154 | #10558 |
| define | #10560 |
| 650 | #10565 |
| surveillance | #10571 |
| persisted | #10581 |
| elucidate | #10582 |
| informed | #10584 |
| trend | #10585 |
| months 95 | #10586 |
| encountered | #10600 |
| 667 | #10608 |
| fewer | #10613 |
| counselling | #10617 |
| doxorubicin | #10617 |
| academic | #10623 |
| include | #10636 |
| concert | #10640 |
| european society | #10663 |
| histories | #10672 |
| curative intent | #10673 |
| upper extremity | #10688 |
| vitamins | #10697 |
| examinations | #10703 |
| treatment chronic | #10721 |
| prognostic significance | #10733 |
| median followup | #10743 |
| tests | #10751 |
| edema | #10753 |
| anticoagulants | #10757 |
| enter | #10757 |
| fat mass | #10763 |
| iiia | #10779 |
| median duration | #10779 |
| patients response | #10788 |
| induction chemotherapy | #10795 |
| 60 years | #10802 |
| 182 | #10803 |
| clinic | #10803 |
| columbia | #10805 |
| 73 | #10812 |
| insufficient | #10814 |
| rcts | #10818 |
| internal consistency | #10826 |
| 21 | #10828 |
| advisory | #10839 |
| noradrenaline | #10843 |
| recurrent | #10863 |
| randomised controlled | #10873 |
| determine | #10873 |
| hydroxy | #10874 |
| neck cancer | #10884 |
| clinicaltrialsgov | #10885 |
| nighttime | #10888 |
| felt | #10892 |
| held | #10899 |
| 1 patient | #10911 |
| 9 patients | #10922 |
| limited | #10928 |
| occurring | #10934 |
| supplements | #10937 |
| kits | #10950 |
| head neck cancer | #10956 |
| cognition disorders | #10958 |
| start | #10961 |
| retrospective review | #10966 |
| failure | #10978 |
| needed | #10981 |
| squamous cell carcinoma | #10982 |
| registry | #10999 |
| physiology | #11017 |
| 155 | #11028 |
| 030 | #11031 |
| agents drug | #11051 |
| rationale | #11080 |
| ascertained | #11084 |
| interventions | #11094 |
| soft tissue | #11097 |
| international society | #11105 |
| smoking | #11105 |
| 3 years | #11121 |
| 043 | #11122 |
| editorial | #11123 |
| years diagnosis | #11128 |
| sleep wake | #11133 |
| practice guidelines | #11135 |
| sick | #11135 |
| 091 | #11146 |
| decrease | #11150 |
| extensive | #11160 |
| head neck | #11164 |
| reduces | #11166 |
| 127 | #11168 |
| subclinical | #11185 |
| decreases | #11199 |
| progesterone | #11207 |
| facilitate | #11216 |
| gamma | #11222 |
| 2004 | #11246 |
| secondary outcome | #11250 |
| anticoagulation | #11251 |
| 1983 | #11257 |
| survival | #11259 |
| prostate | #11267 |
| contributed | #11278 |
| cognitive behavioral | #11279 |
| diploid | #11281 |
| therapy neoplasm | #11287 |
| snps | #11295 |
| closer | #11307 |
| reviews | #11329 |
| benzimidazoles | #11334 |
| vincristine | #11361 |
| 168 | #11373 |
| thrombocytopenia | #11377 |
| 129 | #11387 |
| affect | #11397 |
| radiation therapy | #11423 |
| subgroup analyses | #11428 |
| apparent | #11439 |
| clinical signs | #11439 |
| point | #11449 |
| rating scale | #11457 |
| 78 | #11468 |
| 092 | #11469 |
| label | #11482 |
| 2 trial | #11486 |
| patients patient | #11493 |
| multidimensional | #11498 |
| alive | #11501 |
| 235 | #11509 |
| caregivers | #11509 |
| recombinant human | #11530 |
| 6 | #11541 |
| 130 | #11548 |
| lymphatic metastasis | #11549 |
| 040 | #11553 |
| helps | #11582 |
| computerized | #11583 |
| 109 | #11585 |
| enhancing | #11586 |
| 20 patients | #11588 |
| analgesic | #11591 |
| humans mass | #11616 |
| incontinence | #11617 |
| opioid | #11645 |
| benefits | #11651 |
| pulmonary embolism | #11652 |
| minimal | #11660 |
| peritoneal | #11670 |
| 028 | #11674 |
| gefitinib | #11675 |
| adenocarcinoma adult | #11688 |
| camptothecin | #11691 |
| body image | #11717 |
| docetaxel | #11732 |
| sarcopenia | #11745 |
| lumbar | #11751 |
| small cell | #11764 |
| rheumatic | #11765 |
| comparisons | #11767 |
| nerves | #11789 |
| reduction | #11791 |
| oxidative damage | #11822 |
| aged postoperative | #11823 |
| 128 | #11825 |
| resultsthe | #11835 |
| risk recurrence | #11837 |
| 024 | #11855 |
| definite | #11855 |
| neoplasms cell | #11862 |
| interim | #11864 |
| hematologic | #11897 |
| investigation | #11910 |
| testicular | #11913 |
| cured | #11926 |
| haloperidol | #11938 |
| pelvis | #11956 |
| thirteen | #11969 |
| humanized | #11970 |
| ≥3 | #11995 |
| 1998 | #11997 |
| referral | #11997 |
| involving | #11999 |
| 90 patients | #12014 |
| 24 patients | #12015 |
| humans | #12017 |
| negative breast | #12030 |
| effectively | #12047 |
| thirds | #12053 |
| single nucleotide | #12063 |
| muscarinic | #12067 |
| triphosphate | #12068 |
| committee | #12069 |
| rating | #12071 |
| bone mineral | #12074 |
| − | #12078 |
| toxic | #12079 |
| cumulative incidence | #12103 |
| greater | #12144 |
| expectancy | #12147 |
| dosage | #12148 |
| rectal cancer | #12163 |
| 119 | #12183 |
| 104 | #12187 |
| unadjusted | #12191 |
| validity | #12205 |
| aspirin | #12207 |
| deoxycytidine | #12226 |
| alternatively | #12248 |
| believed | #12251 |
| malignant | #12268 |
| sodium channel | #12270 |
| peri | #12270 |
| 2 weeks | #12279 |
| disease specific | #12302 |
| igf | #12308 |
| compliance | #12317 |
| categories | #12322 |
| cognitive | #12338 |
| terms | #12340 |
| grading | #12342 |
| classic | #12345 |
| tolerability | #12360 |
| sexual | #12361 |
| psychometrics | #12376 |
| 27 | #12378 |
| adjuvants | #12396 |
| falls | #12402 |
| searched | #12414 |
| relapse | #12415 |
| qualitative study | #12416 |
| sentinel | #12421 |
| p21ras | #12426 |
| 1 2 | #12446 |
| anticancer drugs | #12449 |
| science | #12462 |
| drug humans | #12482 |
| 90 | #12485 |
| predictive | #12492 |
| 194 | #12495 |
| embase | #12496 |
| transfusion | #12502 |
| consistency | #12511 |
| reasons | #12523 |
| prognostic factor | #12536 |
| mitomycin | #12540 |
| 010 | #12573 |
| predictors | #12577 |
| bladder cancer | #12581 |
| explored | #12591 |
| bioavailability | #12611 |
| sleep | #12615 |
| attempts | #12621 |
| test | #12626 |
| psychometric | #12641 |
| therapeutic approaches | #12642 |
| supports | #12643 |
| rank test | #12657 |
| fourteen | #12657 |
| recommendations | #12691 |
| problem | #12710 |
| 2013 | #12714 |
| patient outcome | #12719 |
| reliability | #12747 |
| translated | #12749 |
| stiffness | #12752 |
| crc | #12777 |
| missed | #12783 |
| develop | #12817 |
| 023 | #12853 |
| segmental | #12865 |
| cancer nsclc | #12868 |
| patients surgery | #12874 |
| statistics | #12876 |
| subject | #12882 |
| ice | #12886 |
| normal tissue | #12931 |
| interviewed | #12944 |
| inform | #12945 |
| irreversible | #12946 |
| poorer | #12947 |
| coded | #12950 |
| 184 | #12952 |
| single agent | #12954 |
| scale | #12961 |
| univariate | #12983 |
| monoclonal antibodies monoclonal | #13009 |
| 193 | #13020 |
| n4 | #13025 |
| defining | #13026 |
| cancers | #13041 |
| ovariectomy | #13045 |
| paired | #13049 |
| humans logistic | #13082 |
| future | #13082 |
| suggests | #13099 |
| longterm followup | #13101 |
| pharmacotherapy | #13121 |
| trial comparing | #13126 |
| gains | #13129 |
| alter | #13132 |
| aged neoadjuvant | #13151 |
| inflammatory cytokines | #13153 |
| demographic | #13159 |
| originally | #13160 |
| cox regression | #13163 |
| responsiveness | #13183 |
| 44 | #13192 |
| tpa | #13230 |
| multiple myeloma | #13238 |
| humans lymphatic | #13262 |
| epidemiologic | #13262 |
| 21 patients | #13267 |
| longitudinal data | #13270 |
| myeloma | #13286 |
| racial | #13299 |
| requiring | #13322 |
| outpatient | #13334 |
| symptomatic | #13346 |
| cognitive function | #13351 |
| hours | #13376 |
| steroidal | #13380 |
| pg | #13393 |
| measure | #13408 |
| formal | #13409 |
| therapeutic potential | #13414 |
| intermediate | #13433 |
| muscle mass | #13492 |
| ductal | #13505 |
| eventually | #13506 |
| randomised trial | #13513 |
| attending | #13528 |
| psychometric properties | #13563 |
| discriminate | #13564 |
| pharmacological | #13578 |
| typically | #13588 |
| diminished | #13609 |
| improves | #13630 |
| agonists | #13630 |
| 196 | #13634 |
| skin cancer | #13649 |
| tended | #13650 |
| frequency | #13652 |
| participants | #13674 |
| infective | #13701 |
| hypothesis | #13703 |
| tested | #13723 |
| attempted | #13739 |
| initiation | #13758 |
| distress | #13778 |
| foods | #13785 |
| severe | #13795 |
| 192 | #13800 |
| clinical manifestations | #13803 |
| 18 years | #13813 |
| marked | #13813 |
| conditional | #13831 |
| 018 | #13858 |
| colonic | #13890 |
| solid tumors | #13891 |
| negative patients | #13900 |
| march | #13918 |
| lymphatic | #13928 |
| sleep quality | #13935 |
| mechanisms underlying | #13938 |
| 102 | #13944 |
| p00001 | #13946 |
| focus | #13988 |
| aged muscle | #13991 |
| conducting | #13996 |
| estimate male | #13999 |
| igf1 | #14032 |
| calcitonin | #14038 |
| head | #14056 |
| eastern | #14057 |
| substances | #14080 |
| lung cancer | #14080 |
| 0001 | #14090 |
| respondents | #14106 |
| skin | #14109 |
| 169 | #14117 |
| breast cancer cells | #14121 |
| physiologic | #14122 |
| antagonist | #14137 |
| led | #14139 |
| risk death | #14180 |
| her2 | #14186 |
| modality | #14195 |
| protective | #14195 |
| risk developing | #14199 |
| etiology | #14201 |
| 189 | #14202 |
| cytotoxic | #14234 |
| demonstrating | #14236 |
| 124 | #14251 |
| life style | #14259 |
| suboptimal | #14279 |
| careful | #14282 |
| states aged | #14282 |
| cetuximab | #14293 |
| hypothesize | #14318 |
| efficacy safety | #14319 |
| 32 | #14329 |
| recurrence risk | #14331 |
| analysis performed | #14341 |
| instance | #14341 |
| virtually | #14371 |
| 188 | #14375 |
| clinical impact | #14379 |
| cessation | #14403 |
| alpha2 | #14412 |
| produces | #14420 |
| 144 | #14420 |
| 4 patients | #14436 |
| nodal | #14440 |
| extremity | #14440 |
| transitional | #14454 |
| stat | #14456 |
| 178 | #14484 |
| 1997 | #14487 |
| distant metastases | #14504 |
| trial registration | #14517 |
| 2008 | #14518 |
| 8 | #14521 |
| univariate multivariate | #14524 |
| nsclc | #14525 |
| erbb2 | #14544 |
| gm | #14553 |
| 035 | #14567 |
| year survival | #14570 |
| heavily | #14577 |
| iron | #14583 |
| 34 | #14587 |
| prospectively | #14607 |
| 09 | #14626 |
| episodes | #14626 |
| 007 | #14634 |
| tumor response | #14639 |
| hypothetical | #14647 |
| additional | #14648 |
| initial diagnosis | #14674 |
| estrogen receptor | #14679 |
| prophylaxis | #14686 |
| 5 year | #14689 |
| dermal | #14710 |
| 008 | #14729 |
| adult | #14729 |
| menstrual | #14740 |
| examine | #14743 |
| practice | #14751 |
| reflecting | #14758 |
| neoplasm | #14762 |
| 15 years | #14762 |
| neoplasm staging | #14774 |
| interferons | #14781 |
| clarify | #14785 |
| health professionals | #14804 |
| erlotinib | #14821 |
| asian | #14838 |
| relevant | #14863 |
| peer | #14921 |
| 1990 | #14930 |
| cancer cases | #14942 |
| incorporate | #14956 |
| emerged | #14959 |
| cancer diagnosis | #14977 |
| median | #15008 |
| colorectal carcinoma | #15030 |
| cognitive decline | #15047 |
| 07 | #15052 |
| premature | #15064 |
| overexpressing | #15067 |
| expected | #15111 |
| september | #15115 |
| proportions | #15119 |
| 011 | #15123 |
| medical | #15125 |
| 2 | #15153 |
| clear | #15163 |
| p004 | #15169 |
| assessments | #15187 |
| colonoscopy | #15187 |
| odds ratios | #15193 |
| replacement | #15198 |
| ganglia | #15220 |
| specific | #15227 |
| portion | #15240 |
| intervals | #15241 |
| acute | #15247 |
| agreed | #15266 |
| subjective | #15290 |
| area | #15293 |
| subgroups | #15325 |
| achieved | #15344 |
| proliferative | #15352 |
| routine | #15362 |
| releasing hormone | #15390 |
| 131 | #15404 |
| 197 | #15404 |
| 072 | #15431 |
| 070 | #15436 |
| december | #15459 |
| investigate | #15464 |
| reports | #15470 |
| 51 | #15487 |
| race | #15509 |
| education | #15510 |
| 1 | #15515 |
| medication | #15554 |
| basis | #15598 |
| standard | #15614 |
| life expectancy | #15626 |
| ranging | #15639 |
| safely | #15648 |
| estimate | #15652 |
| male | #15673 |
| survival benefit | #15674 |
| 24 months | #15681 |
| criteria | #15693 |
| 502 | #15702 |
| measuring | #15712 |
| animals antineoplastic | #15714 |
| individual | #15716 |
| offered | #15728 |
| option | #15749 |
| updated | #15749 |
| colon | #15751 |
| period | #15756 |
| nutrition | #15780 |
| antagonists | #15789 |
| globulin | #15792 |
| quartile | #15810 |
| nonparametric | #15815 |
| kappa | #15831 |
| rate treatment | #15867 |
| societies medical | #15873 |
| local | #15882 |
| glandular | #15882 |
| 87 | #15905 |
| focused | #15931 |
| pharmacokinetics | #15932 |
| longitudinally | #15937 |
| dfs | #15988 |
| usa | #16013 |
| phenomenon | #16013 |
| roughly | #16039 |
| distant metastasis | #16044 |
| squared | #16045 |
| improvement | #16107 |
| 118 | #16114 |
| 079 | #16120 |
| february | #16127 |
| naïve | #16154 |
| decision | #16179 |
| 95 patients | #16188 |
| analysis survival | #16209 |
| 161 | #16209 |
| drug interactions | #16211 |
| lung | #16212 |
| 081 | #16213 |
| neoadjuvant | #16222 |
| supported | #16222 |
| 162 | #16223 |
| serotonin | #16242 |
| cold | #16243 |
| cation | #16245 |
| cochrane library | #16265 |
| 93 | #16278 |
| alternatives | #16284 |
| exceeded | #16313 |
| colleagues | #16319 |
| neurotransmitter | #16320 |
| detection cancer | #16320 |
| channel blockers | #16348 |
| supplemented | #16355 |
| papillomavirus | #16362 |
| 14 patients | #16380 |
| excision | #16385 |
| releasing | #16393 |
| kras | #16396 |
| neoplasm grading | #16407 |
| progressively | #16413 |
| 0006 | #16416 |
| diagnostic imaging | #16418 |
| improvements | #16418 |
| osteonecrosis | #16452 |
| scales | #16460 |
| 30 | #16525 |
| protect | #16536 |
| declined | #16537 |
| ranged | #16562 |
| black | #16565 |
| support | #16576 |
| population surveillance | #16580 |
| improving | #16587 |
| 13 patients | #16588 |
| condition | #16625 |
| systematic review metaanalysis | #16649 |
| radiation | #16657 |
| understand | #16705 |
| male neoplasm | #16705 |
| tumor size | #16709 |
| treat | #16715 |
| mucosa | #16717 |
| broader | #16719 |
| broadly | #16748 |
| 082 | #16750 |
| 106 | #16760 |
| 10 years | #16780 |
| post operative | #16791 |
| mimic | #16818 |
| studying | #16832 |
| demonstrated | #16842 |
| bayes | #16878 |
| safety | #16885 |
| rarely | #16886 |
| major | #16886 |
| maintained | #16890 |
| inpatient | #16921 |
| aware | #16924 |
| drugs | #16939 |
| 67 | #16962 |
| depletion | #16977 |
| sex | #16982 |
| hormone | #16988 |
| confer | #16998 |
| hemoglobin | #17005 |
| 125 | #17019 |
| maximum | #17031 |
| muscles | #17039 |
| investigating | #17045 |
| issues | #17053 |
| neoadjuvant therapy | #17063 |
| genotype humans | #17068 |
| publication adaptation | #17073 |
| 84 | #17091 |
| directed | #17099 |
| diseasefree survival | #17162 |
| iron deficiency | #17162 |
| disseminated | #17164 |
| utilize | #17166 |
| feasible | #17197 |
| energy intake | #17217 |
| inconsistent | #17247 |
| mineral | #17315 |
| 088 | #17335 |
| valid | #17344 |
| tnfα | #17364 |
| percentage | #17396 |
| interleukin6 | #17416 |
| raf | #17421 |
| describing | #17520 |
| centered | #17529 |
| neck | #17557 |
| functioning | #17582 |
| locally | #17585 |
| physical activity | #17586 |
| survival outcomes | #17596 |
| traditional | #17602 |
| fact | #17609 |
| original | #17648 |
| 080 | #17655 |
| 2019 | #17720 |
| current evidence | #17735 |
| log | #17761 |
| adding | #17766 |
| unrelated | #17776 |
| carcinogenesis | #17789 |
| lactic | #17816 |
| impairment | #17825 |
| assayed | #17837 |
| decreased | #17874 |
| confirms | #17879 |
| 094 | #17886 |
| examination | #17892 |
| graded | #17909 |
| meta | #17936 |
| monoclonal antibodies | #17955 |
| 200 | #17981 |
| minimum | #18048 |
| clinical presentation | #18052 |
| structured | #18083 |
| primary prevention | #18124 |
| 48 | #18131 |
| primary tumors | #18132 |
| formulated | #18148 |
| il6 | #18159 |
| metastasis male | #18162 |
| bone | #18174 |
| medline | #18185 |
| uncommon | #18193 |
| mass screening | #18244 |
| 80 biomarkers | #18256 |
| critically | #18295 |
| assessing | #18322 |
| retinoic | #18359 |
| hazards models | #18394 |
| reporting | #18396 |
| healthrelated quality | #18416 |
| relationships | #18418 |
| respective | #18423 |
| carry | #18439 |
| humans intestinal | #18447 |
| 096 | #18450 |
| 83 | #18485 |
| staging prognosis | #18489 |
| consistently | #18499 |
| akt | #18504 |
| adjustment | #18519 |
| equal | #18526 |
| 2 years | #18534 |
| maintain | #18583 |
| negligible | #18617 |
| nutritional | #18643 |
| 003 | #18655 |
| address | #18711 |
| raised | #18739 |
| 3 patients | #18741 |
| meier estimate | #18762 |
| kaplan meier | #18769 |
| mucosal | #18825 |
| promising | #18832 |
| highlighted | #18856 |
| includes | #18858 |
| 098 | #18862 |
| chronic diseases | #18875 |
| poor | #18878 |
| hormones | #18887 |
| tailored | #18923 |
| status | #18942 |
| united states | #18948 |
| pyridines | #18950 |
| serum | #18956 |
| orr | #18990 |
| histologic | #19009 |
| stimulating | #19056 |
| dysfunction | #19111 |
| meier | #19125 |
| cohort | #19137 |
| inhibitor | #19177 |
| mood | #19177 |
| ≥ | #19195 |
| excessive | #19215 |
| irinotecan | #19250 |
| agents apoptosis | #19258 |
| consensus | #19281 |
| accepted | #19282 |
| candidate | #19292 |
| recombinant proteins | #19298 |
| recorded | #19302 |
| ovarian | #19337 |
| metaanalysis | #19377 |
| newly | #19381 |
| staging | #19391 |
| global | #19431 |
| evidenced | #19433 |
| fats | #19483 |
| inflammatory agents | #19496 |
| proportional hazards | #19507 |
| prone | #19520 |
| asymptomatic | #19544 |
| surgically | #19614 |
| hospitalized | #19617 |
| pretreated | #19680 |
| degree | #19687 |
| predicted | #19728 |
| adaptation psychological | #19769 |
| emotional | #19779 |
| making | #19782 |
| humans kaplan | #19803 |
| scored | #19840 |
| kaplan | #19866 |
| neoplasms carcinoma | #19874 |
| 3 year | #19944 |
| 1995 | #19991 |
| procedures | #20019 |
| 2002 | #20057 |
| cervical | #20082 |
| tumor necrosis factor | #20104 |
| observational studies | #20128 |
| randomised | #20168 |
| mediator | #20189 |
| beneficial | #20254 |
| 24 | #20258 |
| patients risk | #20262 |
| maximal | #20273 |
| log rank | #20282 |
| small | #20300 |
| endocrine | #20301 |
| rates | #20333 |
| involves | #20398 |
| allcause mortality | #20422 |
| exploring | #20500 |
| assess | #20503 |
| adjusting | #20553 |
| successful | #20677 |
| usual | #20690 |
| women aged | #20722 |
| 95 confidence interval | #20729 |
| invasiveness neoplasm | #20747 |
| addressing | #20782 |
| 19 | #20821 |
| concluded | #20831 |
| july | #20847 |
| node | #20854 |
| finding | #21019 |
| remaining | #21031 |
| relationship | #21070 |
| collected | #21085 |
| male mass | #21107 |
| reliable | #21137 |
| year | #21139 |
| january | #21202 |
| statistical | #21265 |
| 1999 | #21287 |
| absence | #21319 |
| mri | #21400 |
| comparison | #21403 |
| extended | #21420 |
| proportional | #21490 |
| feasibility | #21521 |
| rectal | #21541 |
| prognosis | #21551 |
| gradually | #21576 |
| implementing | #21589 |
| models male | #21936 |
| improved | #21939 |
| death | #21941 |
| apply | #21969 |
| morbidity | #22004 |
| intervention | #22038 |
| insulin growth | #22054 |
| verbal | #22139 |
| 10 patients | #22157 |
| urinary | #22186 |
| combination | #22213 |
| 2005 | #22223 |
| authors | #22223 |
| alterations | #22302 |
| aimed | #22386 |
| predictive tests | #22416 |
| event | #22426 |
| fibroblast | #22446 |
| reviewed | #22573 |
| status humans | #22597 |
| elevated | #22633 |
| frequent | #22673 |
| setting | #22759 |
| cox proportional | #22797 |
| malignancies | #22798 |
| allocated | #22808 |
| 95 | #22862 |
| diverse | #23033 |
| imaging mri | #23033 |
| superior | #23111 |
| post | #23144 |
| selected | #23153 |
| june | #23240 |
| surgical resection | #23266 |
| aged neoplasm | #23452 |
| persistent | #23460 |
| term | #23463 |
| represent | #23526 |
| antibodies monoclonal | #23543 |
| comprehensive | #23553 |
| continuously | #23560 |
| remained | #23674 |
| classified | #23739 |
| body | #23757 |
| strong | #23813 |
| monoclonal | #23861 |
| physical | #23883 |
| gastrointestinal | #23900 |
| exclude | #23924 |
| 2017 | #23997 |
| 2011 | #23997 |
| severely | #24141 |
| median follow | #24342 |
| partial | #24353 |
| abnormal | #24383 |
| systemic | #24466 |
| recruited | #24477 |
| general | #24560 |
| dietary | #24683 |
| 1996 | #24713 |
| carcinoma | #24787 |
| susceptible | #24878 |
| providing | #25068 |
| acids | #25078 |
| consistent | #25119 |
| implemented | #25293 |
| attributed | #25373 |
| 17 | #25476 |
| early | #25506 |
| markedly | #25526 |
| inhibition | #25536 |
| free | #25571 |
| lymph | #25627 |
| international | #25729 |
| regional | #25737 |
| sought | #25746 |
| selective | #25748 |
| 0003 | #25751 |
| single | #25859 |
| mechanism | #26084 |
| unclear | #26339 |
| putative | #26419 |
| surgery | #26438 |
| 13 | #26589 |
| unknown | #26785 |
| electronic | #26810 |
| predisposition disease | #26997 |
| accompanied | #26998 |
| multiple | #27050 |
| follow studies | #27065 |
| polymorphism single | #27142 |
| united | #27151 |
| histologically | #27323 |
| inherited | #27404 |
| neoplasm proteins | #27717 |
| prognosis retrospective | #27768 |
| systematic | #27775 |
| functional | #27808 |
| 0005 | #28001 |
| predisposition | #28007 |
| preoperative | #28036 |
| skeletal | #28185 |
| longitudinal | #28189 |
| estimated | #28229 |
| leads | #28238 |
| missing | #28264 |
| acid | #28356 |
| anti inflammatory | #28360 |
| correlate | #28365 |
| larger | #28581 |
| sex factors | #28629 |
| causing | #28688 |
| sensitivity | #28740 |
| vary | #28851 |
| 11 | #28869 |
| matched | #28979 |
| represents | #29258 |
| detection | #29343 |
| active | #29413 |
| differentiate | #29510 |
| objectives | #29543 |
| completely | #29721 |
| factual | #29750 |
| databases factual | #29793 |
| varied | #30036 |
| excluded | #30077 |
| quantified | #30091 |
| occurs | #30143 |
| adjusted | #30189 |
| logistic | #30241 |
| underlying | #30508 |
| allowed | #30520 |
| national | #30765 |
| odds | #30909 |
| 001 | #30996 |
| regression | #31005 |
| unchanged | #31053 |
| separately | #31068 |
| characterize | #31283 |
| recombinant | #31415 |
| adolescent | #31473 |
| dose dependent | #31787 |
| age | #31875 |
| lacking | #31939 |
| attenuated | #31971 |
| lower | #32078 |
| correlated | #32273 |
| postoperative | #32309 |
| negative | #32666 |
| growth factor | #33089 |
| positive | #33861 |
| understood | #33957 |
| confirmed | #33982 |
| reduced | #34048 |
| implicated | #34054 |
| confidence | #34153 |
| defined | #34517 |
| occur | #34659 |
| requires | #35112 |
| directly | #35347 |
| followup | #36532 |
| diagnosed | #36787 |
| suggesting | #37604 |
| remains | #37899 |
| multivariate | #38132 |
| independent | #38886 |
| measured | #38991 |
| proto oncogene | #39186 |
| proto | #39814 |
| biomarkers tumor | #39899 |
| examined | #40295 |
| retrospective studies | #42973 |
| underwent | #43365 |
| 95 confidence | #44196 |
Relatório de execução | |
Prominent publications by Charles L Loprinzi
KOL-Index: 16482
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain.
Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks.
Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United ...
| Conhecido por Zoledronic Acid | Bone Metastases | 2 Years | Patients Breast Cancer | Skeletal Events |
KOL-Index: 16399
Postmenopausal women with breast cancer (BC) are at increased risk for bone loss. Bisphosphonates improve bone mineral density (BMD) in normal postmenopausal women. The purpose of this study was to determine if immediate treatment with zoledronic acid preserves BMD in postmenopausal women with BC starting letrozole after tamoxifen. Postmenopausal women with BC completing tamoxifen were treated with daily letrozole 2.5 mg/vitamin D 400 I.U., calcium 500 mg twice daily and were randomized ...
| Conhecido por Postmenopausal Women | Bone Loss | Zoledronic Acid | Breast Cancer | Versus Delayed |
KOL-Index: 13693
PURPOSE: Risedronate prevents bone loss in postmenopausal women. The purpose of this study was to determine whether risedronate prevents bone loss in premenopausal women undergoing chemotherapy for breast cancer.
PATIENTS AND METHODS: Premenopausal women undergoing chemotherapy for breast cancer were treated with oral calcium 600 mg and vitamin D 400 U daily and randomly assigned to receive oral risedronate 35 mg weekly or placebo, with all these therapies beginning within a month of the ...
| Conhecido por Bone Loss | Premenopausal Women | Breast Cancer | 1 Year | Bmd Baseline |
Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice
[ PUBLICATION ]
BACKGROUND: Cisplatin is primarily used for treatment of ovarian and testicular cancer. Oxaliplatin is the only effective treatment for metastatic colorectal cancer. Both are known to cause dose related, cumulative toxic effects on the peripheral nervous system and thirty to forty percent of cancer patients receiving these agents experience painful peripheral neuropathy. The mechanisms underlying painful platinum-induced neuropathy remain poorly understood. Previous studies have ...
| Conhecido por Trpv1 Trpa1 | Transient Receptor | Cisplatin Oxaliplatin | Mechanical Allodynia | Treated Mice |
KOL-Index: 13187
PURPOSE: Functional iron deficiency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with chemotherapy-associated anemia (CAA). This study evaluated whether coadministration of parenteral iron improves ESA efficacy in patients with CAA.
PATIENTS AND METHODS: This prospective, multicenter, randomized trial enrolled 502 patients with hemoglobin (Hb) less than 11 g/dL who were undergoing chemotherapy for nonmyeloid malignancies. All patients received ...
| Conhecido por Oral Iron | Darbepoetin Alfa | Erythropoietic Response | Phase Iii | Ferric Gluconate |
KOL-Index: 12870
To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a ...
| Conhecido por Cancer Cachexia | International Consensus | Definition Classification | Weight Loss | Reduced Food Intake |
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
[ PUBLICATION ]
PURPOSE: Although it is well-established that fluorouracil- (FU-) based adjuvant therapy improves survival for patients with resected high-risk colon cancer, the magnitude of adjuvant therapy benefit across specific subgroups and for individual patients has been uncertain.
PATIENTS AND METHODS: Using a pooled data set of 3,302 patients with stage II and III colon cancer from seven randomized trials comparing FU + leucovorin or FU + levamisole to surgery alone, we performed an analysis ...
| Conhecido por Adjuvant Therapy | Nodal Status | Colon Cancer | Survival Stage | Pooled Analysis |
Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention
[ PUBLICATION ]
OBJECTIVE: To compare the combination of a nicotine inhaler and bupropion to either treatment alone for initiating smoking abstinence and relapse prevention.
METHODS: Smokers were randomized to receive a nicotine inhaler, bupropion, or both for 3 months. At 3 months, smoking-abstinent study participants were randomized to their initial medications or placebo. Participants who were smoking at 3 months were randomized to an alternative treatment regimen or placebo. This study was conducted ...
| Conhecido por Relapse Prevention | Nicotine Inhaler | Bupropion Placebo | Smoking Abstinence | Treatment Phase |
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas in Patients with Previous Colorectal Cancer
[ PUBLICATION ]
BACKGROUND: Experimental studies in animals and observational studies in humans suggest that regular aspirin use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers.
METHODS: We conducted a randomized, double-blind trial to determine the effect of aspirin on the incidence of colorectal adenomas. We randomly assigned 635 patients with previous colorectal cancer to receive either 325 mg of aspirin per day or placebo. We determined the proportion of ...
| Conhecido por Colorectal Adenomas | Patients Aspirin | Observational Studies | Relative Risks | Cancer Adenoma |
KOL-Index: 12619
BACKGROUND: Stool DNA testing is a new approach to colorectal cancer detection. Few data are available from the screening setting.
OBJECTIVE: To compare stool DNA and fecal blood testing for detection of screen-relevant neoplasia (curable-stage cancer, high-grade dysplasia, or adenomas >1 cm).
DESIGN: Blinded, multicenter, cross-sectional study.
SETTING: Communities surrounding 22 participating academic and regional health care systems in the United States.
PARTICIPANTS: 4482 ...
| Conhecido por Stool Dna | Blood Test | Screen Detection | Colorectal Neoplasia | Humans Specificity |
Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[ PUBLICATION ]
PURPOSE: Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates and the relationship to preoperative MRI and surgical year at Mayo Clinic, Rochester, MN.
PATIENTS AND METHODS: We identified 5,405 patients who underwent surgery between 1997 and 2006. Patients undergoing MRI were identified from a prospective database. Trends in ...
| Conhecido por Mastectomy Rates | Magnetic Resonance | Patients Mri | Surgery Type | Surgical Year |
Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
[ PUBLICATION ]
PURPOSE: Previous double-blind, placebo-controlled, randomized clinical trials have demonstrated that both corticosteroids and progestational agents do partially alleviate cancer anorexia/cachexia. Pilot information suggested that an anabolic corticosteroid might also improve appetite in patients with cancer anorexia/cachexia. The current trial was developed to compare and contrast a progestational agent, a corticosteroid, and an anabolic corticosteroid for the treatment of cancer ...
| Conhecido por Cancer Anorexia | Megestrol Acetate | Cachexia Patients | Progestational Agents | Corticosteroid Treatment |
KOL-Index: 12321
BACKGROUND: Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these hormones may be contraindicated in women with breast cancer and in men with prostate cancer. Pilot trials have suggested that the progestational agent megestrol acetate can ameliorate hot flashes in both groups of ...
| Conhecido por Megestrol Acetate | Hot Flashes | Women Breast Cancer | Deprivation Therapy | Weeks Placebo |
Pessoas importantes para Hot Flashes
Principais kols do mundo
Selecione uma frase de pesquisa hot flashes , hot flashes women , hot flashes sweats , hot flashes patients , hot flashes hfs
Charles L Loprinzi:Impacto especializado
Conceitos para os quaisCharles L Loprinzitem influência direta:Hot flashes, Breast cancer, Megestrol acetate, Peripheral neuropathy, Scrambler therapy, Phase iii, Newer antidepressants, Hot flash.
Charles L Loprinzi:Kol Impact
Conceitos relacionados ao trabalho de outros autores para os quaisfor which Charles L Loprinzi tem influência:Breast cancer, Hot flashes, Adjuvant chemotherapy, Quality life, Weight loss, Oral mucositis, Neuropathic pain.
Tools
Este é o seu perfil? Reivindique seu perfil Copiar URL Incorporar link para o seu perfil |